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This thesis deals with the metabolome screening of blood plasma and cerebrospinal 
fluid (CSF) by Nuclear Magnetic Resonance (NMR). The main focus is the biomarker 
discovery in Multiple Sclerosis (MScl) disease by means of NMR and pattern recognition 
methods. Moreover the disentanglement of CSF samples handling for metabolic 
measurements by NMR and variations in metabolites concentration identified by NMR in 
CSF of “healthy” individuals are presented. This thesis consists of 7 chapters. 
In the introductory Chapter 1, various aspects of metabolome screening of biofluids by 
Nuclear Magnetic Resonance (NMR) and chemometric analysis are reviewed. 
Specifically, attention is paid to data acquisition, data pretreatment and preprocessing 
and multivariate analysis of metabolic data. The chapter gives also an overview of 
current developments in and status of biomarker discovery by means of NMR and 
pattern recognition techniques with emphasis on CSF biomarker research for MScl 
disease.   
In chapter 2 CSF sample handling procedures are presented, including a stability study 
of metabolites identified by NMR in human CSF. To mimic the probable procedure 
occurring in the clinic, CSF was left at room temperature for up to 120 minutes before 
freezing and storing it in -80oC. The changes of metabolites concentration were then 
investigated. 
Chapter 3 covers the analysis of CSF samples of “healthy” human individuals, i.e. 
without neurological disease. In this part, the biological variation of metabolites 
measurable by NMR and other analytical methods is shown. These biological variations 
in “healthy” individuals form a base line for detecting significant fluctuations in disease 
inflicted individuals. Inter-individual fluctuations in metabolite concentrations in the 
“healthy” individuals are compared with analytical variations and found to be much 
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smaller. In addition, the variation in CSF metabolites abundances in gender and group’s 
age is demonstrated.  
In Chapter 4 a metabolic biomarker study on CSF from pre-clinical animal model of 
MScl, namely Experimental Autoimmune Encephalomyelitis (EAE) is investigated. The 
aim was to establish the metabolic profile of CSF of EAE-affected rats (representing 
neuroinflammation, a crucial part of early stage of MScl) and to detect the metabolic 
markers related to neuroinflammation. In order to find disease specific markers the NMR 
spectra were analyzed with two different chemometric techniques.   
Chapter 5 portrays the analysis of blood plasma and CSF of EAE-affected rats. In this 
study both biofluids were measured by NMR spectroscopy. The obtained NMR spectra 
were subsequently joined by means of a mid-level data fusion scheme. Moreover, in this 
chapter a new approach for multi-class classification is presented. 
Chapter 6 brings up a novel approach for data fusion, which is then applied to 
metabolomic CSF datasets from patients suffering from MScl disease. In this study two 
different analytical platforms, namely NMR and Gas Chromatography-Mass 
Spectrometry, were used to generate metabolic profiles of CSF. The approach shown in 
this study consists of concatenating NMR and GC-MS data in kernel space.  
Lastly, chapter 7 briefly summarizes the findings of the research described in this 
thesis, followed by some perspectives on future research.  
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ABSTRACT 
Metabolomics is the discipline where endogenous and exogenous metabolites are 
assessed, identified and quantified in different biological samples. Metabolites are 
crucial components of biological system and highly informative about its functional state, 
due to their closeness to functional endpoints and to the organism’s phenotypes. 
Nuclear Magnetic Resonance (NMR) spectroscopy, next to Mass Spectrometry, is one 
of the main metabolomics analytical platforms. The technological developments in the 
field of NMR spectroscopy have enabled the identification and quantitative measurement 
of the many metabolites in a single sample of biofluids in a non-targeted and non-
destructive manner. Combination of NMR spectra of biofluids and pattern recognition 
methods has driven forward the application of metabolomics in the field of biomarker 
discovery. The importance of metabolomics in diagnostics, e.g. in identifying biomarkers 
or defining pathological status, has been growing exponentially as evidenced by the 
number of published papers. In this review, we describe the developments in data 
acquisition and multivariate analysis of NMR-based metabolomics data, with particular 
emphasis on the metabolomics of Cerebrospinal Fluid and biomarker discovery in 
Multiple Sclerosis. 
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1.1 INTRODUCTION 
The terms metabonomics 1 and metabolomics 2 appeared at the end of the 90’s and 
early 2000’s, respectively 1, 3. They describe, in broad terms, the study of the 
metabolome, which was first defined as the collective set of metabolites produced or 
present in a biosystem 3, 4. Nowadays, metabonomics and metabolomics are often used 
interchangeably 4, 5, although their exact definitions are slightly different. The most often 
cited definition of metabonomics is the one proposed in 1999 in Xenobiotica 1: 
‘Metabonomics is defined as the quantitative measurement of the dynamic multi-
parametric metabolic response of living systems to pathophysiological stimuli or genetic 
modification’. For Metabolomics a very similar definition is often used 4: ‘The study of the 
quantitative complement of metabolites in a biological system and changes in metabolite 
concentrations or fluxes related to genetic or environmental perturbations. Studies are 
typically holistic in nature though targeted studies are also encompassed in the term 
metabolomics’. Since, metabolomics and metabonomics terms are in practice often 
utilized indifferently the analytical and modeling procedures are the same and therefore 
in the rest of the paper we will employ the term metabolomics. 
Metabolomics is a strongly developing field as evident from the exponentially growing 
number of papers. With a doubling time of circa three and half years, approximately 
1420 papers were published in 2011 to which NMR and Mass Spectrometry equally 
contribute about one-third (as defined in Web of Science with keywords [metabolom* or 
metabonom*]. For comparison, the field of proteomics is about twice as large with about 
3600 published papers in 2011. Metabolomics’ approaches have developed in many 
areas of biomedical research, such as toxicology studies, nutritional effects, metabolic 
consequences of genetic modifications, inborn errors of metabolism, diabetes, cancer 
diagnostics, and diagnosing of neurological diseases 6-14. The metabolic profiling was 
first reported in the literature in 1950 but the first progresses were slow until it became a 
separate scientific area15. To date there has been increasing emphasis on obtaining 
spectral “fingerprints” or metabolic profiles that can be correlated with phenotype 2, 16. 
Metabolomics is a reflection of genetic factors and metabolites are often defined as the 
functional endpoint. The closeness of the metabolism to an organism’s phenotypes 
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causes that it will be affected by disease and thus it is relevant to measure metabolites. 
Moreover, the flux of metabolites is measured in seconds in comparison to turnover in 
proteome which is measured in minutes to hours 17. This shorter response time allows 
one to use the metabolomics as indicator of environmental perturbations. This is one of 
the reason why van der Greef et al. described metabolomics as a promising tool for 
clinical systems biology to detect early metabolic perturbations, even before the 
appearance of disease symptoms 18. A single metabolite can be a substrate for a 
number of different enzymes, causing linkage of metabolites through complex pathways. 
This linkage makes difficult to assess the consequence of changes in mRNA products 
and proteins, but at the same time metabolites and their concentrations may report on 
changes in both mRNA and proteins 7, 19. This is another reason why studying disease 
from the metabolic point of view is very attractive. Moreover, only 2766 metabolites (i.e. 
small molecules, <1500Da) are estimated to be derived from men 7 and many 
metabolites are species independent. Therefore, they could form the basis of 
translational studies, i.e. biomarkers that are found in preclinical studies and can be 
applied more directly during clinical studies. Metabolomics can be used either as a 
targeted or a non-targeted analysis of endogenous and exogenous metabolites for 
biomarker discovery 20. According to the official National Institutes of Health, a 
biomarker is defined as ‘characteristic that is objectively measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention’ 21. The Food and Drug Administration defines a 
valid biomarker as: ‘A biomarker that is measured in an analytical test system with well 
established performance characteristics and for which there is an established scientific 
framework or body of evidence that elucidates the physiologic, toxicologic, 
pharmacologic, or clinical significance of the test results 22. Biomarker is defined as a 
laboratory measurement that is an indicator of diseased processes and also the risk of 
the appearance. For instance, magnetic resonance imaging measures in Alzheimer’s 
disease or in Multiple Sclerosis (MScl) and positron emission tomographic scanning of 
dopamine transporters in Parkinson’s disease are such markers 23. Obviously, 
metabolites or metabolic profiles can be utilized as biomarkers 4, 24. Indeed, metabolic 
biomarkers provide, because of their objective nature, an attractive and valuable tool for 
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accurate diagnose of diseases. Metabolic profiles can be particularly valuable to 
determine when a healthy state becomes dysfunctional in the early stage of the disease 
and provide new possibilities for preventing therapies.  
Metabolomics’ approaches have spread in many areas of biomedical research and 
therefore increasing number metabolic biomarkers are established 4, 8, 25. The 
identification of biochemical biomarkers in biofluids for Central Nervous System (CNS) 
disorders has been the aim of many metabolomics studies 11, 25-33. Presently, the clinical 
diagnostic of most neurological diseases is performed based on the identification of a 
variety of symptoms. However, it is very often difficult to identify individuals at risk or 
establish rapidly a definite diagnosis. This is mostly due to the complexity of CNS 
diseases and to the fact that the ethiopathogenesis of most such diseases is very often 
unclear. CNS diseases are likely to arise from deregulations of several genes, leading to 
complex alterations in protein and/or metabolite profiles, but also changes in 
environmental conditions may affect these profiles. All these aspects reflect the 
complexity of the CNS malfunctions34. Therefore, there is an increasing need to learn 
more about CNS diseases at the molecular systems level, to understand at this level the 
changes that can contribute to pathogenesis of these disorders.  
In metabolic biomarker discovery, an important issue is how to extract relevant 
information from the data, i.e. from the metabolic profiles of biofluids. All data produced 
in metabolomics are highly multivariate. Therefore the use of chemometrics is required 
to find trends or significant information in the data, i.e. relevant metabolites. In 
chemometrics different multivariate methods for data exploration, visualization, 
classification and prediction are available. The empirical models constructed on 
experimental data can subsequently be used for biological interpretation and prediction.  
Nowadays, proton Nuclear Magnetic Resonance (1H-NMR), Gas Chromatography-Mass 
Spectrometry (GC-MS) and Liquid Chromatography-Mass Spectrometry (LC-MS) are 
well-established powerful analytical methods for generating metabolomics profiles. For 
the analysis of complex, biological samples like biofluids, these techniques have their 
advantages and disadvantages. For instance, GC-MS requires derivatization, which 
lengthens the sample preparation time.  In general LC-MS and GC-MS need more time 
consuming sample preparation. On the other hand, GC-MS and LC-MS yield a higher 
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sensitivity than NMR and therefore may detect metabolites that are present in a 
concentration below the detection limit of 1H-NMR. On the other hand 1H-NMR requires 
limited sample preparation, is un-targeted, quantitative (absolute), non-destructive, 
reproducible and unbiased 35. 1H-NMR may detect compounds that are too volatile for 
GC, while metabolites without proton (phosphoric acid) are not detected by 1H-NMR.  
We focus in this review on the recent developments in metabolic profiling of 
Cerebrospinal Fluid (CSF) by 1H NMR (and to some extent also blood and urine) aimed 
at identification of biochemical biomarkers for CNS disorders, in particular MScl. Our 
choice of NMR as analytical method was guided by the fact that it is a robust and 
reliable technique for metabolomics application and it allows for detecting a wide range 
of different types of metabolites simultaneously 36. Plasma and urine are historically the 
two biofluids widely used and described for metabolomics application 37-41. Many 
protocols for sampling and measuring of these biofluids can be found 36, 41-43. Metabolic 
profiling of CSF by means of NMR has been performed to find diagnostic biomarkers for 
a number of neurological diseases 17, 32, 33, 44, 45. However, only recently comprehensive 
protocols for metabolic (and proteomic) profiling of CSF have been established 46-48.  
In this review we present comprehensive outlines of data acquisition, data preprocessing 
and data analysis of NMR-based metabolomics data for CSF and discuss its application 
to CSF biomarker discovery for MScl.  
This review covers four main aspects, namely: 
x analytical, i.e. samples preparation and measurements (section 2) 
x data preprocessing (section 3) 
x data analysis, statistical analysis (section 4) 
x biomarker discovery by means of NMR and pattern recognition with focus on CSF 
and MScl (section 5 and 6) 
The first part of the review focuses on recent developments in preparing and measuring 
the metabolic profiles of different biofluids, namely blood plasma, urine and CSF via 
NMR. In this part, the recently established protocol for measurement of the 
metabolomics profiles of CSF is described and discussed. In the next part, the crucial 
steps involved in data preprocessing are described. The third part details the 
multivariate data analysis. The most common pattern recognition methods used in 
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metabolomics are discussed. Also, current progress in data fusion is described. In the 
fourth part, the determination of absolute metabolite concentration and their variations in 
CSF of healthy controls is brought up. In this fourth part, the review centers further on 
providing an overview of recent developments in the application of NMR and pattern 
recognition methods in metabolic biomarker discovery for MScl. 
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1.2 NMR of BIOFLUIDS 
High-resolution NMR spectroscopy is a quantitative and non-destructive technique. It is 
a robust and reliable analytical method with paramount reproducibility and repeatability 
35. In metabolomics studies either biofluids, cell or tissues extracts are used as main 
samples for metabolic fingerprints. Biofluids like urine, blood plasma or serum, CSF are 
the most common investigated samples in metabolomics studies. Most of these biofluids 
can be obtained quite easily with minimal invasion. Moreover, a high sampling frequency 
can be achieved 42. In the late 1960s the developments of Fourier transform NMR 
spectroscopy and next in the 1970s the implementation of superconducting magnets 
permitted the beginning of the application of NMR spectroscopy for the metabolite 
profiling of biofluids. The first real applications of NMR to the analysis of biofluids, dates 
to early 1980s 49-51. Further NMR technical improvements in the 1990s, namely stronger 
magnetic fields and introduction of cryo-cooled NMR probes, have led to an enormous 
boost in NMR sensitivity; the signal to noise ratio of ethylbenzene was circa 800:1 at the 
then highest fields of 600 MHz versus circa 8000:1 for 800 MHz nowadays. Today, the 
detection limit of metabolite concentration is of the order of μM. Although, the sensitivity 
has increased enormously and still improves, it remains a weak point compared to MS. 
Recent developments in spin hyperpolarisation via dynamic-nuclear polarization (DNP) 
or para-hydrogen-induced hyperpolarisation (PHIP) hold great promises in resolving this 
backlog 52, 53. Furthermore, the increase in field strength has tremendously improved the 
resolution. Today, metabolomics is an exponentially growing field in which NMR together 
with MS each contribute about equally. A very important benefit of NMR spectroscopy 
for metabolic profiling is that it is quantitative and does not require time-consuming 
sample preparation steps, like separation or derivatization. Moreover, it does not require 
a-prior knowledge about compounds present in a sample and is thus ideally suited for 
non-targeted profiling.  
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1.2.1 Sampling and NMR sample preparation 
Urine, blood plasma and blood serum are the most commonly used biofluids in 
metabolomics studies, because they contain hundreds to thousands metabolites and 
they both can be obtained in relatively non-invasive manner 36, 54-59.  Another biofluid, 
CSF, is widely used in metabolomics studies of neurological disease 28, 32, 33. In contrast 
to plasma and urine its sampling is much more invasive.31  A number of other biofluids 
like amniotic fluid 60, 61, bile 62, 63, seminal fluid 64-66, saliva 67-69 have been also 
investigated. 
Biological samples should be collected under strict conditions. Usually blood is collected 
by venipuncture into standard vials containing either ethylene diamine tetra acetate 
(EDTA) or lithium heparin as anti-coagulant.  One has to remember that when EDTA is 
used extra resonances can be observed in the NMR spectrum. This is due to formation 
of complexes between EDTA and ions Ca2+ and Mg2+ which are present in plasma 51.  
Plasma and serum can be measured directly with minimal sample preparation. Dilution 
of plasma or serum is recommended, since it reduces the sample’s viscosity and 
releases plasma-protein bound metabolites  
Proteins can be removed before NMR measurements by either organic solvent 
precipitation or by ultra-filtration using a 10kDa molecular weight cut off filter 70.  
However, a recent comparison of organic solvent precipitation with ultrafiltration has 
demonstrated that ultra-filtration was superior for metabolic NMR measurement 71, 72. 
Before usage, the filter has to be cleaned from glycerol, which is present in many 
commercially available filters, by centrifugating it with water. The effect of protein 
removal on the 1H-NMR spectrum of blood plasma is shown in Figure 1. For urine 
samples addition of sodium azide is required to control bacterial growth. Detailed 
procedures to collect, store and measure biofluids such as blood or serum, urine have 
been provided in the literature as guidance 36, 42. 
The pH of samples has a significant influence on the chemical shifts observed in the 
NMR spectrum. Therefore, it is important to control the pH of the biofluid sample. In the 
literature pH 7.2 and 2.5 have been mostly used 33, 73, 74. A very popular and fast method 
to adjust pH is addition of a phosphate buffer stock solution made up in D2O at pH 7.0 or 
7.4 36. Manual adjustment of pH using NaOH and HCl is another possibility 75, 76. In 
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section 1.2.3, we present a detailed protocol for the metaboloic sampling and profiling of 
CSF by NMR. 
 
Figure 1. The 500 MHz 1H-NMR spectrum of blood plasma sample: (a) before, and (b) after 
protein removal. 
 
A very important advantage of NMR is absolute quantification77. The linear response of 
NMR experiment is the key benefit of NMR over other analytical methods. The signal 
intensities observed in NMR spectrum are directly proportional to the concentration (i.e. 
molar amount) of that nucleus in the sample 77, 78. In order to obtain absolute 
concentration of metabolites detected by NMR, usually the addition of internal standards 
is used. The reference compound used for concentration reference as well as for 
chemical shift (δ=0.00) is usually the sodium salt of 3-trimethylsilylpropionic acid-d4 
(TSP-d4) with deuterated methylene groups. Other references standards are 2,2-
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dimethyl-2-silapentane-5-sulfonate sodium salt (DSS) or for organic solvent 
trimethylsilane (TMS). Another internal reference standard, 4,4-dimethyl-4-silapentane-
1-ammonium trifluoroacetate has been proposed by Alum et al. as promising universal 
for metabolic profiling 79. Akoka et al. have introduced a synthetic electronic reference 
signal, Electronic REference To access In vivo Concentrations (ERETIC), for 
quantification purpose 80. Similar approach, QUANTification by Artificial Signal, has been 
recently introduced by Farrant et al.81. In these methods an internal standard is claimed 
to be not required.  The standard way of quantifying compounds in NMR spectrum is 
integrating the different NMR resonances and comparing them to the area of the internal 
standard. Another possibility is spectral deconvolution, available for instance in 
MestReNova 82, where global spectral deconvolution is applied automatically to whole 
NMR spectrum.  In the Chenomx NMR Suite software the spectral signatures (singlets, 
doublets, triplets etc.), i.e. the peak shapes, of a compound from an internal database of 
reference spectra is fitted to the experimental NMR spectrum 83. In contrast, peak 
integration is very sensitive to baseline distortions. Moreover even slightly overlapping 
resonances cannot be reliably quantified. Peak-shape fitting, like in Chenomx, is not 
affected by baseline distortions and still efficient when some of the resonances and/or 
part of a resonance overlap with that of another compound, the peak shape can still be 
fitted with reasonable accuracy and the concentration of the compound reliably 
determined. 
Usually, 5-mm diameter NMR tubes are used for NMR measurements. There are also 
much smaller NMR tubes with diameter of 1-3 mm 84 or a microscale SHIGEMI  tube33 in 
which a reduced sample size is compensated by solid glass beneath the level of sample. 
Recently NMR on small biofluid sample size (600nL) was investigated, where 
microfluidic stripline resonator was used to measure 1H-NMR spectrum of human CSF 
85. 
The number of observed metabolites in biofluids largely depends on the magnetic field 
strength of NMR spectrometer. Therefore, working at the highest available magnetic 
field is recommended. Generally, 500 or 600 MHz NMR instruments are used in 
metabolomics studies, because these fields are easily accessed 16, 32, 67. However, the 
use of 800 or 900 MHz has been reported 33, 47. 
24 
 
1.2.2 Measurements and spectral pre-treatment 
The detection limit for bodyfluid NMR spectroscopy depends on many factors such as 
field strength, number of protons contributing to a resonance and a region of the 
spectrum where the resonance is observed.  In general the detection limit is in the low 
micromolar range in the less crowded regions of the spectrum 86. There are two 
experimental issues in NMR of biofluids. The first one is connected to accurate solvent 
suppression. Even though very effective methods like excitation sculpting 87 or 
WATERGATE 88 exist, the simple presaturation is the prevalent one. The second 
experimental issue is associated with distinction between small molecular weight 
metabolites (typically <1500Da) and macromolecules. Macromolecules produce broad 
resonances due to limited rotational diffusion and short T2 relaxation times, causing 
difficulties in spectral interpretation. To overcome these problems, 1D nuclear 
Overhauser effect spectroscopy with presaturation (1D NOESY-presat) 89, 90 and the 1D 
Carr-Purcell-Meiboom-Gill (CPMG) 91 are two pulse sequences used for metabolic 
profiling. 1D NOESY has become the most popular sequence for NMR-based metabolic 
analysis. This is mostly due to high quality of water suppression with little calibration and 
consistency in obtained spectra. CPMG as special pulse sequence is used to remove 
broad proteins signals if they have not been taken away before NMR measurement.  
In metabolomics studies of biofluids beside 1D 1H-NMR homonuclear 2D J-resolved is 
also very often used 92. Moreover 2D J-resolved spectra increase identification of 
biochemical substances. Other 2D NMR spectroscopy, such as correlation spectroscopy 
(COSY) 93 and total correlation spectroscopy (TOCSY) experiments 94 give spin-spin 
coupling connectivities. They provide information on which hydrogens in a molecule are 
close in chemical bond term. 2D NMR spectroscopy is mostly performed for better 
signals assignment. 
The NMR data are typically processed by Fourier Transformation (FT). Before FT 
apodization and zero filling of Free Induction Decay (FID) is performed. The phase is 
then corrected to obtain absorption line shape. For spectral pre-treatment several 
commercial and free licensed software packages are available, such as PERCH 95, , 
Chenomx NMR Suite 83, MestReNova 82  and the algorithm AutoFit 96. They all provide a 
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number of functions involving spectral pre-treatment, metabolite identifications and 
quantification.  
 
1.2.3 Metabolic protocol of CSF 
CSF is a colourless and crystal-clear fluid that surrounds the brain and spinal cord and 
thus protecting them from immunological and mechanical damage. The main 
composition of CSF is water (around 99%), proteins, nutrients needed for metabolism 
and electrolytes. CSF is also responsible for removing waste from surrounding tissues. 
CSF is constantly produced at rate of circa 500ml per day and its turnover is around 4 
times per day 28. 
CSF is normally sampled via lumbar puncture between the L4 and L5 vertebrae. CSF, 
directly after collection, should be centrifuged to remove all cellular elements. It has 
been shown that several metabolites concentrations were affected in porcine CSF when 
residual white blood cells were present 97. Therefore, it is crucial to not only assess that 
CSF is free of erythrocytes but also white blood cells. After sampling CSF samples 
should be stored in -80oC. This storing temperature assures that the metabolic 
composition is not affected. It has been shown that storing CSF in -20oC causes 
activation of a number of chemical processes, which influence the metabolite 
concentrations 98. Another contradictory study has demonstrated insignificant 
quantitative changes in human CSF after freezing in -20oC and subsequent thawing 48. It 
has further been demonstrated that keeping CSF samples at room temperature for a 
limited (hour) does not affect metabolite composition in human CSF to any great extent. 
Analysis of the impact of a delay in storage of CSF has revealed that out of 93 unique 
identified metabolites, only the concentration of erythronic acid has been elevated 
significantly with increased time left at room temperature 46. Another significant aspect is 
connected to pH of CSF, which is naturally poorly buffered. The CSF pH rises drastically 
upon standing and storing in -20oC 98, 99. This rapid increase may be explained by 
evaporization of CO2.  
CSF in comparison to blood plasma has a relatively low protein concentration 
(<500mg/l). Therefore prior to NMR analysis they are not always removed. In the 
literature, NMR measurements on both native 29, 100-102 and deproteinized samples have 
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been reported 47, 73. In our experience, the presence of protein does not affect the 
measured metabolite concentration to a large extent. If sufficient volume of CSF is 
available, the buffer solution solvated in a mixture of water and D2O consists of TSP, 
mM sodium azide (NaN3) and mM sodium phosphate dibasic dehydrate 
(Na2HPO4•2H2O) are added prior NMR measurements. If CSF sample is deproteinized 
and snap-frozen it is first reconstituted in D2O and next buffer solution with TSP and 
NaN3 are added. The amount of CSF that can be collected in one sampling is often not 
sufficient for measuring it with standard 5 mm NMR-tube. For instance, rat’s brain is 
rather small and only a small volume of CSF can be collected (~100 uL). In that situation 
CSF samples can be diluted and measured in SHIGEMI tube33 or in 1 mm NMR-tube 
103. One should keep in mind that using small volume tube does not mean an increase in 
sensitivity of low abundant metabolites. 
An up-to-date protocol for 1H NMR metabolomic CSF sampling and sample preparation 
is available in Rosenling et al. 46.  
 
 
1.3 DATA PREPROCESSING 
Data preprocessing is an intermediate step between raw spectra and data analysis.  The 
main objective of data preprocessing is to transform the data in such way that the 
samples in the dataset are more comparable in order to ease and improve the data 
analysis.  The crucial role of data preprocessing was pointed and discussed in many 
publications104-107. For NMR spectra preprocessing usually involves, baseline correction, 
alignment, binning, normalization and scaling.   
 
1.3.1 Baseline correction 
Usually, the first step of data preprocessing is the baseline removal. Baseline distortions 
affect not only the statistical analysis but also the quantification of the metabolites. 
These distortions can be corrected in many different ways; usually an automated 
baseline correction is applied.  Currently the most popular methods are based on 
polynomial-fitting such as iterative polynomial fitting 108, robust estimation procedure 
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implemented in Chenomx NMR Suite 109, locally weighted scatterplot smoothing 
(Lowess) fit 110. Asymmetric Least Squares 111 is a method that uses a different 
constraint for baseline correction. It tries to estimate the baseline by fitting a regression 
curve to a spectrum using a penalized least square approach. Baseline can also be 
corrected by using B-splines, B-splines with Penalization (i.e. P-splines) 112 or by 
applying mixture models 113. 
After baseline correction spectral regions not populated with by endogenous metabolites 
are often removed. Therefore, the spectrum outside the window 0.2-10.0 ppm is 
frequently removed. Another region of the spectrum that is usually excluded belongs to 
solvent water. Although suppression techniques are used for water, the remaining signal 
dominates in the spectrum. Moreover the variance contained in water signal is not of 
interest and might interfere with data analysis. In metabolomics of biofluids water signal 
dominates the spectrum between 4.7 ppm and 5.0 ppm.  In case of urine spectra the 
signal of urea, which is very close to the water signal, is excluded. Urea beside water is 
the most concentrated metabolite in urine. Moreover it is not quantitative, because 
protons from urea exchange with water and other exchangeable protons and thus the 
peak intensity varies with quality of water suppression as well as with pH. In CSF and 
plasma spectra no additional exclusion regions are necessary.  
 
1.3.2 Alignment 
One of the most frustrating problems with NMR profiles, from a multivariate data 
analysis point of view, is the presence of peak shifts between different spectra 104. These 
variations obscure the discovery of patterns in the spectra 114-116. Shifts can be due to 
instrumental factors, changes of the pH and temperature, changes of salt concentration, 
overall dilution and relative concentration of specific ions. All these parameters influence 
peaks shifts, although not all peaks are affected to the same extend. Recently Cloarec et 
al. 117 and Giskeodegard et al. 118 have shown that peaks shifts can be beneficial for 
discriminating groups if the locations of peaks are systematically different in studied 
groups. However it is not yet possible to trace back these differences into a single factor. 
Therefore an essential step in preprocessing is to adjust the peaks shifts, i.e. alignment 
or warping. NMR spectra are usually first aligned by spectral referencing. This simple, 
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global method for peaks alignment sets the internal reference signal of each spectrum to 
0 ppm. This type of alignment removes only global shifts and is not sufficient, because in 
NMR mostly local shifts are observable 119. The effect of different alignment methods for 
NMR spectra on classification results is presented by Giskeodegard et al. 118.  
Interval correlated shifting (icoshift) was proposed for NMR spectra 120. In this warping 
method spectra are divided into different length segments and aligned to the 
corresponding segments of a reference spectrum. Warping is performed by shifting 
sideways the segments so as to maximize the correlation between segments. This is 
done by calculating the cross-correlation between the segments by a fast Fourier 
transform which allows for simultaneously aligning all spectra segments of spectra. 
Another segmented warping method is Correlation Optimized Warping (COW) 121, 122 
which also divides spectra into segments but of equal size. By linear stretching and 
compressing it aligns the segments with the segments of a reference spectrum. The 
objective is to maximize the overall correlation between two spectra. COW was originally 
proposed for the alignment of chromatographic data, however it has been successfully 
applied to NMR spectra 46, 123. Peak alignment by beam search was made for NMR 
signals 124. This method also divides spectra into segments but warps them by both 
shifting and stretching/compressing to maximize their respective correlation. Wu et al. 
have proposed fast iterative warping algorithm, i.e. fuzzy warping, for urine NMR 
spectral data 125. This warping procedure tries to establish correspondence between the 
most intense peaks in the spectra to be aligned.  
Recently a method for aligning NMR spectra, called hierarchical Cluster-based Peak 
Alignment (CluPA), has been proposed by Vu et al. 126. The algorithm builds hierarchical 
cluster tree from peaks of reference and target spectra. It aligns two spectra using this 
tree. Several others warping methods have been proposed to remove complex 
misalignments 127-129. It is important to mention that warping may affect peaks area and 
thus quantification. Therefore absolute quantification should be performed on unaligned 
spectra.  Figure 2 shows a set of 82 NMR spectra before and after baseline correction 
(via ALS) and alignment (via COW).  
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Figure 2. Example of NMR spectra: a) before baseline correction and alignment; b) after 
baseline and alignment. 
 
1.3.3 Binning 
For multivariate analysis of NMR metabolic data either quantitative or scored integrals of 
specific spectral peaks is used 130, 131. An NMR spectrum, after excluding certain signals 
(e.g. water, internal reference, urea), contains approximately 22000 data point 
(variables).  Therefore in order to reduce the data dimensionality binning (also called 
bucketing) is commonly used. One has to keep in mind that binning reduces the spectral 
resolution. In binning the spectra are divided into segments (so called bins or buckets) 
and the total area within each bin is calculated to represent the original spectrum. 
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Therefore some minor peaks shifts can be removed by spectral binning. There are many 
types of spectral binning. However the most common type of spectral binning is an 
equidistant binning of 0.04 ppm. This indicates that every spectrum is divided into evenly 
spaced integral regions with spectral width of 0.04 ppm 105, 106, 132. The disadvantage of 
equal size binning is the lack of flexibility of the boundaries. If a peak is split between 
two bins, this peak frequency may significantly influence the data analysis. In order to 
prevent peaks being split by the boundaries of bins, methods which are based on non-
equidistance spacing have been proposed, e.g. adaptive-intelligent binning (AI-binning) 
133, Gaussian binning 134, adaptive binning using wavelet transform 135 and Dynamic 
adaptive binning136. These methods take into account peak positions and thus to focus 
on a better peak definition. Therefore it is possible to obtain binning where one bin 
covers only complete peaks. In Figure 3 an example of two types of spectral binning is 
presented, i.e. AI-binning and equidistance binning (0.04 ppm). 
 
Figure 3.  An example of AI-binning and equal sized binning performed on a fragment of NMR 
spectrum. 
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1.3.4 Normalization scaling and transformation 
This step of preprocessing tries to account for variations of the overall concentrations of 
samples. The main aim is to make all the samples comparable with each other by for 
instance removing or minimizing total amount of material per samples or metabolite 
dilution. This is particularly relevant for urine studies where the variations of overall 
concentrations of samples are very distinctive and can vary by orders of magnitude 50. 
Other inter-sample variations such as different relaxation or variations in RF pulse 
calibration can be corrected by normalization. Typically normalization is a multiplication 
of every row (i.e. every NMR spectrum) by a constant 105. This constant can be 
computed in many different ways. The standard method, integral normalization, 
normalizes the individual spectra to constant total integrated intensity across the whole 
profile 137.  Integral normalization is also referred as constant sum normalization 105. For 
NMR spectra of urine the normalization using the creatinine peak area as reference is 
common practice 138, 139. There are other normalization methods as well, for instance 
probabilistic quotient normalization (PQ) 140, “histogram” normalization 141, group 
aggregating normalization (GAN) 142.  
 
Metabolites can range in concentration over many orders of magnitude. Moreover the 
variation in metabolites level is often linked to concentration in such way that higher 
concentration metabolites have higher variation 104. This causes that such metabolites 
have the highest influence on results of e.g. Principal Component Analysis (PCA) or 
Partial Least Squares (PLS). Therefore it is important to scale metabolites intensities 
before analysis to avoid selection of the most abundant metabolites as significant.  
A number of scaling methods are commonly used, namely meancentering, autoscaling, 
pareto scaling, range scaling, vast scaling, level scaling  104, 105, 143. Meancentering 
adjusts for differences between high-concentrated and low-concentrated metabolites by 
converting all values to vary around zero instead of around mean of metabolite level. It is 
not sufficient if in the data there are sub-populations with different variability 
(heteroscedastic data). Meancentering is usually used in combination with other scaling 
methods. Autoscaling scales all metabolites to unit variance and therefore the data is 
analyzed on the correlations basis instead of covariances. One has to be careful to use 
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this scaling for noisy data. Indeed autoscaling increases the influence of noisy variables.  
Pareto scaling is an intermediate option.  It uses the square root of standard deviation as 
scaling factor instead of the standard deviation. This scaling method stays closer to real 
measurement but it is sensitive to large changes in the data.  In range scaling the 
difference between the minimal and the maximal concentration of each metabolite is 
used as scaling factor. All metabolites in the data become equally important after 
applying ranges scaling. It is important to remember that range scaling is sensitive to 
outliers Because only two values are used to calculate the range. Level scaling focuses 
on relative response by using mean as scaling factor. It is suitable for use when large 
relative changes are of interest. Vast scaling can be considered as extension of 
autoscaling. It focuses at stable metabolites, i.e. the one having small variations.  
Besides scaling methods there are several transformation approaches, like log transform 
143 or the Box-Cox transformation 144 which can be used as preprocessing step. The 
Box-Cox transformation is a parametric preprocessing technique which decreases the 
effect of non-normality and heteroscedasticity. The last methodology described here is 
log transformation, which is nonlinear conversion of data. Large values are reduced in 
the data set relatively more than the small values. Log transformation removes 
heteroscedasticy from data if relative standard deviation is constant.  
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1.4 DATA ANALYSIS 
1.4.1 Unsupervised analysis 
Multivariate statistical methods provide an expert means of analyzing and maximizing 
information recovery from complex NMR data. Precise inspection of NMR data and 
integration of individual peaks can give valuable information on biochemical changes. 
After preprocessing the next stage is to analyse the data. The first step of data analysis 
is to explore and discover the overall structure of the data, find trends and groupings in 
the data. This stage of data analysis is based on blind unsupervised methods, i.e. those 
that do not assume any prior knowledge. These methods allow for an unbiased view of 
the data. There are several unsupervised methods available, among them PCA, robust-
PCA, Hierarchical cluster analysis (HCA), K-means. 
 
PCA is the workhorse 145 in multivariate analysis and is probably the most commonly 
used multivariate statistical analysis in metabolomics 139, 146-148. It was invented by 
Pearson in 1901 149. PCA converts the multidimensional data space into a low-
dimensional model plane. This technique expresses most of the variance within a data 
set using a smaller number of factors, so called Principal Components (PC’s). Each PC 
is a linear combination of the original variables whereby each successive PC explains 
the maximum amount of variance, which was not accounted for by the previous PCs. 
Each PC is orthogonal to the other PCs and therefore exhibits different information. The 
variation in spectral data is described by a few PCs, compared to the number of original 
variables. Usually NMR spectra of 300 bins each can be summarized by a few new 
Principal Components (PC’s). Moreover it enables to find trends, groupings, at to an 
extend outliers in the data. 
Conversion of the original data set by PCA results in two matrices known as scores and 
loadings. Scores are the new coordinates for the samples. In a scores plot, each point 
represents a single spectrum.  It provides a summary of all spectra and shows how they 
are related to each other. Hence, the points that are close to each other have similar 
profiles. On the contrary, objects that lie far away are characterized by different 
properties. The PC loadings describe the way in which the old variables are linearly 
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combined to new variables (PC’s) and indicate which variables have the greatest 
contribution in transforming to the new variables. In the loading plot the relation among 
measured variables is shown. An important feature is that the directions in the score plot 
correspond to direction in the loading plot. Thus, any spectral clustering observed on the 
score plot is interpreted by examination of the loadings.  
Presence of outliers affects all least squares methods, which are commonly used in 
multivariate data analysis. Therefore outliers detection is very essential. PCA can be 
used for outliers detection, however it can detect only certain type of outliers, i.e. good 
leverage objects (lying far away from the majority of objects). It cannot detect the 
orthogonal outliers, since after projecting them into PCA space they fall into cloud of 
data majority. Therefore robust-PCA should rather be used for outliers detection. Up till 
now, many robust versions of classical estimators have been proposed and their 
description can be found in 150. Matlab implementation of robust-PCA can be found in 
151, 152. 
HCA is another unsupervised method which is widely used in modeling of metabolic 
data 153-155. This method has the ability to group samples according to their similarity. 
HCA requires the choice of two input functions, namely the metric to be used as 
similarity between metabolic profiles (e.g. Euclidian, Mahalanobis or Minkowski 
distances) and the so-called linkage function (e.g. single, average complete or Ward’s) 
156, 157. The choice of similarity metric and linkage have influence on the clustering 
structure. The HCA clusters the data forming a tree called dendrogram. In order to use 
HCA for classification, one has to decide the similarity cut-off, which divides the 
dendrogram into separate clusters. The main drawback of HCA is that it does not 
provide the information about the reason for a certain clustering. This means that HCA 
does not reveal which metabolites are responsible for the differences between clusters.  
K-means is clustering approach has become extensively used in post-genomics, 
especially in analysis of transcriptomic data 156, 158-160. Despite the popularity of k-means 
in many areas, in metabolomics it has not been widely applied. This might be due to the 
fact that there is no associated visualization or diagnostic tool. Although, recent 
applications involving the k-means for metabolomics data have been demonstrated 154, 
161.  
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Lately a method called statistical correlation spectroscopy (STOCSY) 162, 163 has been 
developed to increase the information recovery from complex 1D-NMR metabolomics 
spectra. This method is based on the correlation matrix computed from 1D-NMR 
spectra. The correlation is calculated between all intensities in a set of NMR spectra. In 
this way the connections between signals from molecules that fluctuate in concentration 
between samples can be generated.  By plotting the correlation matrix a graphical 
representation of samples spectra set comparable to that of a 2D correlation NMR 
experiment performed on one sample, namely total correlation spectroscopy (TOCSY).  
STOCSY is combined with supervised techniques to provide the link between relevant 
metabolites 117, 162. STOCSY has been utilized for identification of drug metabolites in 
human urine164. Application of STOCSY to NMR data coupled with Liquid 
Chromatography arising from complex biological mixture has been demonstrated by 
Smith et al. 165. STOCSY approach can be applied to 1D as well as to 2D data and to 
homo or heteronuclear spectral data. Heterospectroscopic-STOCSY takes into account 
a correlation between two different experimental data 166, 167.  
Recently a combination of STOCSY and HCA has been developed, namely cluster 
analysis statistical spectroscopy (CLASSY) 168. This approach has advantages over 
STOCSY, because correlations between the peaks from the same molecule are 
detected with higher accuracy.  
 
1.4.2 Supervised analysis 
Supervised techniques make use of a priori known structure. They use this knowledge to 
learn patterns and rules to predict new data. In these methods the relation between a 
matrix of predictors (i.e. NMR spectra) and a matrix or vector of responses (e.g. class 
membership or enzyme activity) is learnt. Regression is an example of supervised 
approach. In regression the responses are usually continuous parameters, e.g. age, 
blood pressure. Another major type of supervised method is classification in which 
responses are discrete and represented as class membership. In classification one 
searches for a rule that classify the objects into one of several classes. It is important to 
mention that regression and classification are closely related, since most regression 
methods can be used as classification approach. A very important aspect of 
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classification method is validation. Supervised methods are very powerful but it is often 
possible to construct a model which fits the data perfectly, giving 100% correct 
classification even if there is no real relation in the data. This is mostly caused by the 
high dimensionality of the metabolomics data (i.e. there are too many degrees of 
freedom with which the response can be predicted). Therefore validation of the model is 
a very crucial step in classification methods and will be discussed in the section entitled 
Validation. A wide range of methods has been used in metabolomics; here we focus on 
a few of them, i.e. on discriminant techniques. The advantage of these methods is to 
provide information about those variables that indicate differences between two or more 
classes. Therefore they are popular in metabolomics for biomarker discovery studies. 
 
One of the most widely used classification method is Partial Least Squares Discriminant 
Analysis (PLS-DA), which is an alternative of the regression version of this technique, 
namely PLS 169, 170. This technique, similarly to PCA, is a latent variable approach. It 
assumes that the data can be well approximated by a low dimensional subspace, i.e. by 
latent variables, which are assumed to be linear combinations of the original variables. A 
PLS-DA model can be expressed by: 
Model of X: X=TPT + E       
Model of Y: Y=UQT + F   (1) 
where X is an (n x m) matrix of predictors, Y is an (n x p) matrix of responses, T and U 
are an (n x l) matrices of projections of X (the X score) and Y (the Y scores), 
respectively, P and Q are, (m x l) and (p x l) loading matrices, respectively and matrices 
E and F are the error terms, and T indicates transposition. 
The PSL-DA model can be expressed as well as: 
Y=Xb+r     (2) 
Where, X is data matrix, y a vector of group memberships, b a vector of regression 
coefficients and r a vector of model residuals. 
In Figure 4 it is shown how PCA and the PLS-DA model is obtained. As can be seen the 
first PC is constructed in the direction of highest variance in the data, while the first LV in 
the direction explaining the between-class variation of the objects.  
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Figure 4. An illustration of PCA and PLS-DA model for simulated data containing 4 classes 
(pink, red, green and blue circles). 
 
PLS-DA is a latent variable method, therefore it is possible to project the data into this 
new space, showing the relation between samples and variables. PLS-DA is well suited 
for highly correlated variables. Moreover PLS-DA can be used for two classes modeling, 
as well as when more than two classes are available, and then it is called PLS2-DA. In 
metabolomics it has been used in many applications 9, 32, 33, 58, 171.  
The recent modification of PLS-DA is orthogonal PLS-DA (OPLS-DA) 172 in which the 
model is split into two parts. The systematic variations in X are split into two parts, i.e. 
one that is linearly related to response and one that is linearly uncorrelated to response 
(orthogonal).  In that way only variation related to response are used to model it. The 
OPLS-DA model contains two modeled variations, namely the response-predictive 
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(related variation TpCTp) and the response-orthogonal (ToPTo). The OPLS-DA model can 
be expressed as: 
Model X:  X=ToPTo + TpPTp + E 
Model of Y: Y=TpCTp + F 
In terms of prediction power OPLS-DA and PLS-DA are comparable (for the same 
amount of latent variable). However in terms of interpretability the OPLS-DA has 
advantages over standard PLS-DA, since the irrelevant variation is filtered out.  This 
variation unrelated to response is often called structured noise and is caused by 
differences between subjects (e.g. different diet, age, gender). OPLS-DA similarly to 
PLS-DA has been successfully applied to many metabolomics data 117, 162, 173. One has 
to be aware of that OPLS-DA never outperforms PLS-DA 174. Moreover it has been 
shown by Kemsley and Tapp that the splitting of PLS models into y-related and y-
unrelated parts can be obtained from the factorization proposed by Martens 175, 176. It is 
important to mention that this is restricted to PLS1, i.e. when one y-response is 
available. 
 
In the field of pattern recognition methods many other discriminant techniques are 
available to analyze metabolomics datasets. However metabolomic data contain highly 
collinear variables, usually with many more variables than samples. This causes 
problems with many standard pattern recognition methods, e.g. Linear Discriminant 
Analysis (LDA) and Quadratic Discriminant Analysis (QDA) 156, 177-179. Therefore in order 
to use them for metabolomics data special adaptations for high-dimensional data have 
to be undertaken. One possibility is to perform data reduction on beforehand by means 
of PCA. This method is then called Principal Component Discriminant Analysis (PCDA) 
180, 181. Lately a modification of the standard Canonical Variates Analysis (CVA) method 
to cope with collinear high-dimensional data has been developed, namely extended 
CVA (ECVA)  182. This approach can be used as a supervised compression method and 
be used in combination with LDA as a classifier a tool for classification and 
discrimination of collinear data is obtained. LDA is applied to the canonical variates 
obtained from ECVA. This new method was recently used for extracting and 
compressing the information contained in metabolomics and proteomic datasets183 . 
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1.4.2.1 Variable selection  
In metabolomics data many variables are irrelevant or redundant for classification 
purpose and therefore the number of variables can be reduced with minor loss of 
information. It is common to apply variable selection methods to obtain a small panel of 
variables that are related to the response. Variable selection generally improves the 
model accuracy and/or reduction of the model complexity; moreover it can also be 
relevant for reducing the risk of overfitting. It is not straightforward to find a subset of 
relevant variables. An optimal variable selection approach is to perform all combinations 
and select the best subset. This is however rarely doable because of computational 
reasons. Moreover the chance of overfitting is much bigger if the number of variables is 
much higher than the number of samples.  Many variable selection techniques exist. 
They work in different ways and have been developed for many different applications 184.  
The simplest variable selection technique is a univariate approach, where every variable 
is evaluated individually. In these methods statistical values are calculated for each 
variable after testing (e.g. t-statistics) the differences between two classes. The 
disadvantage of these methods is that it is relatively easy to get high correlation by pure 
chance for high-dimensional datasets. To avoid such situation and to control false 
discovery rate multiple testing correction is needed 185, 186. On the contrary to proteomics 
in the metabolomics field these univariate variable selection methods are not very 
popular 48, 187, 188. 
Other popular techniques in metabolomics are multivariate 189-193. Many are incorporated 
with the PLS algorithm (e.g. uninformative variable elimination PLS 194, 195, Cross-model 
Validation PLS 196, 197, backward selection method for PLS 198, iterative PLS 199, interval 
PLS 200, selectivity ratio plot 201. A recent tutorial by Anderssen and Bro gives an 
overview of many variable selection methods with focus on regression-based calibration 
models 202. Analysis of Variance-Principal Component Analysis can also be used for 
variable selection, as well as for classification 203. It has been successfully applied to 
metabolomics data 33.  
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1.4.2.2 Validation of models 
As was mentioned earlier validation is a very important aspect of classification. Note that 
validation is also essential from biological point of view. Properly validated statistical 
models give confidence to the findings (i.e. relevant metabolites). This is significant if the 
results from statistical analysis are used later, for instance in clinical application. If there 
are many more variables than samples it is possible to find by chance a perfect model 
that fits data 204. Therefore it is obligatory to check the model for its predictive ability. 
There are several options for validating a model for predictive performance196, 205, 206. 
Cross-validation and double cross-validation are the preferable ones. Permutation is 
another way of validating the classification model. However validation by an external test 
sets provides a means to establish a more reliable predictive performance of the 
classification model. In order to obtain training and test set the data are partitioned by 
using different approach, e.g. the Duplex algorithm207, Kennard-and-Stone 208, 209 or 
random selection. The test set is then used to validate the classification model. 
Validation can be also performed using a completely new set of samples, coming from 
independent new experiment. This kind of validation is the ultimate one, because it 
allows one to test the outcomes of analysis on different population. Unfortunately such 
validation is rarely applied.  
 
1.4.2.3 Non-linear methods 
Biological processes are very often following a non-linear response. This is due to the 
complex interactions occurring in the many levels of biological organization. Some 
external factors (e.g. diet, medications) may produce metabolic effects that are not 
linearly related to group differences 210. Therefore a number of characteristics in 
metabolic data argue for the consideration of non-linear pattern recognition methods. 
Among many non-linear techniques that have been developed in machine learning and 
pattern recognition area, we will discuss a particular class of non-linear models, i.e. 
kernel-based models (namely Support Vector Machines (SVM) and kernel-PLS). 
Kernel-based models require a kernel transformation which is used beforehand to map 
objects into high dimensional space, called the feature space. By mapping the original 
space of size (n x p, where n is the number of samples and p is the number of variables) 
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into the feature space a kernel matrix is obtained of size (n x n). There are many kernel 
functions that can be used and the choice of kernel transformation is user dependent. 
The kernel matrix is required to be positive semi-definite and there are many kernel 
functions which fulfils this requirement 211. The simplest kernel function is the dot product 
of the data matrix. Another commonly used kernel function is the radial basic function, 
which has a tuning parameter related to the width of the Gaussian. It is important to 
optimize this parameter, since its value has influence on the predictive ability of the 
classification model. An Important aspect of any kernel-based method is the loss of 
variable information (due to the kernel transformation). As mentioned above the kernel 
matrix is of size (n x n, where n is the number of samples).  This causes that the 
information regarding the original input variables is vanished and direct interpretation of 
kernel-based-models is not possible. This weakness of kernel-based-methods was 
recently solved by Krooshof et al. 212 by applying a procedure, based on the non-linear 
biplot principle described by Gower 213. 
 
Note that after kernel transformation any of the above discussed method can be applied. 
Therefore PLS-DA as well as OPLS-DA can be applied to the kernel matrix, leading to 
K-PLS 214, 215 and KO-PLS 216. Another kernel-based method, SVM was introduced in 
the early nineties by Vapnik and coworkers 217. SVM is a powerful, supervised method, 
used for binary classification. This state-of-the-art technique first maps the objects into 
feature space then tries to find a hyperplane which separates the data into its two 
classes. SVM uses a set of objects, so called support vectors, which span the range of 
the separating hyperplane. Kernel-based methods have been applied in many areas 
also in metabolomics studies 218-222.  
 
1.4.3 Data fusion 
It is common to study a single system, for instance a disease, by using different 
analytical platforms. Therefore in the last decade data concatenation or data fusion has 
become widespread in the field of metabolomics. Data fusion is an approach that 
combines data from different sources into a single and more complete description. Each 
analytical technology demonstrates different strengths and limitations regarding its 
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capability to distinguish between different biological conditions or to measure 
metabolites, depending upon factors such as sensitivity, sample preparation, analytical 
stability, and analytical reproducibility. The joint use of two or more analytical 
technologies gives then a more robust strategy for data analysis than the use of a single 
platform.  
Different strategies for data fusion have been described by Hall et al. 223. Three 
approaches for concatenating data can be distinguished, namely low-level, mid-level 
and high-level 224, 225. In low-level fusion, different data sources are concatenated at the 
data level. All measured variables (or absolute metabolite concentrations) are put next to 
each other. This strategy is the simplest and the most straightforward. In the mid-level 
fusion, data from different sources are first treated separately for pre-processing and 
variable selection. Next the most optimal set of variables are concatenated into a single 
set. Note that datasets can be combined at the latent variables level. In high-level data 
fusion, different model responses (for instance prediction for each available data set) are 
joined to produce a final response. In high-level data fusion the individual results are 
usually weighted 226. This kind of data fusion has two pitfalls, first interpretation of the 
model results is difficult and second it does not take into account correlation between 
measurements in different data sources. In low-level and midlevel data fusion the 
information about relevant metabolites can be easily determined. The choice of strategy 
for data fusion depends on the goal of the study 227. The overview of different intra and 
inter-omics data integration can be found in 228. 
It is also possible to fuse the datasets in a kernel space. In this approach the different 
sources of data are first mapped into a kernel space. The obtained kernel matrixes are 
then concatenated by linear combination 123, 229. This kernel fusion falls outside the 
range of the classical low-, mid- and high-level fusion. 
It is possible to perform data integration on pathway level.  Using known metabolic 
pathway, data from multiple omics platforms are incorporated. This provides a more 
global investigation of a studied problem. 
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1.5 METABOLOMICS ANALYSIS of CSF by NMR 
Metabolomics plays significant role in the discovery of biomarkers (or risk factors) 
connected with particular disorders. Many metabolomic studies are based on animal 
models, where inter-animal variations are limited, or directly in humans. The 
concentrations and fluxes of individual metabolites are the final product of interactions 
between gene, protein and cellular environment. Thus information delivered by 
metabolomics is complementary to other omics related fields. The metabolic fingerprints 
of biofluids obtained by NMR contain many signals related to both genetic and 
environmental contributions 4, 24, 230. An important benefit of metabolic profiling for 
biomarker discovery is that metabolites are defined chemicals irrespective of species, 
genotype. Because many metabolites are not dependent on species, they can form the 
basis for translational study, i.e. biomarkers that are found in preclinical (animal) studies 
can be applied during clinical studies. A single biomarker found in metabolomics will not 
capture the complex process underlying a disease. Therefore, it is common practice to 
look at the perturbations in biological pathways and networks. This allows overall 
understanding of the metabolism and/or metabolic dynamics associated with the 
disease. Biomarker discovery is not a small task and typically requires years of 
validation before the clinical application phase is reached. An ideal biomarker should be 
sensitive, predictive, measureable in an easy accessible biofluid and cost effective 231. 
The relevance of metabolomics is reflected by the fact that  over 95% of diagnostic 
clinical assays look for small molecules, 89% of known drugs are small molecules, 50 % 
of all drugs are derived from pre-existing metabolites, and 30% of identified genetic 
disorders involve disease of small molecules metabolism 15. A number of complex 
diseases result from a chronic imbalance of normal metabolism (e.g. cancer or type 2 
diabetes) 232. Therefore, metabolomics can be useful for finding biomarkers of 
pathological states.  
 
1.5.1 Metabolomics profile of CSF of “healthy” control 
The number of studies that use CSF for finding new metabolic biomarkers has been 
increasing. However, only a limited number of works focused on inspecting variations 
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occurring in CSF of individuals with no neurological disorders (i.e. “healthy” control). 
Nevertheless, it is very important to establish a comprehensive list of metabolites 
detectable in CSF and the corresponding variations.  A proper understanding of 
biological fluctuation of metabolites concentrations in CSF of subjects considered as 
neurologically normal is crucial for trustworthy interpretation of the results in biomarker 
discovery studies. It is important to investigate if the variations between control and 
disease are caused by disease and not by inter-individual fluctuations. In the study of 
Jukarainen et al. 1H-NMR has been used to obtain the absolute quantification of 
metabolites in CSF of 45 neurological controls 233. The neurological controls chosen in 
the study consisted of patients examined for various neuropsychiatric symptoms, such 
as depression or headache but who did not give any signs of dementia and chronic 
neurological disease. The authors detected large inter-individual variations in 
metabolites concentration. In another study, Wishart et al. investigated the absolute 
concentration of metabolites identified in CSF by NMR and mass spectrometry in 35 
individuals screened for meningitis 234. Similar to the previous study they found 
considerable inter-individual variations. Wishart et al. reported that “normal” 
concentrations for many metabolites can vary by more than 50%. Moreover, they 
concluded that NMR appears to be the most suitable method for performing non-
targeted metabolic profiling of CSF. Metabolic profile of CSF of controls has been 
investigated by Kolokolova et al. 48. In this study, NMR was used to quantify in total 25 
metabolites identified in human CSF. The absolute metabolites concentrations in CSF of 
controls were compared to metabolites level of patients suffering from motor neuron 
disease and ischemic stroke. The final findings indicated that patients with ischemic 
stroke had higher concentration for 19 CSF metabolites in comparison to controls. 
In a recent comprehensive study by Stoop et al., 47CSF samples of patients without 
neurological disease were investigated. Broad analysis of metabolite and protein 
concentrations, biological variation and analytical variations has been investigated in 32 
human CSF samples by means of NMR and MS. Moreover, the effects of age and 
gender on biological variations were also addressed and found to be insignificant. 
Biological variations of metabolites identified by NMR and/or MS are reported to 
fluctuate from 15 % to 70% for the majority of metabolites. The analytical variations were 
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smaller than the biological variation in all cases. For NMR analysis the biological 
variation ranged from 8% to 53%, while the analytical error was between 2% and 9% for 
all metabolites. It should be pointed out that the biological variation found in Stoop et al. 
study was lower than in study published by Wishart et al. 232. This difference is mostly 
due to the type of CSF samples used. The biological variations of CSF of “healthy 
controls” were also compared with fluctuations occurring in CSF of subjects with 
neurological diseases. Most interestingly, for a significant number of metabolites, the 
biological variation in diseased subjects are similar to that of normal controls, indicating 
that part of the CSF metabolome is more influenced by inter-individual differences and 
that the contribution of the diseases is only minor. Overall, it can be concluded that an 
understanding of the biological variation of metabolites in CSF of neurologically normal 
individuals is critical for a trustworthy interpretation of biomarker discovery studies for 
CNS disorders.  
 
1.5.2. Metabolomics biomarkers by means of NMR  
One promise of NMR is the identification of biomarkers in biofluids for early diagnosis. 
Metabolomics has the potential to show early biochemical changes in disease and thus 
gives a chance to develop biomarkers that can trigger early interventions (i.e. before 
symptoms are observable). Metabolic profiling of blood plasma, urine and CSF by 
means of NMR and chemometrics has been used effectively in clinical research for the 
studying a wide range of diseases. For instance plasma or serum samples have been 
used to evaluate lipids metabolism in obese patients 235, to detect pancreatic cancer 6 
and to detect coronary heart disease and predict the severity of this disease 236. While 
urine samples have been used to detect inborn metabolic diseases 14, the efficacy of 
immunosuppressant in renal transplant 237, for investigation of physiological 
perturbations during radiation sickness 56, bladder cancer 238, the effect of acute 
cysteamine supplementation 239 and dysfunction in peroxisomal proliferation 240. More 
examples of using NMR for identifications of potential biomarkers in cancer, heart 
disease, diabetes, neurological disease and asthma can be found in the following 
references 4, 6, 8, 32, 241-244. Each of these metabolic profiling studies was able to describe 
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an accurate relationship between the biofluid metabolic spectral patterns and a disease 
state in humans.  
Finally, CSF has been used for studying a variety of neurological diseases, e.g. the 
detection of meningitis 245 and ventriculitis 246, Huntington disease 103. Metabolic profiling 
of CSF has been conducted to distinguish first-onset schizophrenia patients from healthy 
controls 26. CSF was also utilized to diagnose differentially viral, bacterial meningitis and 
tuberculosis in children247. Using an NMR-based metabolomics approach, it has been 
possible to investigate HIV-1-infected individuals, who are known to be susceptible to 
neuropsychological dysfunction166. In the study by Blasco et al. NMR-based 
metabolomic profiling of CSF in combination with PCA was used to find biomarkers of 
early amyotrophic lateral sclerosis 11. Another recent study used NMR spectroscopy to 
identify CSF biomarkers for early diagnosis of Alzheimer’s disease 27.  
 
1.6 METABOLOMICS BIOMARKER STUDIES in MScl 
MScl is a common disease of CNS which is an inflammatory, presumably autoimmune 
disease in which the fatty myelin sheaths which surrounds the axons of the brain and 
spinal cord are damaged, leading to demyelization. MScl can usually be diagnosed 
based on clinical examination, CSF analysis, observation from MRI and patient's history. 
Nevertheless, often, abnormalities found in the CSF and supported by MRI findings are 
not specific and sufficient enough. Many diseases can mimic conditions characteristic for 
MScl causing a rate of misdiagnosis of approximately 5%. An overview about different 
diagnosis in MScl can be found in 248-252. Recently, new diagnostics criteria for MScl 
have been introduced 253. Two factors, genetic and environmental, have influence on the 
risk and course of MScl. However, there is still uncertainty on aetiology and 
pathogenesis of MScl. MScl lesions are rarely biopsied. Therefore, there is an urgent 
need for new biological markers measured in CSF to better diagnose MScl. Many efforts 
have been made to develop such a better diagnostic for this heterogeneous disease 254.  
Magnetic Resonance Techniques, 1H-NMR and Magnetic Resonance Imaging and 
Spectroscopy (MRI/MRS), are commonly used to investigate MScl disease. 1H-NMR is 
used to obtain metabolic profiles characteristic of distinct MScl manifestations, while 
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MRI/MRD is mostly employed for looking at plaques and lesions in the brain. In spite of 
1H in vivo Magnetic Resonance Spectroscopy (MRS) has been widely used to 
investigate the metabolic alterations occurring in the brain of MScl patients 255-260, it is 
important to notice that there are limited amount of studies where CSF of MScl is 
investigated by NMR. 1H in vivo MRS spectra of MScl revealed increased lactate, 
choline, inositol and acetate level and decreased concentration of N-acetylaspartae, 
CSF is mostly used to study metabolic malfunctions occurring in MScl patients. 
However, there are some studies where blood plasma and urine are used to find 
metabolic differences between MScl patients and controls 32, 261. MScl can be studied 
either in pre-clinical models, e.g. the Experimental Autoimmune Encephalomyelitis 
(EAE) model or directly in humans. Until now there are only three studies reported 
where CSF of EAE animals is investigated by means of NMR 33, 183, 262. We focus on the 
studies where 1H-NMR of CSF was utilized. 
Glucose concentrations have been measured in the CSF of MScl patients for diagnostic 
purpose before metabolomics was used to investigate MScl. Later it turned out that in 
most MScl patients the glucose concentration was normal 28.  Presently various clinical 
and pre-clinical metabolic studies have been carried out to characterize MScl. The first 
NMR studies of metabolic profile of CSF of MScl patients consisted of finding the 
differences between MScl patients and controls without using pattern recognition 
methods. Most of the NMR-based studies focus on absolute metabolite concentrations 
or ratios. One of the first NMR study of metabolic profiles of CSF of MScl patients was 
published by Lynch et al. in 1993, where a relatively big group size was investigated, i.e. 
30 MScl patients and 27 controls 263. In this study an unidentified N-methyl compound 
was found in MScl patients and increased acetate level and decreased formate 
concentration in comparison to controls. Few years later Nicoli et al. 30 have reported 
significant change in concentrations of several unidentified resonances in NMR spectra 
of CSF in MScl patients. Moreover, they found that some metabolites are slightly 
modified in MScl patients, i.e. increased lactate and fructose concentrations, decreased 
creatinine and phenylalanine concentrations. They reported as well that metabolic profile 
of CSF does not allow one to differentiate relapsing-remitting MScl and primary 
progressive MScl. This study 30 did not confirm the reduced formate level reported by 
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Lynch et al. Simone et al. 264 report increased ratios of lactate/creatine and 
acetate/creatine and reduced ratio of formate/creatine. Minor differences in lactate and 
acetate ratios were detected between RR-MScl and chronic progressive MScl. Later 
Simone et al. 265 have shown that the increased ratio of lactate/creatine is directly 
related to elevated level of lactate of demyelinating MScl plaques. In contrast to previous 
findings, in the study of Aasly et al. 266 the level of lactate in MScl patients was found to 
be down regulated.  
Next a study where NMR was used to find markers of MScl in CSF was published by 
Lutz et al. in 2007 45. A highly homogenous patient group was used to characterize 
metabolic profile of MScl patients with and without inflammatory plaques. They 
demonstrated that there is a correlation between β-hydroxyisobutyrate (BHIB) 267 
concentration and the presence of active inflammatory plaques. Lactate and BHIB 
concentrations were found to be elevated in CSF of MScl patients. In the same study, 
differences between clinically isolated syndromes (CIS) without any inflammatory 
plaques and controls were investigated. Small differences in fructose concentration were 
discovered. Lutz et al. 45 have shown PCA results obtained for different metabolites 
concentration. This is the first study, where pattern recognition methods are applied to 
NMR spectra of CSF of MScl patients. The PCA score plots demonstrate some groups 
clustering but hampered by some overlapping.  
In Sinclair et al. 32, the potential of CSF NMR spectroscopy is combined with supervised 
analysis to find differences among MScl, idiopathic intracranial and hypertension 
patients. This is the first study where relative metabolite concentrations are investigated 
instead of absolute ones. By using PLS-DA, the sensitivity and specificity for MScl group 
was 83% and 53%, respectively. These results indicate that the obtained classification 
model is not specific enough for MScl, since almost half of the other patients were 
classified as MScl. Several significant changes in metabolites concentration in MScl 
patients were found, namely elevated levels of 2-aminobutyrate, 1,3-dimethylurrate, 
glutamate and acetate, and reduced levels of oxaloacetate, citrate, alanine and 3-
hydroxybutyrate. 
Another study applying pattern recognition, namely decision-tree-fuzzy classifier, by 
Aymerich et al. 245 investigated differences in metabolic profile of RR-MScl (8 patients), 
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PP-MScl (7 patients) and patients with other neurological disease (7 individuals. They 
focus on spectral regions with poor signal to noise ratio (i.e. between 6.0 and 9.7ppm). 
Excellent classification efficiency for cross validation was obtained.  Due to the small 
groups size they did not present classification accuracy for independent test set. The 
relevant metabolites are not specified. The results presented by Aymerich et al. are 
promising, but it should be kept in mind that the study was performed on a small patient 
group.   
In the last study described here, a novel approach for data fusion is applied to 
metabolomics datasets coming from patients suffering from MScl disease 123. In this 
study, metabolic profiles of MScl patients are compared with CIS patients. The K-PLS-
DA was used as classification model. The overall correct classification obtained for K-
PLS-DA model of NMR data was 92.86% for the test set (one MScl sample was 
classified as CIS).  A number of metabolites have been found as changing during 
progression of disease, e.g. the levels of lactate and of valine both increase, while the 
concentration of glutamine and citrate is reduced with disease progression. The high 
level of correct classification is very promising.  However, the limitation is the relatively 
small number of studied patients (26 for MScl and 20 for CIS) and obviously, before 
usage in clinical practice, validation studies with larger number of patients is needed.  
To summarize, the changes in several metabolites concentration in CSF were identified 
as related to MScl. Elevated lactate level and reduced acetate level in CSF of MScl 
patients were found in most studies. However, there was only one study where lactate 
concentration was found as being down regulated in CSF of MScl patients. Creatinine, 
oxaloacetate, alanine, citrate, glutamine and 3-hydroxybutyrate and phenylalanine 
concentrations have been reported to be decreased in CSF of MScl patients, while 2-
aminobutyrate, 1,3-dimethylurrate and glutamate elevated. Interestingly, reduced 
alanine and citrate concentrations have been found in CSF of EAE affected animals 33.  
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1.7 CONCLUSIONS 
In this review, a complete overview of the main steps involved in acquiring NMR spectra 
of biofluids, data preprocessing and modeling of NMR metabolic profiles is given. We 
have described the most commonly used techniques for acquiring NMR spectra of 
biofluids and presented an NMR-based metabolomics for CSF. Moreover different steps 
of data preprocessing and data analysis are described.  
Metabolomics represents a major and rapidly evolving field.  The development of NMR 
experiments allows for accurate measuring of many metabolites in different biofluids. 
The versatility of NMR has enabled this analytical technique to make valuable 
contributions to biomarker discovery in metabolomics field of biofluids. The application of 
NMR to the study of MScl disease is increasing. We have demonstrated several studies 
where several differences in the biochemical composition of CSF between MScl patients 
and controls were found. However, there are some discrepancies between the findings. 
There are several reasons why the results may differ. The most straightforward one may 
originate from the various sample preparations and acquisition methods.  Another 
reason is connected to variation in CSF composition which may be dependent on the 
MScl patients used in the study.  
Biomarker discovery by means of NMR of CSF in combination with pattern recognition 
techniques is likely to make an increasing contribution in uncovering disease 
mechanisms of complex neurological disease, like MScl. Collectively, NMR and pattern 
recognition methods offer great promise for the identification of clinically relevant 
biomarkers.  
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ABSTRACT 
BACKGROUND: Cerebrospinal fluid is in close contact with diseased areas in 
neurological disorders and is therefore an important source of material in the search for 
molecular biomarkers. CSF is withdrawn from patients in a clinical setting where sample 
handling might not always be adequate in view of proteomics and metabolomics studies. 
To study the effect of a time delay between sampling and freezing, we have performed a 
combined proteomics and metabolomics study.  
METHODS: CSF was left for 0, 30 and 120 min at room temperature directly after 
sample collection and centrifugation/removal of the cell pellet. CSF samples were 
analyzed at five separate laboratories using five different analytical platforms. The 
techniques used for proteome analysis were nanoLC Orbitrap-MS and chipLC QTOF-
MS after tryptic digestion. Metabolome analysis was performed by NMR, GC-MS, and 
LC-MS. Targeted analyses of Cystatin C and Albumin were performed by LC-MS/MS in 
the selected reaction monitoring mode. 
RESULTS: Our results show that storage of CSF at room temperature after 
centrifugation does not lead to significant changes in the measured proteome and 
metabolome except for two peptides and one metabolite 2,3,4-trihydrobutanoic acid 
among 5780 identified peptides and 93 identified metabolites. A sensitive protein 
stability marker, Cystatin C, was not affected.  
CONCLUSIONS: The measured proteome/metabolome profile of centrifuged, human 
CSF with all cells removed is stable at room temperature for up to two hours. This gives 
the laboratory personnel at the collection site sufficient time to aliquot samples before 
freezing and storage at -80 °C. 
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2.1 INTRODUCTION 
Conditions during the journey of a biological sample from the clinical collection site to the 
analytical research laboratory might not always be adequate for subsequent proteomics 
and metabolomics analyses, especially in cases where the sample collection was not 
originally performed with these large-scale analyses in mind. In order to detect reliable 
molecular biomarkers it is imperative to handle biological fluids according to 
standardized procedures and to evaluate the effect of pre-analytical parameters on the 
final result to avoid artifacts 1, 2. Earlier studies on urine, plasma and cerebrospinal fluid 
(CSF) have shown that sample handling can affect the stability of proteins as well as 
metabolites 3-11. Sample handling according to standardized procedures is also 
important when trying to compare results between different laboratories 12-14. In the 
search for molecular biomarkers related to disorders of the central nervous system, CSF 
is the most promising bio-fluid because of its close contact to the affected tissue 13, 15-20. 
In this study we analyzed a set of human CSF samples in order to assess protein and 
metabolite stability at room temperature after a low-speed centrifugation step to remove 
cells. To cover a wide range of proteins and metabolites, the results from a number of 
analytical platforms comprising LC-MS, GC-MS and NMR were combined. 
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2.2 MATERIALS and METHODS 
2.2.1 Sample set  
Six human CSF samples were obtained from the Department of Neurology at the 
Erasmus University Medical Center (Rotterdam, The Netherlands). The CSF samples 
were collected as part of routine clinical examination of patients with various symptoms 
(Table 1). All samples were withdrawn via lumbar puncture between the 3rd and 4th 
lumbar vertebrae using a Spinocan needle (0.90 × 88 mm). The Medical Ethical 
Committee of the Erasmus University Medical Center (Rotterdam, The Netherlands) 
approved the study protocol and all patients gave their informed consent. Samples were 
centrifuged (10 min at 956 g) within five minutes after collection to remove cells. Aliquots 
were directly snap-frozen in liquid nitrogen or left at room temperature for 30 and 120 
min before snap freezing and storage at -80 °C. Routine CSF diagnostics including total 
protein and albumin concentration measurements as well as intrathecal cell count were 
performed and absence of hemoglobin and apolipoprotein B100 was assured to 
eliminate the possibility that samples were contaminated with blood. Sample H1 was 
analyzed by the chipLC QTOF-MS and the nanoLC Orbitrap-MS/MS platforms only. 
Samples H2 - H6 were analyzed by all platforms. Protein digestion for proteomic 
analysis was performed as previously described 21. Before analysis on each platform the 
samples were exposed to two freeze-thaw cycles. 
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Table 1. Description of CSF samples used for stability studies.1 
Sample Age Gender Diagnosis Protein 
conc. 
(mg/L) 
Albumine 
conc. 
(mg/L) 
Clinic 
Albumine 
conc. 
(mg/L) 
SRM2 
# Cells/ μL 
(after 
centrifugation) 
H1 49 M Migraine 415 193 192.3 0 
H2 56 M Idiopathic 
intracranial 
hypertension 
472 247 237.5 0 
H3 69 F Headache 395 236 221.0 0 
H4 48 M Idiopathic 
intracranial 
hypertension 
436 241 225.6 0 
H5 29 F Clinical isolated 
syndrome 
(Neuromyelitis 
optica) 
387 226 213.9 0 
H6 38 F Epilepsy 381 184 194.2 0 
1 Sample H1 was only analyzed with respect to proteomics 
2 Average over 3 time points (supplementary Table S4). 
 
 
2.2.2 ChipLC QTOF-MS proteomic analysis 
Half a microliter trypsin-digested CSF was randomly injected in quintuplicate with 0.5 μL 
digested QC samples (pooled CSF spiked with cytochrome C; Fluka, part # 30396, final 
concentration: 375 fmol/μL) and blanks injected between every 10th sample for LC-MS 
analysis on an Agilent chipLC QTOF-MS system as reported previously 21. Enrichment 
and separation was done using an LC chip (G4240-63001 SPQ110, Agilent 
Technologies [separation column: 150 mm × 75 μm Zorbax 300SB-C18, 5 μm; trap 
column: 160 nL Zorbax 300SB-C18, 5 μm]). The LC separations were carried out as 
described earlier using the following gradient:  80 min linear gradient from 3 to 40% B; 
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10 min linear gradient from 40 to 50% B; 10 min linear gradient from 50 to 3% B 21. MS 
analysis was performed under the following conditions; mass range: 200-2000 m/z in 
profile mode, acquisition rate: 1 spectrum/s, fragmentor voltage: 175 V, skimmer 
voltage: 65 V, OCT 1 RF Vpp: 750 V. The spray voltage was ~1800 V and the drying 
gas (N2) was 6 L/min at a temperature of 325 ºC. Mass correction was done for each 
spectrum using internal standards (methyl stearate m/z: 299.294457 and HP-1221 m/z: 
1221.990637) evaporating from a wetted wick inside the spray chamber. Reproducibility 
was monitored on selected cytochrome C peaks in the QC samples. Mass difference 
between theoretical and measured values was within +/- 4 ppm. The selected peaks 
showed a peak area RSD of less than +/- 20% and a retention time (RT) RSD of less 
than 2%. 
Data was processed using a pipeline developed in C++ as previously described 21, 22. 
MzData.XML data were converted to ASCII format over a mass range of 200 to 1600 
m/z (no multiply charged peptide ions were detected outside this range), a retention time 
range of 3 to 80 min (peptide elution range) and an intensity threshold of 300 counts. A 
double cross validated Nearest Shrunken Centroid (NSC) algorithm was applied to the 
complete peak matrix; the NSC comparison gives a cross validation error between 0 and 
1 depending on the shrinkage value, where 1 implies that class assignment is incorrect, 
0.5 that class assignment is random and 0 that class assignment is correct 23. NSC 
selected features were compared by univariate statistical analysis (Student’s t-test with 
Bonferroni correction for multiple comparisons) and ANOVA (Microsoft Excel 2007 and 
SPSS 16.0). Features were considered significantly different based on a p-value below 
0.05 (T0 vs. T120 and T0 vs. T30) in at least five out of six samples (T0 vs. T120 and T0 
vs. T30). Each discriminatory feature was analyzed by targeted tandem MS for 
identification. Principal component analysis (PCA) 24 was applied to the complete peak 
matrix (10 000 peaks) as well as to the NSC-selected features (MatLab, R2009a). For 
visualization, box and whisker plots were created in Origin 7.0. 
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2.2.3 Nano LC ORBITRAP-MS/MS SHOTGUN proteomics analysis 
Trypsin-digested CSF samples were injected in random order and analyzed by MS/MS 
(shotgun approach) on an Ultimate 3000 nano LC system (Dionex, the Netherlands) 
online coupled to a hybrid linear ion trap/Orbitrap mass spectrometer (LTQ Orbitrap XL; 
Thermo Fisher Scientific, Bremen, Germany) as previously described 21. 
Data files were analyzed and pre-processed using the Progenesis LC-MS software 
package (Nonlinear Dynamics, United Kingdom). Retention times were aligned and the 
intensities of the ions were normalized. To assess inter-patient variability all identified 
peaks were analyzed by PCA. All identified peaks were also analyzed by the NSC 
algorithm for classification 23. Peptides were analyzed for differential abundance 
between the groups by ANOVA. P-values below 0.01 were considered significant.  
All MS/MS spectra were searched against the UniProt/SwissProt database (version 
57.6, taxonomy: Homo sapiens, 20070 sequences) using Mascot (version 2.2.06). 
Search parameters were; parent ion tolerance: 2 ppm, amino acid modifications: 
carbamidomethylation of cysteine (fixed) and oxidation of methionine (variable).  
 
2.2.4 Nano LC-MS/MS Analyses in the selected reaction monitoring (SRM) mode  
Trypsin-digested CSF samples were spiked with known concentrations of stable isotope-
labeled peptide standards corresponding to sequences 427-434 (FQNALLVR) of human 
serum albumin and 52-62 (ALDFAVGEYNK) of human cystatin C for quantitation by 
Selected Reaction Monitoring (SRM) (supplementary Table S1 and S2).  
Chromatographic separation of spiked CSF digests, was performed on an Ultimate 3000 
nano LC system (Dionex). One microliter of spiked CSF digest was loaded onto a C18 
trap column (PepMap C18, 300 μm ID x 5mm, 5 μm particle size and 100 Å pore size; 
Dionex, the Netherlands) and washed for 5 min at a flow rate of 20 μL/min 0.1% TFA in 
H2O. Next, the trap column was switched in line with the analytical column (PepMap 
C18, 75 μm ID x 150 mm, 3 μm particle size and 100 Å pore size; Dionex). Peptides 
were eluted at a flow rate of 300 nL/min with the following gradient: 0-45% solvent B in 
30 min, solvent A (H2O/acetonitrile (ACN) 98/2 (v/v), 0.1% formic acid (FA)) and solvent 
B (H2O/ACN 20/80 (v/v), 0.1% FA). The separation of the peptides was monitored at 214 
nm. 
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SRM detection was performed by means of a triple quadrupole tandem mass 
spectrometer (4000 QTRAP; AB SCIEX, Concord, Ontario, Canada) in the positive ion 
mode. As technical control for the measurements, a single spiked CSF digest was 
measured after every 6th run. A technical control for the enzymatic digestion (one 
sample digested at three separate times) was included in this quantitative analysis. Data 
Analysis was performed using the SRM data analysis program Skyline (version 0.7) 25, 
using the ratio of the analyte peptide to the known concentration of the spiked 
isotopically labelled internal peptide standard to calculate the concentrations of the 
original peptides. For the cystatin C peptide the average of both fragment ion ratios was 
used for the determination of the protein concentration. A paired, two-sided t-test was 
used to test for differences in peptide concentrations between time points.  
 
2.2.5 GC-MS metabolomics analysis 
CSF samples were treated with an oximation reagent followed by silylation prior to GC-
MS analysis 21, 26. Each sample was injected twice in random order and analyzed on an 
Agilent 6890 gas chromatograph coupled to an Agilent 5973 quadrupole mass 
spectrometer as described earlier 21.  
Peaks were characterized by retention time and m/z ratio and identified by comparison 
with a spectral data base (TNO) 21. All detected metabolites were analyzed by PCA. A 
two tailed Student’s t-test was applied to all known metabolites (T0 vs. T30 and T0 vs. 
T120). Metabolites with a p-value below 0.05 were considered significantly affected by 
storage time. 
 
2.2.6 NMR metabolomics analysis 
Samples were randomized prior to sample preparation and analysis. Fifty microliters of 
CSF were diluted in 200 μL of D2O (99.99 % D). Twenty-five μL of 8.8 mM TSP-d4 (3-
(Trimethylsilyl)propionic acid-d4 sodium salt, 99 % D) stock solution in D2O were added 
to 250 μL CSF to a final concentration of 0.8 mM TSP as internal standard and as 
chemical shift reference (δ0.00). The TSP-d4 stock solution was prepared from dry TSP-
d4. The pH was adjusted (7.0 – 7.1) by adding phosphate buffer (9.7 μL of a 1 M stock 
solution) to a final concentration of 35 mM 27. Finally the sample (284.7 μL) was 
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transferred to a SHIGEMI microcell NMR tube for measurements. Each sample was 
analyzed once. 
1D 1H NMR spectra were acquired on an 800 MHz Inova (Varian) system equipped with 
a 5 mm triple-resonance, Z-gradient HCN cold-probe.  Suppression of water was 
achieved using WATERGATE (delay: 85 Ps) 28. For each spectrum 256 scans of 18000 
data points were accumulated with a spectral width of 9000 Hz. The acquisition time for 
each scan was 2 s. An 8 s relaxation delay was employed between scans. Prior to 
spectral analysis, all acquired Free Induction Decays (FIDs) were zero-filled to 32000 
data points, multiplied with a 0.3 Hz line broadening function, Fourier transformed and 
manually phased. Calibration of the chemical shift scale was done on the external 
reference standard TSP-d4 by using ACD/SpecManager software (Advanced Chemistry 
Development Inc., Toronto, Canada). Spectra were transformed to MatLab, version 7.6 
(R2008b) (Mathworks, Natick, MA) for further analysis.  
NMR spectral data was preprocessed by baseline correction using the Asymmetric 
Least Squares method 29 and aligned with the Correlation Optimized Warping (COW) 
method 30. Each spectrum was divided (along the chemical shift axis) into equally sized 
bins (0.04 ppm) and each data point was averaged over each bin. The areas of the bins 
were summed to provide an integral so that the intensities of the peaks in such defined 
spectral regions were extracted. Each NMR spectrum was reduced to 210 variables, 
calculated by integrating regions of equal width (0.04 ppm) corresponding to the regions 
of δ0.7-9. To remove effects of variation in water resonance suppression, spectral 
regions between δ4.4-5.4 were removed. All spectra thus reduced were normalized to 
unit area. 
The data was further processed by supervised vast scaling, in order to determine group-
specific scaling factors 31. To visualize possible systematic variation, grouping, trends 
and outliers, PCA was applied to the entire data set.  To remove biological (patient-to-
patient) variation, data was further mean-centered per patient and vast-scaled (see 
supplementary Fig. S1). 
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2.2.7 LC-MS/MS amino acid analysis  
CSF samples were prepared in triplicate as previously described (21). One microliter of 
each reaction mixture was injected in duplicate on an ACQUITY UPLCTM system 
(Waters Chromatography B.V., Etten-Leur, The Netherlands) coupled to a Quattro 
Premier Xe tandem quadrupole mass spectrometer (Waters Corporation) operated 
under the MassLynx data acquisition software (version 4.1; Waters). Quantification and 
pre-analysis of the data was done using LC-QuanLynx (Waters) and Microsoft Excel 
2003, respectively. The complete set of amino acids in all samples was examined by 
PCA. The data was analyzed by a two-tailed Student’s t-test (T0 vs. T30 and T0 vs. 
T120) and amino acids with p-values below 0.05 were considered discriminatory. 
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2.3 RESULTS 
2.3.1 Proteomics analysis  
The Orbitrap-MS/MS shotgun analysis resulted in a list of 55421 peaks out of which 
5780 peptides were identified. All identified peptides from the Orbitrap-MS/MS data and 
the 10000 most intense QTOF-MS peaks (complete peak matrix) were used for 
unsupervised multivariate statistical analysis (PCA). No trend with respect to delay 
before storage was visible (Fig. 1A and 2A). PCA showed that biological variation was 
more prominent than the effect of delay time, since data points clustered according to 
the individual patients rather than according to time points (Fig. 1B-D and 2B-D).  
 
 
Figure 1. Multivariate statistical analysis (PCA) of the 10.000 most intense peaks selected from 
the chipLC QTOF-MS proteomic data (quintuplicate sample analysis).  There is no separation 
based on time between sampling and freezing (T0 [▼] / T30 [ ٭] / T120 [O]), while data from 
individual samples cluster together indicating that the inter-individual differences are larger than 
those related to time. (A) All samples. (B) Samples H2 (٭) and H5 (■). (C) Samples H1 (+) and 
H6 (▲). (D) Samples H3 (x) and H4 (♦). 
 
Comparison of the Orbitrap-MS/MS data by ANOVA according to delay time resulted in 
only 56 peaks with a p-value below 0.01, which is well below 554, the number of peaks 
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that would receive this p-value when comparing samples containing no differences (null 
hypothesis). NSC analysis pointed also to only random differences between the time 
groups with a cross validation error of 0.5. This lead to the conclusion that there was no 
significant discrimination between the samples stored at -80 °C immediately after 
centrifugation and samples left at room temperature for 30 or 120 min prior to being 
frozen and stored based on the observed peptides.  
 
 
Figure 2. Multivariate statistical analysis (PCA) of 5780 identified peaks from nanoLC Orbitrap-
MS/MS proteomic data (single sample analyses). There is no separation based on time between 
sampling and freezing (T0 [▼] / T30 [٭] / T120 [O]), while data from individual samples cluster 
together indicating that the inter-individual differences are larger than those related to time. (A) 
All samples, (B) Samples H2 [٭]) and H5 (■). (C) Samples H1 (+) and H6 (▲). (D) Samples H3 
(x) and H4 (♦) 
 
NSC analysis of the QTOF-MS data confirmed that differences between T0 and T120 
were random, with a double cross validation error of 0.5. Comparison of T0 versus T30 
by NSC reached a minimal average cross validation error of 0.34. PCA on the NSC-
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selected peaks (T0 vs. T30) from the QTOF data showed no clear discrimination but a 
weak tendency of clustering according to time groups (Fig. 3A). 
 
 
Figure 3. Multivariate statistical analysis by PCA based on NSC-selected peaks derived from 
chipLC QTOF-MS proteomics data (T0 [▼] vs. T30 [٭]). (B and C) and univariate statistical 
analysis of two peaks that decreased significantly with respect to delay time between CSF 
sampling and freezing at room temperature. Data are represented as box and whisker plots with 
significant p-values marked (p < 5 x 10-5) (T0 vs. T30 and T0 vs. T120). (A) PCA of NSC-
selected peaks for T0 vs. T30. (B) Peak at m/z: 656.335 that decreased significantly after 30 and 
120 min at room temperature. (C) Peak at m/z 736.383 that decreased significantly after 30 and 
120 min at room temperature. The statistical analysis was based on two-tailed Students t-tests 
with Bonferroni correction of the combined data from five repetitive analyses of six human CSF 
samples (H1-H6). 
 
The concentration of two proteins in CSF, albumin and cystatin C, were determined by 
targeted mass spectrometric analysis in the SRM mode. These proteins are exemplary 
of the vast majority of CSF proteins, which we found to remain unchanged after 120 min 
at room temperature. Albumin was chosen as it represents the largest part of CSF total 
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protein, a parameter that is often used in CSF-based clinical diagnostics, and Cystatin C 
was chosen as a protein that is sensitive to storage conditions1, 2 .  Concentrations of 
cystatin C and albumin were calculated based on the measured ratios of the 
corresponding spiked isotopically labeled internal peptide standards to their biological 
counterparts, confirming that variation between different time points was not statistically 
significant (supplementary Tables S3 and S4). The measured concentrations of both 
proteins were both found to agree with reported CSF concentrations 32, 33.The albumin 
concentrations measured by SRM were also in agreement with albumin concentrations 
measured by standard clinical chemistry techniques (Table 1). Additionally, trypsin 
cleavage efficiency was assessed by monitoring the release of a tag from the lysine end 
of the cystatin C peptide during the regular digestion procedure. After overnight 
digestion the entire peak in the LC-MS data corresponding to the peptide including the 
tag had completely disappeared, indicating that complete digestion had taken place. The 
observed relative standard deviation for the cystatin C measurements was below 10% 
and those for albumin were less than 4%. Technical variability with sample pre-treatment 
was below 4% and without sample pre-treatment less than 2% (Table 2). 
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Table 2. Relative standard deviation (RSD) of SRM measurements of cystatin C and albumin. 
Relative standard deviations of protein concentrations in individual patients are slightly higher 
than technical controls (measuring a single sample multiple times). Average RSD for cystatin C 
in the 6 patient samples ± 2SD = 6.25 ± 4.99. Average RSD for albumin in the 6 patient samples 
± 2SD = 2.40 ± 0.66. 
Sample No. of samples 
RSD cystatin C 
(%) 
RSD albumin 
(%) 
H 1 3 5.20 2.19 
H 2 3 6.62 1.78 
H 3 3 7.72 3.13 
H 4 3 7.55 3.05 
H 5 3 9.15 2.59 
H 6 3 2.72 1.51 
Technical variation sample pre-
treatment 
3 3.74 2.34 
Technical variation mass 
spectrometry measurement 
4 0.82 1.74 
 
 
2.3.2 Metabolomics analysis 
GC-MS analysis quantified 88 metabolites, of which 67 were assigned to known 
compounds based on spectral libraries. This analysis was complemented by targeted 
LC-MS of 19 natural amino acids. NMR analysis identified and quantified 51 metabolites. 
Thirteen of the metabolites were detected by all three methods, 24 were detected by 
GC-MS and NMR, 14 by GC-MS and LC-MS and 16 by NMR and LC-MS. In total 93 
unique identified metabolites were quantified. PCA of the data from the different 
analytical platforms showed that clustering occurs primarily according to the individual 
patients rather than to the time points when all data are considered (Fig. 4A-C). 
Meancentering the NMR data per patient and vast scaling showed further that there is 
no variation in the metabolome according to delay time (supplementary Fig. S1). The 
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absolute metabolite concentrations identified by NMR can be found in supplementary 
material. Statistical analysis revealed that the concentration of 2,3,4-trihydrobutanoic 
acid (erythronic acid, threonic acid), detected by GC-MS (Fig. 4D) increased in all 
samples with increasing delay time at room temperature. In sample H2 the increase of 
this metabolite was extremely high after 120 minutes. Non-parametric ANOVA (Kruskal-
Wallis) showed that discrimination between T0 and T120 was significant (p < 5 x 10-3).  
 
 
 
Figure 4. Statistical analysis of metabolomics data derived from human CSF (patients H2-H6). 
Multivariate statistical analysis by PCA based on all detected metabolites and univariate 
statistical analysis (Kruskal-Wallis non-parametric ANOVA) of 2,3,4-trihydroxybutanoic acid (T0 
vs. T120; (*) p < 5 x 10-3). (A) GC-MS (90 metabolites, duplicate sample analysis). (B) NMR (51 
metabolites, single analysis), (C) LC-MS targeting 19 natural amino acids (sextuplicate analysis) 
and (D) 2,3,4-trihydroxybutanoic acid ((*) p < 5 x 10-3). 
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2.3 DISCUSSION 
We present a study of the stability of the measured proteome and metabolome of human 
CSF when leaving samples at room temperature for up to 2 h between lumbar puncture 
and storage at -80 °C to mimic delayed storage in clinical routine practice. 
Unsupervised multivariate statistical analysis (PCA) showed that patient-to-patient 
variation is most prominent overriding variation that is due to delay time. Following 
variable selection based on pre-classification of the samples according to delay time, we 
found that only two peptides and one metabolite changed significantly over time from 
amongst approximately 6000 detected peptides and 93 identified and quantified 
metabolites. Our results demonstrate that human CSF prepared according to the 
described procedure is suitable for proteomics and metabolomics analysis even when 
left at room temperature for 2 hours provided that all cells have been removed by 
centrifugation. Quantitation of albumin and cystatin C by targeted mass spectrometry in 
the SRM mode using stable isotope labeled internal standard peptides confirmed that 
there is no statistically significant difference over two hours of delay time. 
Another study on the stability of the proteome in CSF at room temperature pointed in the 
same direction, with the detection of only two polypeptides that changed after storage 33. 
These samples were, however, contaminated with blood since both polypeptides were 
derived from hemoglobin. Another study showed that blood contamination decreases the 
stability of the CSF proteome 11 corroborating our earlier results 21. Metabolomics 
revealed increased levels of 2,3,4-trihydroxybutanoic acid after storage at room 
temperature. This increase may be caused by oxidative degradation of ascorbic acid 32, 
34, 35 as ascorbic acid levels were slightly decreased with increased time at room 
temperature (statistically not significant).  Interestingly, 2,3,4-trihydroxybutanoic acid 
decreased in CSF containing white blood cells 21, which might be due to further 
metabolism of the acid by enzymes released from white blood cells. The concentration 
of 2,3,4-trihydroxybutanoic acid was too low for NMR detection.  
The biological variability of metabolites and proteins is another important factor when 
designing biomarker studies. A study from our team showed that biological variation of 
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some proteins and peptides in CSF can exceed 100% which limits their potential as 
biomarker candidates 36. 
In conclusion, we assessed the stability of CSF with respect to delay time using five 
different analytical platforms. Overall we observed only minor changes in either peptides 
(two out of approximately 6000) or metabolites (one out of 93). Earlier studies showed 
that blood or white blood cell contamination reduces CSF stability considerably, 
emphasizing the importance of the initial centrifugation step. As we did not add 
antioxidants, we cannot draw conclusions about oxygen-sensitive metabolites such as 
the catecholamines. The observed increase in 2,3,4-trihydroxybutanoic acid over time 
indicates, however, that oxygen-sensitive metabolites require additional protective 
measures during sample preparation and storage. 
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ABSTRACT 
The analysis of cerebrospinal fluid (CSF) is employed in biomarker discovery studies for 
various neurodegenerative central nervous system disorders. However, little is known 
about variation of CSF proteins and metabolites between patients without neurological 
disorders, a baseline for a large number of CSF compounds appears to be lacking. To 
analyze the variation in CSF protein and metabolite abundances in a number of well-
defined individual samples of patients undergoing routine, non-neurological, surgical 
procedures we determined the variation of various proteins and metabolites by multiple 
analytical platforms.  
A total of 126 common proteins were assessed for biological variations between 
individuals by ESI-Orbitrap. A large spread in inter-individual variation was observed 
(RSDs ranged from 18% to 148%), for both high abundant and low abundant proteins. 
Technical variation was between 15% and 30% for all 126 proteins. Metabolomics 
analysis was performed by means of GC-MS and NMR and amino acids were 
specifically analyzed by LC-MS/MS, resulting in the detection of more than 100 
metabolites. Interestingly, the variation in the metabolome appears to be much more 
limited compared to the proteome, as the observed RSDs ranged from 12% to 70%. 
Technical variation was below 20% for almost all metabolites.   
Consequently, an understanding of the biological variation of proteins and metabolites in 
CSF of neurologically normal individuals appears to be essential for reliable 
interpretation of biomarker discovery studies for central nervous system disorders, 
because such results may be influenced by natural inter-individual variations. Therefore 
proteins and metabolites with high variation between individuals ought to be assessed 
with caution as candidate biomarkers because at least part of the difference observed 
between the diseased individuals and the controls will not be caused by the disease, but 
rather by the natural biological variation between individuals.  
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3.1 INTRODUCTION 
The analysis of cerebrospinal fluid (CSF) is indispensable in the diagnosis and 
understanding of various neurodegenerative central nervous system (CNS) disorders 1-3. 
CSF is a fluid that has different functions, such as the protection of the brain to forces 
from outside, transport of biological substances and excretion of toxic and waste 
substances. It is in close contact with the extracellular fluid of the brain. Therefore, the 
composition of CSF can reflect biological processes of the brain 4. By characterization of 
the proteome and metabolome of CSF better insight in, for example, the pathogenesis of 
CNS disorders may be achieved; as for many of these disorders the aetiology is still 
unclear.  
CSF is produced in the ventricles of the brain and in the subarachnoidal spaces. 
Humans normally produce around 500 mL of CSF each day, and the total volume of 
CSF at a given time is approximately 150 mL. CSF reflects the composition of blood 
plasma although the concentrations of most proteins and metabolites in CSF are lower. 
However, individual proteins and metabolites can act differently. Active transport from 
blood and secretion from the brain contribute to the specific composition of CSF. This 
composition can be disturbed in neurological disorders 5, 6. Since CNS specific proteins 
and metabolites are typically low in abundance compared to blood, this change in 
composition is more likely to be found in CSF, because in blood the higher abundant 
plasma proteins can completely mask the signal of the lower abundant proteins. Also, if 
the disease markers do not cross the blood-brain-barrier (BBB), then CSF is the only 
viable biofluid source. CSF might therefore be an excellent source for biomarker 
discovery for CNS disorders, following the hypothesis that neurological diseases induce 
alterations in CSF protein and metabolite levels.  
Analysis of metabolites in CSF has been common practice in clinical chemistry for 
decades to analyse biomarkers for inborn errors of metabolism. The approaches used 
are either metabolite profiling of CSF using NMR 7, or targeted analysis of one or a few 
metabolites using specific analytical methods 8. Metabolomics includes the analysis of 
metabolites in biofluids by NMR or MS-based approaches, i.e. LC-MS or GC-MS. 
Several metabolite profiling studies were carried out on CSF using NMR, some of which 
were published only recently 9, 10. Surprisingly, very few metabolomics studies using MS-
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based methods have been performed on CSF yet 11, 12. One of the reasons is the fact 
that the human CSF metabolome has not been characterized very well yet. Many CSF 
metabolites remain unidentified and for those that have been identified there is not much 
known about normal concentration ranges. A systematic categorization of the CSF 
metabolome is necessary and expected to be beneficial for future biomarker discoveries. 
Recently Wishart et al. made a good start in exploring the human CSF metabolome. 
Computer-aided literature survey resulted in 308 detectable metabolites in human CSF 
13.  
The CSF proteome has been characterized to a much larger extent than the CSF 
metabolome and is currently topic of investigations in several research groups 
worldwide. Recently, studies have been published with numerous identities and 
quantities of CSF proteins. Pan and co-workers were able to identify 2.594 proteins in 
well-characterized pooled human CSF samples using strict proteomics criteria with a 
combination of LTQ-FT and MALDI TOF/TOF equipment 14. Also they were able to 
quantify several proteins using a targeted LC MALDI TOF/TOF approach 15. Hu and co-
workers have studied the intra- and inter-individual variation in human CSF, and found 
large variations in protein concentrations in six patients by means of 2D-gel 
electrophoresis 16, focussing mainly on the variations within individuals at two different 
time-points. Although only a limited number of proteins was analyzed, the variation 
between the time-points was profound, exceeding 200% for seven proteins. 
 Unique CSF biomarkers may contribute to a deeper understanding of the mechanisms 
of CNS disorders. However, for this assumption to come true, there are still challenges 
ahead. Even though CSF is not as complex as blood (almost missing the cellular part 
and the clotting system present in blood), it is expected to consist of thousands of 
organic- and non-organic salts, sugars, lipids and proteins. A large part of the CSF 
consists of a few high abundant metabolites and proteins, which hamper, if no 
precautions are undertaken, the identification and quantification of metabolites and 
proteins that occur in lower amounts. The analysis of the CSF metabolome is 
complicated due to the diverse chemical nature of metabolites and the lower 
concentration of metabolites compared to blood. Analytical method development is still 
required as it is not possible to identify the entire range of CSF metabolites with one 
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single analytical method. Though in proteome research efforts have been made to 
quantify proteins, metabolomics studies up to now do not provide quantitative 
information or only give information for the most abundant metabolites.  
Another challenge is the sample amount obtained by lumbar puncture to collect CSF. 
Lumbar puncture is an invasive method that is not performed as frequently as blood 
sampling. However, often after the analysis of various clinical parameters only a limited 
amount of CSF sample is available for biomarker discovery. Metabolomics studies are 
hampered by limited CSF sample amount. Therefore analytical methods are required 
that are suitable to handle relative small sample volumes.   
The main objective of this study was firstly to analyze the variation in CSF protein and 
metabolite abundances in a number of well-defined individual samples by multiple 
analytical platforms. Secondly, the goal was to integrate metabolomics and proteomics 
and to present biological variations in metabolite and protein abundances and compare 
these with technical variations with the currently employed analytical methods. The 
results will facilitate and increase the application of CSF for future biomarker discovery 
studies in the field of neurodegenerative diseases and neuro-oncology. 
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3.2 EXPERIMENTAL PROCEDURE 
3.2.1 CSF sampling 
CSF samples were obtained by lumbar puncture in the Erasmus University Medical 
Centre (Rotterdam, the Netherlands). An experienced medical doctor selected ten 
samples, which were taken from patients receiving spinal anaesthesia prior to non-
neurological surgery. These subjects had no neurological diseases, were not using any 
medication and were considered to have neurologically normal CSF. Immediately after 
sampling, the CSF samples were centrifuged (10 minutes at 3.000 rpm) to discard 
cellular elements. The samples were subsequently used for routine CSF diagnostics. 
This included quantification of total protein concentration by routine clinical chemistry 
measurements and quantification of the cell count (< 5 white blood cells per mL). The 
remaining volume of the samples was aliquoted and stored at –80°C immediately after 
centrifugation. As a standard procedure the samples were checked for blood 
contamination, and any sample in which a hemoglobin or apolipoprotein B100 peptide 
was identified with a significant score by nanoLC-Orbitrap MS was excluded from the 
study. 
For pooling of the samples (n=10), the originally obtained samples were thawed on ice 
and 0.75 mL from each of the samples was joined, resulting in a 7.5 mL pooled CSF 
sample. This pooled CSF sample was vortexed for 30 seconds and then subdivided into 
75 portions of 100 μL in sterile cryogenic vials (Nalgene Nunc Int., Rochester, NY, USA). 
The portions were immediately frozen at –80 °C. The characteristics of the pooled 
sample are described in Table 1. This pooled sample was used to assess the technical 
variation in the proteomics experiments by measuring it five times. For the 
measurements of the individual patients only nine CSF samples were used because 
there was insufficient volume of one sample.  
The 28 CSF samples from the validation sample set were also taken by an experienced 
anesthesiologist from patients receiving spinal anaesthesia prior to non-neurological 
surgery, but these samples were taken at another hospital (Sint Franciscus Gasthuis 
(Rotterdam, the Netherlands)). These subjects had no neurological diseases, were not 
using any medication and were considered to have neurologically normal CSF.  
 
97 
 
Table 1. Details on the pooled sample, including gender, average age and average protein 
concentration. 
Gender Male 8; Female 2 
Mean age (years) 51 (SD = 14) 
Total protein concentration (g/L) 0.4 (SD = 0.1) 
Glucose concentration (mmol/L) 3.3 (SD = 0.3) 
 
The CSF samples used in the experimental sample set were selected by an experienced 
neurologist and taken from patients undergoing tests for clinical diagnosis. These 
samples, taken from multiple sclerosis and headache patients were subjected to the 
same, strict post-sampling procedure as the samples mentioned previously. In these 
samples no significant difference in protein concentration between the two groups was 
observed, so there was no leakage in the blood-CSF barrier. All CSF samples used in 
this study were taken in the morning at approximately 10 AM. The Medical Ethical 
Committees of the Erasmus University Medical Centre in Rotterdam, The Netherlands, 
and the Sint Franciscus Gasthuis in Rotterdam, The Netherlands, approved the study 
protocol and all study participants gave written consent. The average age and protein 
concentration of the samples in all three sample sets is listed in Table 2 and age, gender 
and protein concentration of the individual samples is listed in the Supplementary 
Material. 
 
Table 2. Details on the three sample sets: the original sample set (n=9), the validation sample 
set (n=28), and the experimental sample sets (n=36/42). Age and protein concentration values 
are averages (standard deviation in brackets). The gender, age and protein concentration of all 
individual patients is listed in the Supplementary Material. 
 
Original 
sample set 
Validation 
sample set 
Experimental 
sample set 
proteomics 
Experimental 
sample set 
metabolomics 
Gender 7M / 2F 13M / 15F 13M / 23F 23M / 19F 
Age (years) 51.0 (14.8) 44.5 (14.5) 41.7 (10.8) 43.5 (12.8) 
Protein 
concentration 
(g/L) 
0.39 (0.12) 0.37 (0.11) 0.38 (0.11) 0.38 (0.13) 
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3.2.2 Proteomics 
3.2.2.1 Sample preparation for nanoLC-Orbitrap MS and MALDI-FT-ICR MS 
For measurement of proteins in CSF, samples were enzymatically digested with trypsin 
to obtain peptides. An amount of 50 μL Rapigest (Waters, Milford, USA) in 50 mM 
ammonium bicarbonate and 1 μL 100 mM DTT was added to 50 μL CSF. The mixture 
was heated at 60°C for 30 minutes, upon which it was cooled down to room temperature 
in approximately 20 minutes. Iodoacetamide (5 μL of 0.3 M solution) was added and this 
mixture was left for 30 minutes in dark at room temperature. Trypsin was added (10 μL, 
0.1 mg/mL) and all samples, processed in one batch, were incubated overnight at 37°C. 
To stop digestion, 2 μL of a 50% TFA/50% water solution was added. The sample was 
then incubated for 45 minutes at 37°C. 
 
3.2.2.2 NanoLC-Orbitrap MS analysis 
These measurements were carried out on a Ultimate 3000 nanoLC system (Dionex, 
Germering, Germany) online coupled to a hybrid linear ion trap / Orbitrap MS (LTQ 
Orbitrap XL; Thermo Fisher Scientific, Bremen, Germany). Five μL digest were loaded 
on to a C18 trap column (C18 PepMap, 300μm ID x 5mm, 5μm particle size, 100 Å pore 
size; Dionex, Amsterdam, The Netherlands) and desalted for 10 minutes using a flow 
rate of 20 μL /min 0.1% TFA. Then the trap column was switched online with the 
analytical column (PepMap C18, 75 μm ID x 150 mm, 3 μm particle and 100 Å pore size; 
Dionex, Amsterdam, The Netherlands) and peptides were eluted with following binary 
gradient of solvent A and B: 0% - 25% solvent B in 120 min and 25% - 50% solvent B in 
further 60 minutes, where solvent A consist of 2% acetonitrile and 0.1% formic in water 
and solvent B consists of 80% acetonitrile and 0.08% formic acid in water. Column flow 
rate was set to 300 nL/min. For MS detection a data dependent acquisition method was 
used: high resolution survey scan from 400 – 1800 Th. was performed in the Orbitrap 
(value of target of automatic gain control AGC 106, resolution 30,000 at 400 m/z; lock 
mass was set to 445.120025 u (protonated (Si(CH3)2O)6) 17). Based on this survey scan 
the 5 most intensive ions were consecutively isolated (AGC target set to 104 ions) and 
fragmented by collision-activated dissociation (CAD) applying 35% normalized collision 
energy in the linear ion trap. After precursors were selected for MS/MS, they were 
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excluded for further MS/MS spectra for 3 minutes. Proteins were identified using the 
Bioworks 3.2 (peak picking by Extract_msn, default settings) software package (Thermo 
Fisher Scientific, Bremen, Germany), and SEQUEST (Thermo Fisher Scientific, Bremen, 
Germany), taking the HUPO criteria, with XC scores of 1.8, 2.2 and 3.75 for single, 
double and triple charged ions, respectively, into account. The used database was the 
SwissProt-database (version 56.0, human taxonomy (20069 entries)). 
Carboxymethylation of cysteine (+57.021 u) as fixed and oxidation of methionine 
(+15.996 u) as variable modifications and tryptic cleavage were considered. The number 
of allowed missed cleavages was 2, the mass tolerance for precursor ions was 10 ppm 
and for fragment ions 0.5 Da. The cut-off for mass differences with the theoretical mass 
of the identified peptides was set at 2 ppm. 
The Orbitrap data was subsequently analysed using the Progenesis LC-MS software 
package (version 2.5, Nonlinear Dynamics, Newcastle-upon-Tyne, United Kingdom), in 
which the LC runs were aligned and the biological variation between the samples was 
calculated to assess variation between individuals in this data set. A S/N > 4 and the 
presence of at least 3 isotope peaks per peptide were used as a minimum threshold for 
quantitation. Variation was assessed by comparing the area-under-the-curve of all 
peptides of a protein. The mean area-under-the-curve, corrected for the total ion current, 
of all peptides of a protein was compared between the individuals, and the relative 
standard deviation (RSD) of this value was considered to be the inter-individual variation 
(listed as RSD (in percentages) in the supplementary material). Technical variation was 
assessed by performing the same comparison on the five replicas of the pooled sample.  
 
3.2.2.3 MALDI-FT-ICR MS analysis 
The CSF samples were handled according to the same protocol we reported previously 
18, in which the samples were tryptically digested and desalted using C18 material. 
Using a 2,5-dihydroxybenzoic acid matrix the samples were all measured manually on 
an APEX IV Qe 9.6 Tesla MALDI-FT-ICR mass spectrometer (Bruker Daltonics, 
Billarica, USA), using a multishot accumulation as recommended by Mize et al., Moyer 
et al., and O’Connor et al. 19-21. External mass calibration was applied using a quadratic 
equation. Quantitative MALDI-FT-ICR has previously been applied to quantify HIV-1 
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protease inhibitors in cell lysates 22 as well as peptides in CSF 18, indicating that 
quantitative MALDI-FT-ICR methods are readily applicable, which is due to the fact that 
variation in peak height in MALDI-FT-ICR mass spectrometry is much more reproducible 
than in, for example, MALDI-TOF mass spectrometry. The sum of the height of 14 
omnipresent albumin peaks of each sample was then compared to albumin 
concentrations obtained by routine clinical chemistry measurements. Standard 
deviations of the peak height of the albumin peaks were between 9-16% for all 14 
albumin peaks.  
 
3.2.2.4 Biological variation in an experimental setting  
To compare the results on the variation of protein abundances found in the 
neurologically normal individual CSF samples to an experimental setting, an identical 
experiment was performed on a larger set of samples. A total of 36 CSF samples, taken 
from patients with either multiple sclerosis or headaches, was used. It must be noted 
that these samples, especially those of the multiple sclerosis patients, originate from 
people suffering from neurological problems. Hence the variation in protein abundance, 
like for example immunoglobulin levels, which are known to be elevated in neuro-
inflammatory diseases such as multiple sclerosis 23-25, is potentially far more extensive 
than in the nine well-defined individuals measured previously. 
 
3.2.3 Metabolomics 
3.2.3.1 GC-MS analysis 
Human CSF samples from the original sample set (60 μL) were deproteinized by adding 
250 μL methanol and subsequently centrifuged for 10 min at 10000 rpm. Human CSF 
samples from the validation sample set (100 μL) were deproteinized by adding 400 μL 
methanol. The supernatant was dried under N2 followed by derivatization with methyl-N-
(trimethylsilyl)-trifluoroacetamide (MSTFA) in pyridine similar to Koek et al. 26. During the 
different steps in the sample work-up, i.e. prior to deproteinization, derivatization and 
injection, different (deuterated) internal standards were added at a level of approx. 20 
ng/μL. The final volume was 45 μL for the original sample set and 135 μL for the 
validation sample set and 1 μL aliquots of the derivatized samples were injected in 
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splitless mode on a HP5-MS 30 m x 0.25 mm x 0.25 μm capillary column (Agilent 
Technologies, Palo Alto, USA) using a temperature gradient from 70oC to 320oC at a 
rate of 5oC/min. GC-MS analysis was performed using an Agilent 6890 gas 
chromatograph coupled to an Agilent 5973 mass selective detector (Agilent 
Technologies, Palo Alto, USA). Detection was carried out using MS detection in electron 
impact mode and full scan monitoring mode (m/z 15-800). The electron impact for the 
generation of ions was 70 eV. 
Sample work-up was carried out in duplicate for the original sample set. For the 
validation sample set samples were injected in duplicate. For both sample sets a pooled 
human CSF sample was analyzed in sextuplicate to determine the analytical error in the 
analysis of metabolites by GC-MS. Data-pre-processing was carried out by composing 
target lists of peaks detected in the samples based on retention time and mass spectra 
and these peaks were integrated for all samples. All peak areas were subsequently 
normalized using internal standards. The resulting target lists were used for further 
statistical analysis. Identities were assigned based on the presence of identical mass 
spectra in an in-house database. 
 
3.2.3.2 LC-MS/MS analysis 
To 10 μL of human CSF sample, 10 μL of an internal standard solution containing 
13C15N-amino acids was added followed by addition of 100 μL of MeOH. The mixture 
was vortexed for 10 s and centrifuged at 10.000 rpm for 10 min at 10 ºC. The 
supernatant was dried under N2. The residues were dissolved in 80 μL borate buffer (pH 
8.5) and after 10 s vortexing 20 μL of AQC reagent (Waters, Etten-Leur, The 
Netherlands) was added and the mixture was vortexed immediately. The samples were 
heated 10 min at 55ºC. After cooling down, a 1μL sample of the reaction mixture was 
injected into the UPLC-MS/MS system. 
An ACQUITY UPLCTM system with autosampler (Waters, Milford, USA) was coupled 
online with a Quattro Premier XE Tandem quadrupole mass spectrometer (Waters, 
Milford, USA) and was used in positive-ion electrospray mode. The instrument was 
operated under Masslynx data acquisition software (version 4.1; Waters). The samples 
were analyzed by UPLC-MS/MS using a AccQ-TagTM Ultra 100 mm x 2.1 mm (1.7μm 
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particle size) column (Waters, Milford, USA). A binary gradient system of water – eluent 
A (10:1, v/v) (AccQ Tag, Waters) and 100% eluent B (AccQ Tag, Waters), was used. 
Elution of the analytes was achieved by ramping the percentage of eluent B from 0.1 to 
90.0 in approx. 9.5 minutes using a combination of both linear and convex profiles. The 
flow-rate was 0.7 mL/min. the column temperature was maintained at 60ºC and the 
temperature of the autosampler tray was set to 10ºC. After each injection the injection 
needle was washed with 200 μL strong wash solvent (95% ACN), and 600μL weak wash 
solvent (5% ACN). 
The Quattro Premier XE was used in the positive-ion electrospray mode and all analytes 
were monitored in Selective Reaction Monitoring (SRM) using nominal mass resolution 
(FWHM 0.7 amu).  Next to the derivatisation reagent all amino acids were selectively 
monitored via the transition from the protonated molecule of the AccQ-Tag derivative to 
the common fragment at m/z 171. Collision energy and collision gas (Ar) pressure were 
22eV and 2.5 mbar, respectively. The complete chromatogram was divided into 6 time 
windows, restricting the number of SRM transitions to follow and allowing quantitative 
information to be gathered in each segment. Acquired data was evaluated using 
Quantlynx (Waters, Milford, USA). All samples were analyzed in duplicate. 
Data pre-processing was carried out by calculating the concentration of 18 amino acids 
in all samples by peak integration, followed by normalization using relevant internal 
standards and quantification using external calibration curves. The analytical variation 
was determined from the duplicate analysis of the samples using weighted regression 27, 
28  
 
3.2.3.3 NMR analysis 
CSF samples from the original sample set (280 PL) were centrifuged (2000g, 15 
minutes) using a filter with a cut-off of 10 kDa (Centrisart I 13239-E) to remove proteins. 
Next, 25 μL of 8.8 mM TSP-d4 stock solution in D2O was added to 250 μL filtrated CSF 
to a final concentration of 0.8 mM TSP. The pH of the filtrated CSF was adjusted to 
around 7 (7.0 – 7.1) by adding phosphate buffer (9.7 μL 1M, to a final concentration of 
35 mM). The final CSF NMR sample (284.7 μL) was then transferred to a Shigemi 
microcell NMR tube for NMR measurements (called non-diluted CSF samples). For the 
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validation sample set, samples (100 μL) were first diluted with 270 μL D2O before 
protein removal. 
As a duplicate, for establishing the analytical variation, 100 PL of CSF of the individuals 
was diluted into 180 PL D20 and subsequently worked up as described above (called 
further on diluted CSF samples).    
The 1D 1H NMR spectra of diluted and non-diluted CSF samples were acquired on an 
800 MHz Inova or 600 MHz (Varian Inc., Palo Alto, USA) system equipped with either a 
5 mm triple-resonance, XYZ-gradient HCN room-temperature probe or a 5 mm triple-
resonance, Z-gradient HCN cold-probe, respectively. Suppression of water was 
achieved by using WATERGATE (delay: 85 Ps) 29 or presaturation. For each 1D 1H 
NMR spectrum 512 scans of 18K data points were accumulated with a spectral width of 
9000 Hz. The acquisition time for each scan was 2 s. Between scans an 8 s relaxation 
delay was employed. Prior to spectral analysis, all acquired Free Induction Decays 
(FIDs) were zero-filled to 64K data points, multiplied with a 0.3 Hz line broadening 
function, Fourier transformed and manually phase - and baseline corrected by using 
ACD/SpecManager software. Spectra were subsequently transformed to the Chenomx 
NMR Suite Professional software package version 5.1 for further analysis 30. Metabolite 
identification and quantification were done by using the 800 MHz library of metabolite 
NMR spectra from the Chenomx NMR Suite 5.1 (pH 6-8) for the original sample set 
(Chenomx NMR Suite 6.1 for the validation sample set). The metabolite spectra in the 
library are predicted based on a database of pure compound spectra acquired using 
particular pulse sequence and acquisition parameters, e.g. the tn-noesy-presaturation 
pulse sequence with 4s acquisition time and 1s of recycle delay. The Chenomx NMR 
Suite software fits the spectral signatures (singlets, doublets, triplets etc.), i.e. the peak 
shapes, of a compound from an internal database of reference spectra to the 
experimental NMR spectrum. The resonance assignments derived from the Chenomx 
NMR Suite software were further checked against literature spectra. For quantification, 
Chenomx NMR Suite 5.1 uses the concentration of the known reference signal as 
calibration (in this case TSP-d4).  
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The analytical variation on the individual metabolite concentrations was determined from 
the NMR analysis of the dilute and non-dilute CSF samples, completely independently, 
and the quintuplicate measurement of the diluted CSF sample of one individual.  
 
3.2.3.4 Biological variation in an experimental setting  
To assess the results on the variation of metabolite abundances found in original and 
validation sample set, i.e. neurologically normal CSF, an identical experiment was 
performed using GC-MS on a set of 42 human CSF samples (100 μL), taken from 
patients with multiple sclerosis and other (inflammatory) neurological diseases.  
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3.3 RESULTS 
3.3.1 Proteomics 
None of the CSF samples was contaminated with plasma, as according to the criteria 
set hemoglobin and apolipoprotein B100 were not identified in any of the samples. All 
sequenced peptides and identified proteins are listed in the supplementary material 
(including the number of unique peptides per protein and the sequence coverage for all 
proteins identified with two or more peptides).  
Using MALDI-FT-ICR mass spectrometry we analysed the height of albumin peptide 
peaks of the nine samples of the original sample set and their correlation to albumin 
concentration levels in CSF as measured by routine clinical chemistry diagnostics. The 
sum of the height of 14 omnipresent albumin peaks showed positive correlation to the 
values measured by clinical chemistry (R2 = 0.919). These values (median: 0.219 g/L, 
range 0.097-0.403 g/L) clearly show a large variation between individuals, which was 
also apparent from the differences in height of the peaks measured by MALDI-FT-ICR 
(Figure 1). The area under the curve of all peptides identified to be part of albumin in the 
ESI-Orbitrap experiments was also plotted against the albumin concentration, showing 
good correlation (R2 = 0.971). Relative standard deviations (RSD) were comparable for 
all three methods (43.7% for clinical chemistry, 66.7% for MALDI-FT-ICR and 39.1% for 
ESI-Orbitrap).  
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Figure 1. Correlation between the measured albumin concentration by clinical chemistry 
diagnostics and the sum of the height of 14 omnipresent albumin peaks as measured by MALDI-
FT-ICR (R2 = 0.919) and by ESI-Orbitrap (R2 = 0.971). 
 
A total of 126 proteins, all identified by multiple peptides and present in all nine normal 
CSF samples, was analysed in the nine individual CSF samples by ESI-Orbitrap to 
assess the variance in protein abundances in CSF, based on the averages of peak 
heights of all the peptides of a single protein. The RSD ranged from 18% to 148% 
(median: 43%) in peak height. The far greater part of the examined proteins (119 of 126, 
i.e. 94.4%) showed lower than 100% RSD in average peptide peak height per protein 
between the nine individual CSF samples. These results were subsequently tested in 
two larger sample sets, a validation set (28 samples) and an experimental sample set 
(36 samples), in which similar profiles for the variation in protein abundance, based on 
the averages of the area-under-the-curve of the peptides in the ESI-Orbitrap, was 
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observed (Figure 2). In this figure the variation (in RSD (%)) for all proteins is plotted for 
all three data sets, and the protein-numbers used here are the same as in the 
Supplementary Material. The slightly lower RSD’s found for the validation sample set are 
at least partially due to the fact that a longer nanoLC column (50 cm) was used and 
consequently more peptides were measured per protein. Using these data the 
correlation of the individual protein variations between the datasets was calculated. This 
resulted in an R2 of 0.94 for the correlation between the original dataset and the 
validation dataset, and an R2 of 0.66 for the correlation between the original dataset and 
the experimental dataset. This is a strong indication that the same proteins have a high 
inter-individual variation in the healthy CSF patients in both the original and the 
validation sample set, but that this is quite different in the experimental sample set of 
patients with known neurological disorders. In the original sample set the 126 proteins 
were observed in all 9 normal control samples, but in the experimental sample set 11 
proteins were not observed in all 36 samples. This may indicate a greater variance in the 
experimental samples, while in the validation sample set the variation is slightly lower 
than in the original sample set. In the experimental sample set, the RSD in peptide 
abundance per protein ranged from 30% to 182% (median: 91%). The greater variation 
in the experimental sample set is at least partially due to the sample choice for this set of 
samples. As referenced earlier, in multiple sclerosis it is known that immunoglobulins are 
elevated and since this sample set contained both multiple sclerosis CSF samples and 
samples from patients with headaches it is not surprising to note that many of the 
proteins with the highest RSD between individuals are all immunoglobulin types and 
proteins related to inflammatory response, which were indeed elevated in the multiple 
sclerosis samples. In essence, in the normal controls we observed the biological 
variation between the individuals, whereas in the experimental sample set both the 
biological variation as well as the disease-related variation was observed.  
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Figure 2. The proteins sorted by the variation in the original samples paired to the variation in 
the validation samples and the experimental samples. A trend is clearly visible, but due to the 
nature of the experimental samples (multiple sclerosis and headaches), the immunoglobulins do 
not correspond with the overall trend, which is to be expected considering the well-known 
inflammatory component of multiple sclerosis. Numbers on x-axis correlate to protein numbers 
mentioned in Supplementary Material. 
 
Although all three sample sets are distinct, a number of similarities can be observed. In 
the sample sets, there is a clear division that can be seen between proteins whose 
abundances vary highly among individuals and proteins that show a much more limited 
variation between individuals. Among the proteins that showed limited variation between 
individual CSF samples were serotransferrin (25% RSD in the original sample set, 18% 
RSD in the validation sample set and 50% RSD in the experimental sample set), 
tetranectin (21%, 18% and 52%, respectively), and gelsolin (24%, 19% and 58%, 
respectively). Proteins with high variation between individuals in all three sample sets 
included cadherin-13 (82% RSD in the original sample set, 60% RSD in the validation 
sample set and 143% RSD in the experimental sample set), contactin-2 (124%, 80% 
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and 156%, respectively), and haptoglobin (135%, 84% and 182%, respectively). The full 
list of variations between the individuals for the 126 proteins can be found in the 
Supplementary Material. 
Gender and age related inter-individual variations were assessed in the validation 
sample set. In this sample set the number of males and females was roughly equal (13 
males and 15 females) and we defined 3 different age groups (below 35 years of age, 
between 35 and 50 years of age and above 50 years of age). Although both parameters 
(gender and age) appear to influence the variation, their influence appears limited 
(complete list of individual protein variations specified for age-group and gender is listed 
in the Supplementary Material). The inter-individual variation in protein abundance 
appears slightly larger in females than in males, especially in proteins that have a high 
inter-individual variation, but this is not exclusively the case as there are also proteins of 
which the variation is higher in males. The same is true for the inter-individual variation 
of the proteins when comparing age groups. The variation seems slightly larger in the 
oldest age group, again most clearly for the proteins with the highest inter-individual 
variation. But, as with age, this is not exclusively so, as there are also proteins that have 
a higher inter-individual variation in the group of patients below age 35 (full list of age 
and gender variation in Supplementary Material (Figures S1 and S2)). T-test show 1.6% 
and 3.2% of the proteins to be significantly different based on variation of their RSD 
between males and females and between the age groups, respectively (p<0.01, 
Supplementary Material). 
Total abundance of most of the measured proteins was slightly higher in males than in 
females, and with regards to age the abundance of most of the measured proteins was 
highest in the oldest patient group of the validation sample set. 
 
3.3.2 Metabolomics 
Three different analytical methods were applied to analyse the individual as well as the 
pooled CSF samples. The methods included untargeted GC-MS and NMR methods and 
a targeted LC-MS/MS method specifically for amino acids. 
First a small set of CSF samples, i.e. original sample set consisting of 9 samples for GC-
MS, 8 for LC-MS/MS and 5 for NMR, was analyzed by the three methods followed by a 
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larger set of samples, i.e. validation sample set consisting of 28 samples for GC-MS and 
27 samples for NMR and LC-MS/MS. The original sample set was used to have a quick 
screen of what type of metabolites could be detected and to have a rough idea of 
biological variation and analytical error. However, for reliable data with respect to 
biological variation as well as possible gender and age effect and comparison of the 
three methods, the validation sample set was used.      Analysis of original samples CSF 
with GC-MS resulted in a list of 108 metabolites of which 93 could be identified (see 
Supplementary Material). The unknown metabolites covered both metabolites that were 
observed in other biofluids, i.e. plasma and/or urine, as well as metabolites that seemed 
to be specific for CSF. The metabolites detected by GC-MS cover many different 
compound classes, i.e. amino acids, organic acids, nucleosides, fatty acids, mono- and 
disaccharides. Of the 93 identified metabolites, some were only present in trace 
amounts and were therefore not used for further analysis. Interestingly, all identified 
metabolites were observed in all samples. The analytical variation for each metabolite 
was determined from the repeated (n=6) analysis of the pooled CSF sample. Results 
show that the analytical variation (< 20%) was less than the biological variation for all 
metabolites (15 to 85%) (see Supplementary Material). The concentration or relative 
peak area for each metabolite in the pooled human CSF sample is given in 
Supplementary Material. As expected, the average concentrations and relative peak 
areas found for the 9 individual CSF samples were very similar to that of the pooled 
human CSF sample.  
Next, the validation sample set was analyzed by GC-MS using a somewhat different 
sample work-up including different sample volumes leading to a less concentrated 
extracts. As a result some of the low abundant compounds could not be detected. In 
total 68 metabolites could be detected and most of them were also detected in the 
original sample set. The biological variation of these 68 metabolites ranged from 7 to 
214%, while the analytical error ranged from 1 to 36% and in all cases the analytical 
error was equal or less than the biological variation (see Table 3 and Supplementary 
Material). The biological variation for the metabolites observed with GC-MS in the 
validation sample set shows a normal distribution, as can be deduced from Figure 3.  
 
111 
 
 
Figure 3. Metabolites detected by GC-MS in both the validation (blue) as well as the 
experimental (red) sample set, sorted by variation in the validation samples paired to the 
variation in the experimental samples. A trend is visible, but due to the nature of the 
experimental samples (multiple sclerosis and other neurological disorders), a number of 
metabolites do not correspond with the overall trend and show significantly higher biological 
variation. Numbers on x-axis correlate to metabolite numbers mentioned in Supplementary 
Material. 
 
Multivariate data analysis using PCA (principal component analysis) showed that overall 
biological variation was dominant over age and gender effects (see Figures S3 and S4 
in the Supplementary Material).   
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Table 3. Metabolites detected by GC-MS, NMR and LC-MS/MS in the validation  
sample set and their biological variation. 
Metabolite 
GC-MS 
RSD (%) 
n=28 
LC-MS 
RSD (%) 
n=27 
NMR 
RSD (%) 
n=27 
1,5-anhydro-D-Glucitol 34     
1-methylhistidine     49 
1-monopalmitoylglycerol 30     
1-monostearoylglycerol 19     
2,3-dihydroxybutanoic acid 28     
2,4-dihydroxybutanoic acid 26     
2-aminobutyric acid 22   28 
2-hydroxybutanoic acid 35   29 
2-hydroxyisovaleric acid 24   30 
2-piperidinon 113     
3,4-dihydroxybutanoic acid 54     
3-hydroxybutanoic acid 106   15 
3-hydroxyisovaleric acid 31   15 
3-hydroxypropanoic acid 14     
3-methylhistidine     143 
Acetic acid     52 
Acetoacetic acid 38   26 
Acetone     20 
Aconitic acid     28 
Alanine 28 32 27 
Arabinose 19     
Arginine   25 19 
Ascorbic acid 25     
Asparagine   22   
C16:0 Fatty acid 23     
C18:0 Fatty acid 7     
C18:1 fatty acid 58     
Cholesterol 30     
Choline     24 
Citric acid 18   15 
Citrulline   34   
Creatine     15 
Creatinine 63   17 
Dimethylamine     25 
Erythronic acid 28     
Formic acid     19 
Fructose 38   24 
Fucose 17     
Galactitol     23 
Gluconic acid 26     
Glucose 12   12 
Glutamic acid 30     
Glutamine   14 18 
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Glyceric acid 14     
Glycerol 16     
Glycerol-galactopyranoside 22     
Glycine 35 30 24 
Glycolic acid 13     
Histidine   16 15 
Inositol 68     
Inositol related compound 26     
Iso-citric acid 21     
Iso-leucine 36 30 25 
Lactic acid 13   14 
Leucine 22 27 26 
Lysine 43 22 16 
Mannitol 26     
Mannose 17     
Meso-erythrytol 16     
Methanol     21 
Methionine 57 34 31 
Myo-inositol 19   25 
Ornithine 46     
Phenylalanine 19 23 30 
Phosphoric acid 214     
Phosphorylethanolamine 47     
Proline 45 49   
Pseudo uridine 21     
Pyroglutamic acid 31     
Pyruvic acid 28   23 
Quinic acid 90     
Ribitol 30     
Ribonic acid 26     
Ribose 12     
Serine 36 17   
sn-Glycerol-3-Phosphate 48     
Succinic acid     23 
Sucrose 64     
Threonic acid 33     
Threonine 38 27 20 
Trimethylamine-N-oxide     18 
Tryptophan   24   
Tyrosine   30 27 
Urea 28     
Uric acid 69     
Valine 33 28 28 
Xanthine     86 
Xylonic acid 45     
Xylose 82     
 
 
114 
 
For the experimental sample set of 42 human CSF samples from patients having 
neurological diseases a similar profile for the variation in metabolite level could be 
observed as for the validation sample set from neurologically normal individuals (see 
Figure 3 and Supplementary Material). A number of metabolites show a significantly 
higher RSD for the experimental samples, which is most probably due to the 
heterogeneity of the experimental CSF samples, as discussed in the proteomics section. 
Metabolites that show significantly higher RSDs for the experimental samples are 3,4-
dihydroxybutanoic acid, fructose, ascorbic acid, glyceric acid, pyruvic acid and 2-
aminobutyric acid. However there is no clear relation between these metabolites and the 
neurological disease in the experimental sample set.  
For NMR only five individual CSF samples were analysed in the original sample set due 
to limited available sample volumes. Analysis of the CSF samples by NMR resulted in a 
list of 51 metabolites of which 41 could be quantified (see Supplementary Material). All 
metabolites observed with NMR were detected in all samples. The biological variation 
ranged from 8 to 53% while the analytical error was between 3 and 9 % for all 
metabolites (Supplementary Material). The concentrations found for the pooled CSF 
sample were very similar to that of the averages of the individual samples.  
The 27 CSF samples in the validation sample set were analyzed by NMR using 
somewhat different conditions, i.e. more diluted and 600 MHz instead of 800 MHz. 
However, the same set of metabolites could be quantified in these samples, except for 
urea. In this sample set the biological variation ranged from 12 to 143% which is 
somewhat higher compared to the original sample set (see Table 3 and Supplementary 
material). The analytical error is in the same range as observed for the original sample 
set, i.e. 2 to 9%. PCA on the NMR data did not show any significant age or gender effect 
(see Figures S5 and S6 in Supplementary Material).   
Of the 41 metabolites quantified by NMR in the validation sample set, 21 were also 
detected by GC-MS. Some of the more volatile metabolites, like acetone and methanol, 
can only be analyzed by NMR, showing that despite the overlap, NMR and GC-MS are 
complementary techniques. Furthermore, NMR can detect a number of metabolites that 
are difficult to analyze by GC-MS, because they cannot be derivatized, like choline, or 
they can give unstable derivatives, like arginine. On the other hand, a range of 
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metabolites was only observed by GC-MS and not by NMR. In most cases these 
metabolites either have no proton signal, e.g. uric acid and phosphoric acid, or the 
concentration is below the detection limit of NMR, e.g. dihydroxybutanoic acids and 
proline. 
The absolute concentrations of amino acids in eight individual CSF samples of the 
original sample set were determined by a targeted LC-MS/MS. One of the individual 
CSF samples was omitted due to technical failure. The analytical error is less than the 
biological variation for all amino acids. The biological variation ranges from 28 to 52% 
while the analytical error is less than 12% (see Supplementary Material). Despite the 
differences between samples, all amino acids were present in every individual sample. 
Again, it can be seen that the concentrations found for the pooled CSF sample were 
very similar to that of the averages of the individual samples. Glutamic acid and aspartic 
acid could not be quantified in a reliable way in the CSF samples. 
Analysis of the same amino acids in the 27 samples of the validation sample set resulted 
in similar biological variation, i.e. 14 to 49%, and analytical error, i.e. 1 to 9% (see Table 
3 and Supplementary Material). PCA showed no significant age or gender effects (see 
Figures S7 and S8 in Supplementary Material).  
Most of the amino acids analyzed by LC-MS/MS were also detected either by GC-MS or 
NMR. However, one of the advantages of the targeted LC-MS/MS method is the low 
sample volume required for analysis, i.e. 10 μl vs. 60-100 μl for NMR and GC-MS, 
respectively. 
Comparison of the RSD of metabolites that could be analyzed with more than one of the 
analytical methods, as shown in Table 3, shows that on average the biological variation 
of a metabolite is similar for different methods. Deviations occur mainly for low abundant 
metabolites, like 3-hydroxybutanoic acid, and metabolites that show relative high 
analytical errors for certain methods, e.g. creatinine with GC-MS. 
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3.3 DISCUSSION 
In this study, we investigated metabolite and protein identities, and their abundances 
and inter-individual variations in abundance in CSF by analyzing a unique and well-
defined set of CSF samples and a corresponding pooled CSF sample. Here we have 
strictly defined criteria to exclude blood contaminated CSF. These criteria warrant that at 
a certain threshold no contamination is observed, however contamination not exceeding 
this threshold can still exist and cannot be ruled out.   
Combination of three different analytical techniques for metabolites used in this study 
resulted in a list of about 89 identified metabolites in CSF that can routinely be analyzed, 
which is about a third of the metabolites in CSF present in the human metabolome 
database 30. It is expected that many of the metabolites that are not detected by NMR 
and GC-MS are low abundant metabolites, i.e. neurotransmitters, steroids, eicosanoids, 
for which more specific, targeted methods are required 31-33. However, these methods 
often require significant amounts of CSF and should therefore only be used in 
metabolomics studies when there is evidence that these metabolites are of importance 
and/or when enough sample volume is available. Furthermore, some metabolites are 
(almost) absent in normal controls and are only detectable in diseased persons 7.  
All endogenous metabolites detected with the three analytical methods in this study 
were observed in all individual CSF samples. This implies that the qualitative metabolite 
composition of CSF in normal controls is relatively similar between individuals. This is 
generally also observed for plasma of healthy persons in contrary to urine, which is more 
influenced by dietary intake. 
With NMR and LC-MS/MS it was possible to determine the absolute concentration of 
metabolites. This in contrast to GC-MS for which metabolites can only be quantified 
when either internal standards or calibration curves for each metabolite are used, which 
is practically not feasible and therefore this method, like many other non-targeted 
methods, is used to measure relative differences in metabolite concentrations between 
groups or individuals. The absolute concentrations determined by LC-MS/MS and NMR 
agree well with values reported in literature (13, 34-36). For example, comparison of the 
concentrations of metabolites detected by NMR with values determined by Wishart et al. 
(13) and literature values referred to in this paper show that in most cases the values fall 
117 
 
within the same concentration range (see Supplementary Material). Furthermore, the 
concentrations of metabolites determined by more than one method in the validation 
sample set are also in good agreement.  
Although the study of Hu et al. 16 mainly focussed on the variation of specific protein 
abundances within individuals, they concluded that inter-individual variation is far more 
extensive than intra-individual variation. Yet in that study two different stages of 
Alzheimer’s disease were included, which could potentially influence the levels of protein 
variation between individuals. Here we examined well-defined CSF samples taken from 
patients without neurological disorders, and also found profound differences in protein 
abundances between individuals. Characterization of variation of CSF levels of amyloid 
beta 34 and apolipoprotein E 35 in patients with Alzheimer’s disease have been 
published, but this is the first attempt to characterize a large number of proteins in CSF 
of patients without neurological afflictions. Some proteins, such as serotransferrin and 
fibulin-1 appear to be more constant than others with regards to abundance levels in 
CSF, as these showed only limited variations in both the sample set of nine non-
neurological individuals and the validation set as well as in the experimental sample set. 
Other proteins, such as contactin-2 and cadherin-13, showed large variations in 
abundance levels in all three data sets, while proteins related to inflammatory response 
showed the largest variation in the experimental sample set (Figure 2). This is, in all 
likelihood, due to the well-known neuroinflammatory component of multiple sclerosis 36-
38, because the abundance of neuroinflammatory proteins was far higher in the multiple 
sclerosis samples. This was most obvious in the primary progressive multiple sclerosis 
patients, so the increased variance of immunoglobulin proteins in this data set is likely 
due to this group of samples as this type of multiple sclerosis is characterized by 
continuous inflammation in the central nervous system, which would result in higher 
concentrations of inflammation-related proteins.  
Additionally, it must be noted that the proteins with high inter-individual variation were 
not only low abundant proteins, but also high abundant proteins such as haptoglobin, 
indicating that these high variations were not caused by measuring at the limit of the 
detection capabilities of the machines. Proteins specific to the central nervous system 
appear to be more variable between individuals than proteins that originate from blood. 
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The majority of the central nervous system specific proteins have high inter-individual 
variations, like for example neurotrimin and neuroserpin, whereas a large number of the 
proteins from blood show low inter-individual variation, such as serotransferrin and 
ceruloplasmin. However, there are also blood specific proteins that display high inter-
individual variation, like haptoglobin. 
Matching biological samples for age, gender and protein concentration is an essential 
step in biomarker research. However, in the validation sample set we observed that 
proteins with high inter-individual variance were influenced by gender and age only in a 
limited way. A good example of this is apolipoprotein E, a protein that is reported to be 
present at lower concentrations in CSF of patients with Alzheimer’s disease, regardless 
of age and gender variability 35. Here we found a similar RSD (23-29%) for all variables 
(gender and age-group) tested, suggesting a limited influence of both age and gender 
on the inter-individual protein abundance of apolipoprotein E. 
Although all metabolites detected were present in all individual samples the 
concentration of metabolites differed strongly between individuals. For all metabolites 
the analytical variation was significantly less than the biological variation. The biological 
variation was not caused in a significant way by age or gender. The biological variation 
in this study is about 15% for 70% for the majority of the metabolites which is lower than 
was observed by Wishart et al. 13, but very similar to the variation reported in the recent 
study of Crews et al. 39. The main difference between the two studies is the type of CSF 
sample that was used, i.e. persons without neurological disorders vs. patients screened 
for meningitis. Therefore, it can be concluded that the biological variation for normal 
controls is, as expected, less than for neurologically diseased individuals.   
Lactic acid and glucose, two high abundant metabolites that can be detected by both 
NMR and GC-MS, show relatively low biological variation, i.e. < 20%, as well as some 
medium abundant metabolites like citric acid and glutamine (Table 3). In general most 
medium abundant compounds show RSD < 30%. Most compounds that show high 
biological variation are relatively low abundant, e.g. proline, 1- and 3-methylhistidine, 
xanthine. Even more interesting is the fact that some low abundant metabolites 
observed with GC-MS show low biological variation, like 3-hydroxypropionic acid, 
arabinose, fucose, glyceric acid, glycerol, glycolic acid, ribose, while others show very 
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high biological variation, e.g. 3-hydroxybutanoic acid, 2-piperidon, inositol, phosphoric 
acid, sucrose, uric acid and xylose (see Table 3). Both types of metabolites include 
organic acids and carbohydrates and there is yet no clear biological reason why some 
metabolites in this study show much higher biological variation than others. The 
biological variation of the experimental sample set of 42 human CSF samples showed a 
similar trend as the nine CSF samples, although for a number of metabolites the 
biological variation was significantly higher (Figure 3). The latter can of course be 
attributed to the different diseases of the subjects that might lead to general differences 
in metabolite levels. Metabolites that showed a significant higher biological variation in 
the experimental samples could not be directly related to neurological disorders. Further 
analysis of the data of the experimental samples is necessary in order to find relations 
between metabolites and the different types of neurological disorders present in the 
samples set, including the different stages of multiple sclerosis. More interestingly, for a 
significant number of metabolites, the biological variation in diseased subjects are 
similar to that of normal controls, indicating that part of the CSF metabolome is more 
influenced by person to person differences and that the contribution of the diseases is 
only minor.  
The biological variation of metabolites that were detected by more than one analytical 
method, showed in general good agreement (see Table 3). Amino acids determined by 
LC-MS/MS and NMR showed in general <10% difference in RSD and the same was 
true, with some exceptions, for metabolites analyzed by both GC-MS and NMR.  
The work discussed above showed that metabolomics, i.e. non-targeted analysis of as 
many metabolites as possible, of CSF is possible with a combination of analytical 
techniques currently available. Depending on the amount of CSF available and existing 
knowledge with respect to the biological question that has to be answered, a 
combination of non-targeted and targeted analytical methods is preferred to cover 
different classes of metabolites ranging from high to low abundant metabolites. The 
metabolites that were detected in CSF seemed to be quite similar between normal 
controls although the concentration of metabolites can differ between individuals up to 
60% depending on the specific metabolite.  
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3.4 CONCLUDING REMARKS  
From the previous discussion we conclude that for most proteins the biological variation 
in two sets of normal control CSF samples, i.e. patients without any significant 
neurological disorders, appears to be limited, e.g. serotransferrin with RSD 25% (original 
sample set) and 18% (validation sample set), which includes a technical variation of 
approximately 20%. The majority of the identified proteins show lower than 60% RSD. 
However, for 28% of the identified proteins the RSD is above 60% and for a limited 
number of proteins (5% of total) the inter-individual variation is extensive (RSD > 100%, 
original sample set). The results of extensive inter-individual variation for 5% of the 
identified proteins is not limited to low abundant proteins but also several high abundant 
proteins shows extensive biological variation, e.g. haptoglobin with RSD of 135% in the 
original sample set (Table 4).  
 
Table 4. Proteins with high and low biological variation in normal control CSF samples (original 
sample set). 
Low variation between individuals High variation between individuals 
Accession number, 
protein 
Biological 
variation 
(%) 
Technical 
variation 
(%) 
Accession number, 
protein 
Biological 
variation 
(%) 
Technical 
variation 
(%) 
P01011, Alpha-1-
antichymotrypsin 26 17 
Q9BYH1, Seizure 
6-like protein 102 21 
P07339, Cathepsin 
D 26 17 
Q8TCZ2, Voltage-
dependent calcium 
channel subunit 
alpha-2/delta-1 
103 19 
P23142, Fibulin-1 27 16 P54764, Ephrin type-A receptor 4 107 19 
P02774, Vitamin 
D-binding protein 29 21 
Q02246, Contactin-
2 124 19 
P17900, 
Ganglioside GM2 
activator 
29 23 P00738, Haptoglobin 135 28 
P02749, Beta-2-
glycoprotein 30 18 Q86YZ3, Hornerin 148 28 
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Metabolomics analysis on the same CSF samples showed that the biological variation 
for most CSF metabolites is limited especially compared to the proteomics results. Only 
a few metabolites were observed with a biological RSD > 70%. However, within the 
group of metabolites that could be quantified with the different analytical methods, 
substantial differences in RSDs could be observed between individual metabolites. For 
example, glucose, a high abundant metabolite, showed a RSD of only 12% while for 
acetic acid a RSD of 52% was observed.  
These results show that for CSF biomarker discovery research, it is essential to have an 
understanding of the biological variation between normal controls, because observation 
of differential abundance between controls and diseased individuals must necessarily be 
weighed against known inter-individual variations in normal controls. Proteins and 
metabolites showing high RSD in healthy CSF ought to be assessed with caution as 
candidate biomarker, since a large part of the observed difference will not be due to the 
disease under investigation, but to the natural biological variation between individuals. 
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ABSTRACT 
Multiple Sclerosis (MScl) is a neurodegenerative disease of the CNS, associated with 
chronic neuroinflammation. Cerebrospinal fluid (CSF), being in closest interaction with 
CNS, was used to profile neuroinflammation in order to discover disease-specific 
markers. We used the commonly accepted animal model for the neuroinflammatory 
aspect of MScl: the Experimental Autoimmune/Allergic Encephalomyelitis (EAE). An 
combination of advanced 1H-NMR spectroscopy and pattern recognition methods, was 
used to establish the metabolic profile of CSF of EAE-affected rats (representing 
neuroinflammation) and of two control groups (healthy and peripherally inflamed) to 
detect specific markers for early neuroinflammation. We found that the CSF metabolic 
profile for neuroinflammation is distinct from healthy and peripheral inflammation and 
characterized by changes in concentrations of metabolites such as creatine, arginine 
and lysine. Using these disease specific markers we were able to detect early stage 
neuroinflammation, with high accuracy in a second independent set of animals. This 
confirms the predictive value of these markers. These findings from the EAE model may 
help to develop a molecular diagnosis for the early stage MScl in humans. 
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4.1 INTRODUCTION 
Multiple Sclerosis (MScl) is a chronic progressive inflammatory, presumably 
autoimmune disease of the human central nervous system (CNS) in which the fatty 
myelin sheaths which surround the axons of the neurons of the brain and spinal cord are 
damaged, leading to demyelination.1 MScl is one of the most common neurological 
diseases and usually starts in early adulthood and progresses to serious neurological 
disability. It has an enormous impact on the health care system and economy of different 
countries.  Currently, MScl afflicts approximately one million people worldwide and the 
total cost of MScl has been estimated at 12.5 billion € per year.2, 3 
The animal model of MScl, the Experimental Autoimmune/Allergic Encephalomyelitis 
(EAE) model,4-9 has become an important tool for understanding the human disease. 
EAE is a cell-mediated experimental autoimmune disorder of the CNS and shares its 
clinical expression and pathological picture with that of MScl. For instance, the Lewis 
rats in which neuroinflammation is induced by means of Myelin Basic Protein (MBP), as 
in our study here, display a typical disease curve resembling that of the beginning of 
MScl Relapsing-Remitting type (RR-MScl). RR-MScl is the most common type of the 
early stage of MScl. EAE is therefore a useful model for the neuroinflammatory aspect of 
MScl. Note that EAE does not mimic neurodegeneration and widespread demyelination 
seen in MScl.10 In EAE demyelination might be present in the ventral root exit and dorsal 
root entry zone of the spinal cord or even absent. Also, EAE is monophasic, whereas 
MScl has a random relapsing-remitting or chronic progressive pattern.11 It is worth 
mentioning that EAE has led to development of the hypothesized immunological basis of 
MScl pathology.12 Moreover, the EAE has been instrumental in discovering and 
developing three of the six currently approved therapies for MScl that diminish its 
symptoms: Copaxone, Mitoxantrone, and Natalizumab.13, 14 For instance, Mitoxantrone, 
a known cancer drug, was tested in EAE and found to have positive effects, which led to 
its use in relapsing-remitting MScl, slowing its progression into secondary progressive 
MScl.15  
Unambiguous current clinical diagnosis of MScl remains difficult, particularly in its early 
stage, due to the complexity of its pathology and the similarities of these pathologies to 
that of other neurological diseases/inflammations. Diagnosis in an early stage is 
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important as early intervention appears beneficial to slow down the long-term 
progression of the disease.16 A molecular biomarker derived for neuroinflammation in 
the animal model EAE may form a first step towards such an early diagnosis. 
The main objective of this study is to find in the cerebrospinal fluid (CSF) of EAE 
induced Lewis rats metabolic markers of neuroinflammation and to differentiate 
neuroinflammation from peripheral inflammation. For this a controlled animal study was 
set-up, with a healthy control group, a group injected with inflammatory ‘booster’ 
(Complete Freund Adjuvant emulsion, CFA) to induce peripheral inflammation and a 
group injected with CFA and in addition MBP to induce neuroinflammation. Disease 
progression was monitored and CSF samples were collected at two different time points. 
To analyze the metabolic profile of the CSF we used an untargeted and unbiased 
biomarker discovery approach in which high-field 1D 1H-NMR is combined with pattern 
recognition methods. To our knowledge, this is the first study applying 1H-NMR to 
analyze rat CSF in the EAE model. A fact that very few rat CSF metabolite studies have 
been done by NMR is likely due to the limited amount of CSF in rodents. This is not a 
standard procedure to use such little sample volume in NMR. High quality data could be 
obtained using only 10 μL of CSF, thanks to the use of advanced NMR including high-
field and cryo-probe technology.  
We found that the CSF metabolic profile for neuroinflammation is distinct from that of 
healthy and peripheral inflammation. The metabolites, identified as specific for 
neuroinflammation, were investigated in a second independent set of animals for the 
prediction of the early stage of neuroinflammation. The validation of the findings with an 
external experiment is often acclaimed but rarely practiced in a single study. These 
disease specific markers, detected in the animal model, may lead to a better 
understanding of the metabolism underlying neuroinflammation and help to develop a 
molecular diagnosis for the early stage of MScl in humans.   
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4.2 MATERIALS AND METHODS 
4.2.1 Experimental design of EAE models 
The Experimental Autoimmune/Allergic Encephalomyelitis (EAE) is one of the most 
intensively examined and best characterized animal models of autoimmune disease 9. 
EAE shares similarities with MScl. Although the EAE model does not mimic all aspects 
of MScl, this rodent disease model is an excellent experimental system for 
understanding aspects of the MScl disease.  
The first set of male Lewis rats (Harlan Laboratories B.V., the Netherlands) was 
inoculated on Day 0 as previously described.17 Briefly, a 100 μL saline based emulsion 
containing 50 uL Complete Freund Adjuvant H37 RA (CFA, Difco Laboratories, Detroit, 
MI), 500 μL Mycobacterium tuberculosis type H37RA (Difco) and 20 μg guinea pig 
myelin basic protein (MBP) was injected subcutaneously in the pad of the left hind paw 
of isoflurane anaesthetized animals. CFA was injected for boosting of the immune 
system, while MBP was injected for induction of neuroinflammation. Next to these MBP 
challenged rats, referred to as the EAE group (or neuroinflamed group), two control 
groups were included: a group of animals receiving the same emulsion without MBP 
(CFA group = peripheral inflammation) and a healthy group undergoing anesthesia only 
(healthy control). Each group consisted of 30 animals. In each group half of the animals 
was sacrificed to collect CSF on Day 10 (Day of onset in EAE group) and the other half 
on Day 14 (peak of disease in EAE group). The typical progression of disease is shown 
in Figure 1a, while the design of the first EAE experiment is summarized in Table 1. 
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Figure 1. (a) EAE disease progression. (b) The average neurological score screened for group 
“N14”.  The vertical bars indicate standard error of the mean; (c) 1H-800 MHz NMR spectrum of 
rat CSF. Vertical lines indicate the bins; (d) PCA score plot of the 1H-NMR spectra of rat CSF. 
 
Animals were kept under normal housing conditions with water and food and libitum, 
weighing between 175 and 225 grams at the start of the experiment. Animals were 
group housed per 3 and cages were randomized across treatments and disease 
duration. 
A second set of male Lewis rats was used to perform another EAE experiment, one year 
after the first one. The animals were inoculated with CFA and/or MBP as described 
above. The experimental design, the amount of animals (i.e. 15 animals per group) and 
settings of this model were similar to the first one. The experimental design and the 
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number of animals per group are summarized in Table 1S in the supplementary 
material.  
 
Table 1. Experimental Design of EAE model; “n” indicates number of rats (samples) for each 
group.  
Treatment Day 0 Group description Day 10 Day 14 
Anesthesia only Healthy C10 n=15 
C14 
n=15 
CFA Peripheral inflammation P10 n=15 
P14 
n=15 
CFA+MBP Neuroinflammation + peripheral inflammation N10* n=15 
N14** 
n=15 
*1 sample was discarded due to blood contamination 
**3 samples were discarded due to blood contamination 
 
4.2.3 Data acquisition and analysis  
 
4.2.3.1 Neurological scores 
Disease symptoms and weights of all animals from both EAE models were recorded 
daily. The following scores for motor dysfunctions were used: 0, healthy animal with 
normal curling reflex at the tail; 1, paralysis of the tip of the tail; 2, loss of muscle tone at 
the base of the tail; 3, low posture of hind limbs; 4, instability at hips; 5, partial hind limb 
paralysis; 6, complete hind limb paralysis; 7, paralysis include midriff; 8, quadriplegia; 9, 
moribund; 10, death due to EAE (supplementary material). All experimental procedures 
were approved by Abbott’s Institutional Animal Care and Use Committee. 
 
4.2.3.2 CSF sampling, sample preparation and data acquisition  
On Day 10 and 14, animals were euthanized with CO2/O2. Terminal CSF samples were 
obtained by direct insertion of an insulin syringe needle (Myjector, 29G x 1/2") via the 
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arachnoid membrane into the Cisterna Magna. For this purpose a skin incision was 
made followed by a horizontal incision in the musculus trapezius pars descendens to 
reveal the arachnoid membrane. A maximum volume of 60 μL of CSF was collected per 
animal. Each sample was centrifuged within 20 min after sampling, for 10 min at 2000g 
at 4°C. After centrifugation the supernatants were stored at -80   ْ◌ C for further analysis. 
Previous experiments have shown that collecting up to 60 μL using this technique under 
these conditions provides hemoglobin-free CSF samples as measured by ESI-Orbitrap 
(unpublished data). As an additional check fresh samples, supernatant and pellet size 
were visually scored for hemolysis and samples were discarded if positive. 
From the set of 90 samples from the first EAE experiment (Table 1) 4 were 
contaminated with blood therefore they were excluded from the measurements. A set of 
86 CSF samples were prepared and measured as described below.  
10μL of rat CSF were thawed at room temperature and 240 μL D2O (99.96 at.%D) were 
added to the biofluid in order to obtain sufficient amount of sample for the NMR 
measurement. TSP-d4 (Sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4 ) (99 at.%D) was 
used as internal standard for chemical shift reference (δ 0.00 ppm). For the latter, 25μL 
of 8.8 mM TSP-d4 stock solution in D2O was added to 250 μL of rat CSF to a final 
concentration of 0.8 mM TSP. The TSP-d4 stock was prepared by weighing in dry TSP-
d4. The pH of the CSF was adjusted to around 7 (7.0 – 7.1) by adding phosphate buffer 
(9.7 μL 1M, to a final concentration of 35 mM). The final CSF NMR sample (284.7 μL) 
was then transferred to a SHIGEMI microcell tube for measurements. 
The 1D 1H NMR spectra of rat CSF samples were acquired on an 800 MHz Inova 
(Varian) system equipped with a 5 mm triple-resonance, Z-gradient HCN cold-probe.  
Suppression of water was achieved by using WATERGATE (delay: 85 Ps).18 For each 
1D 1H NMR spectrum 512 scans were accumulated with a spectral width of 9000 Hz 
resulting in a total of 18K points. The acquisition time for each scan was 2s. Between 
scans, a 8s relaxation delay was employed. Prior to spectral analysis, all acquired Free 
Induction Decays (FIDs) were zero-filled to 32K data points, multiplied with a 0.3 Hz line 
broadening function, Fourier transformed, manually phased and the TSP internal 
reference peak was set to 0 ppm - by using ACD/SpecManager software version 11.0.19 
All 86 rat CSF spectra were acquired and preprocessed as described above. However 
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due to high line broadening of the internal standard (TSP) four spectra were not included 
in spectral analysis. In total 82 spectra were subsequently transferred to Matlab, version 
7.6 (R2008b) (Mathworks, Natick, MA) for further analysis.  
The preparation and data acquisition of CSF samples from the second EAE experiment 
is described in the supplementary material.  
 
4.2.3.3 Preprocessing of NMR spectra  
The NMR spectral data was preprocessed, which typically involves baseline correction, 
alignment, binning, normalization and scaling.  Baseline correction of NMR spectra was 
performed by applying Asymmetric Least Squares method.20  Fluctuation in 
experimental conditions like sample temperature, pH, ionic strength can lead to chemical 
shift variations, therefore NMR spectra were aligned by using improved parametric time 
warping (I-PTW).21 A further problem is the high dimensionality of the data (circa 10000 
variables). It is common to apply binning to this kind of data, which reduces the number 
of variables. To perform proper spectral bucketing we used adaptive intelligent binning.22 
The chemical shift range G 0.75 – 4.15 was used for the binning procedure because it 
contained relevant information. Next, spectral resonances corresponding to one 
metabolite were summed and regrouped in one bin. This procedure was applied to the 
resonances where no overlapping was present and it led to 153 bins in total. To make 
spectra comparable between different samples, the final step of preprocessing consisted 
of integral normalization and supervised vast scaling applied to the binned data.23  
 
4.2.3.4 Metabolites identification and quantification 
Metabolite identification was carried out by using the 800 MHz library of metabolite NMR 
spectra from the Chenomx NMR Suite 5.1 (pH 6-8). The library of metabolite spectra is 
obtained based on a database of pure compound spectra acquired using a particular 
pulse sequence and acquisition parameters, the tn-noesy-presaturation pulse sequence 
with 4s acquisition time and 1s of recycle delay.24 The Chenomx NMR Suite software fits 
the spectral signatures (singlets, doublets, triplets etc), i.e. the peak shapes, of a 
compound from an internal database of reference spectra to the experimental NMR 
spectrum.  
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For quantification, that is determination of the concentrations of individual metabolites, 
Chenomx NMR Suite 5.1 uses the concentration of the known reference signal as 
calibration (in this case TSP-d4). Note that Chenomx approach is that peak shapes are 
fitted to the experimental ones.  In contrast, peak integration, which is often employed 
for quantification, is very sensitive to baseline distortions and even slightly overlapping 
resonances cannot reliably be integrated. Peak-shape fitting, like employed in Chenomx, 
is instead not much affected by base-line distortions. Moreover, even when some of the 
resonances and/or part of a resonance signature (triplet etc.) of a compound overlap 
with that of another compound, the peak shape can still be fitted with reasonable 
accuracy and the concentration of the compound reliably determined. 
 
4.2.3.5 Data analysis strategy 
Explorative analysis, by means of Principal Component Analysis (PCA),25 was used first 
in order to extract and display the systematic variation in the data. 
The strategy for multivariate supervised analysis, using Discriminant Analysis by 
Projection on Latent Structures (PLS-DA) 26 was designed in accordance with the 
experimental design summarized in Table 1. The data contain three main groups 
(healthy control “C10” and “C14”, peripheral inflammation “P10” and “P14” and mixture 
of neuroinflammation and peripheral inflammation “N10” and “N14”) in two time points 
(Day 10 and Day 14). The two time points (Day 10 and Day 14) were analyzed 
separately and we always differentiated between two groups. We have used PLS-DA, 
since it gives more interpretable results and it enabled us to observe the influence of 
single effects (i.e. peripheral inflammation, neuroinflammation or disease-progression) 
on the CSF metabolic profile. 
To corroborate the results we used another supervised method, ANalysis Of VAriance-
Principal Component Analysis (ANOVA-PCA). The analysis was performed on each time 
point separately as well as on the two time points combined.  Variables (metabolites) 
differentially profiled across groups of interest were selected based on regression 
coefficients in PLS-DA and on ANOVA-PCA, Hotelling T2 statistic with p-value inferior 
than 0.05).27   
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4.2.3.6 Model construction and validation 
PLS-DA is a variation of PLS.28 PLS-DA uses the group information to maximize the 
separation between groups of observations. It is currently widely used in metabolomics 
because of its ability to cope with high correlations between variables. In PLS-DA a 
linear model is constructed according to equation 1: 
 
y=Xb + r  (1) 
 
Where, X is a dataset matrix, y a vector of group memberships, b a vector of regression 
coefficient and r a vector of model residuals. The regression coefficients reflect the 
relative importance of the variables in the PLS-DA model. We divided the data into a 
training and a test set using the Duplex algorithm29 in such a way that the number of 
samples in the training set was equal for every considered group. The amount of 
samples in the test set was equal to at least 25% of the total number of samples but not 
more than 30%. To prevent model overfitting we applied the cross model validation 
(CMV) procedure, introduced by Anderssen et al. and Gidskehaug et al. 30, 31 in which 
double cross validation procedures are included for model optimization, the variable 
selection based on jack-knifing and final model performance assessment. All MATLAB 
routines for performing variable selection can be found in this reference.31 
Finally, all PLS-DA models were validated with the independent test set.  For every 
considered model the specificity and sensitivity of the test set were calculated. The final 
PLS-DA model was applied to the whole dataset if the accuracy of the independent test 
set was satisfactory (i.e. above 90% of correct classification). 
In order to predict the class labels (Ŷ) of validation set the scaled spectra (Xnew) have to 
be multiply by regression coefficient (b) obtained from PLS-DA model (i.e. Ŷ=Xnewb). 
Please keep in mind that scaling performed on validation set applied all necessary 
parameters (i.e. mean and standard deviation) from training set.   
 
4.2.3.7ANOVA-PCA  
Previously we showed that this approach allows identifying the relevant variables to 
distinguish groups.27 In this study the main factors are the metabolites effect (M) and the 
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treatments effect (T) (groups) plus a random dimension linked to the individual 
variations. The ANOVA model is given in equation 2: 
Xijk=μ + +Mi + Tj + MTij + eijk  (2)  
 
Where μ is a general mean, e is the error term and MTij indicates the interactions 
between main effects. The interaction between metabolites and treatments, i.e. groups, 
(MTij) is of highest interest because it reflects the influence of the different treatments on 
the intensity of metabolites when all others effects are averaged out. Therefore PCA is 
performed on the matrix of interaction effects to identify metabolites that contribute to 
this interaction. If the treatment (j) is relevant for the metabolite (i), the interaction MTij is 
significantly different from zero. 
 
4.2.3.8 Heat map and correlation network map  
In order to represent the relevant metabolites concentrations in groups “C14”, “P10” and 
“N14” we generated a heat map from NMR metabolomics data. The heat map is a 
graphical representation of NMR data in two-dimensional map, where the metabolites 
concentrations are illustrated as colors. Every concentration value was standardized 
according to the reference group (healthy group “C14”), i.e. by subtracting mean and 
dividing by the standard deviation of healthy controls. In that way the metabolites 
concentrations are expressed in values of standard deviation from the control group.  
The concentration of a certain metabolite does not fluctuate independently, but may be 
correlated and change with the others metabolites. To examine the level of observed 
changes among metabolites we calculated the Spearman’s correlation between relative 
metabolites concentrations in groups “C14” and “N14”, as well in groups “P10” and 
“N14”. Spearman correlation calculates the correlation of the ranks for metabolites 
concentrations, given in equation 3. 
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Where, Cr is a Spearman’s correlation, di is a difference between ranks of each sample 
on the two metabolites, n is the number of samples. 
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Extreme variations in concentration values have less influence on the Spearman 
correlation than on the Pearson’s correlation. The calculated correlations are then 
transferred to Graphviz 1.01 for network map visualization (http://www.graphviz.org). 
In the network map two metabolites are connected with a link if their correlation 
coefficient is relevant, i.e. exceeds a given threshold. The correlation between 
metabolites concentrations was significant if its value was superior than 0.7 and p-value 
was inferior than 0.05. 
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4.3 RESULTS 
4.3.1 Overview of the available data  
86 NMR spectra were measured, while 82 spectra were included in further analysis. An 
example of a 1H-NMR spectrum of rat CSF is shown in Figure 1c in the chemical shift 
region between 0.8 and 2.7 ppm. This region contains several signals from carboxylic 
acids and amino acids protons. Some of the metabolites are named in Figure 1c. For the 
analysis the NMR spectra were divided into 153 bins, which contain resonances of 33 
identified metabolites and some unidentified signals. The identified metabolites are listed 
in the supplementary material. The information concerning the second EAE model can 
be found in the supplementary material.  
The average neurological scores and standard deviations for group “N14” are shown in 
Figure 1b, the information of each individual animal is listed in the supplementary 
material. As can be observed the animals showed motor dysfunction at day 11. The 
average day of onset was 11.56 (+/- 0.2). This means that on average, animals were 
disabled for a period of 2.4 days (+/- 0.2) at the sampling day. In group “N14” only one 
animal showed disease duration shorter than 2 days (onset on day 13). The maximum 
score reached was on average 4.5 (+/- 0.2). Six animals showed a maximum score 
above this average. The average peak day (as defined by the first day of maximum 
score per individual animal) was 13.3 (+/-0.2). An idea would be to use the neurological 
scores for regression purpose for groups “N10” and “N14”. However all animals in group 
“N10” had neurological scores equal zero, while animals in group “N14” quite spread 
values from 0 till 6. This would cause an artificial compactness of samples from group 
“N10”, while group “N14” very spread. This would lead to biased PLS results. Therefore 
the neurological scores were not used. 
 
4.3.2 Explorative analysis by PCA  
Before performing pattern recognition, the spectra of 82 rat CSF samples were checked 
for outliers. In total 3 spectra were detected as outliers and were removed from the final 
analysis. Figure 1d shows the PCA score plot of the total dataset (79 vast scaled 
spectra). This plot shows that the samples belonging to group “N14” are clearly 
separated from the others samples along PC2. It also reveals that a large source of 
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variance in the data does not correspond to the available groups. No clear grouping is 
present since most of the groups overlap. With PCA only, we are not able to distinguish 
all analyzed groups. Therefore we needed to use more dedicated methods. 
4.3.3 Supervised multivariate analysis by PLS-DA and ANOVA-PCA 
 
4.3.3.1 PLS-DA of 1H-NMR CSF data 
PLS-DA models of the 1H-NMR spectra were performed to extract information on the 
metabolic effects of the different group treatments as presented in Table 1.  In Table 2S 
in the supplementary material the specificity, sensitivity, the correct classification rate for 
the test set and the total number of variables in the PLS-DA models are presented. 
Metabolites that contributed significantly to the group separation are listed in Table 3S in 
the supplementary materials. The results of these PLS-DA models urged us to revise the 
assumed effects for some groups of Table 1. The summary of the particular effects 
investigated by the different PLS-DA models is presented in Table 4S in the 
supplementary materials. As the first part of supervised analysis the comparison 
between “C10” and “C14” has been performed in order to find the metabolites that 
represent metabolic evolution over days. Later, this information was used to check if any 
of the discriminating metabolites are related to metabolic variation over time. In the 
remaining of this paragraph a detailed analysis of the results of the different models is 
given. 
The score plots of final PLS-DA models are presented in Figures 2a-2e. Note that score 
plots are used only for illustration purpose not determine the classification of PLS-DA 
model. 
Effect of neuroinflammation and peripheral inflammation 
The PLS-DA model for groups “C10” versus “N10” allows one to study the combined 
effect of neuroinflammation and peripheral inflammation.  This model has a high 
prediction ability of 100% for the independent test set. The area under the curve (93.4%) 
indicates that group “C10” and group “N10” are well separated and the PLS-DA has a 
high model performance. The CSF metabolic profile of the EAE-affected group can thus 
without a doubt be differentiated from the metabolic profile of the healthy group.  
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Figure 2. PLS-DA score plots derived from 1H-NMR spectra of rat CSF belonging to: (a) groups 
“C10” and “N10”. The amount of Y explained variance for two latent variables was equal to 
87.9%. (b) groups “P10” and “N10”. The amount of explained variance in Y for two latent 
variables was equal 58.3%. (c) groups “N10” and “N14”. The amount of explained variance in Y 
for one latent variable was equal to 89.6%.  (d) groups “C14” and “N14”. The amount of 
explained variance in Y for one latent variable was equal to 95.2%. (e) groups “P10” and “N14”. 
The amount of explained variance in Y for one latent variable was equal to 97.1%. (f) The 
projection of the independent samples from the second EAE model (group “P10-2” and group 
“N10-2”) on the PLS-DA score plot derived from group “P10” versus “N14” of the first EAE 
model. 
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Effect of neuroinflammation  
The PLS-DA model for groups “P10” versus “N10” allows one to discriminate the effects 
of peripheral inflammation and neuroinflammation on the CSF metabolic profile. This 
model shows poor prediction (accuracy for the independent test set is 62.5%) and the 
sensitivity for group “N10” is very low (predicted as belonging to group “P10”). The score 
plot (Figure 2b) illustrates two subgroups in group “N10”, one overlapping with group 
“P10” and a second cluster further away. This result suggests that animals in group 
“N10” are heterogeneous regarding to the disease response. Probably, within group 
“N10” some animals did not show any neuroinflammation yet, indeed at Day 10, no 
neurological deficits have been observed in this particular experiment. Therefore for 
some animals the peripheral inflammation is still the dominant effect since the 
neuroinflammation has not developed yet. A hierarchical clustering was performed on 
group “N10” to confirm the heterogeneity of the group (data not shown). Three samples 
were identified as outliers for group “N10”. This suggests that the response of the 
animals to the disease in the EAE model was not uniform and some animals’ response 
is shifted along time. The neurological scores recorded for group “N10” on average were 
equal to 0. This means that by examination of the rat’s motor system no external 
neurological or pathological physical signs were observed.  The heterogeneity of group 
“N14” was further investigated with ROC curve analysis. The area under curve (60%) 
shows that group “P10” and group “N10” are not well separated.  
The PLS-DA model for groups “N10” versus “N14” allows one to study the progression 
of disease. The classification model has perfect accuracy (overall classification of 100% 
for independent test set).  
Investigation of the second time point (Day 14) by PLS-DA allows one to identify the 
metabolites differently profiled during the peak of disease. The PLS-DA model of “C14” 
versus “N14” has perfect prediction ability (overall classification is 100% for independent 
test set).  
Effect of peripheral inflammation during the peak of the disease 
The overall correct classification rate for independent test set of this model is only 65%. 
The area under the ROC curve is 59%. These results suggest that the metabolic profiles 
of group “C14” and group “P14” are quite similar. Based on these data we can make the 
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statement that at Day 14 the effect of an immunopotentiator, i.e. CFA, was not 
measurable based on the metabolite profile. Our interpretation of these results is that 
peripheral inflammation has vanished by Day 14 and group “P14” is actually healthy. 
This interpretation is coherent with the absence of external symptoms (i.e. fever and 
swelling pad). Since group “P14” is not  
inflamed anymore the PLS-DA models of group “P14” vs. “N14” and “N14” vs. 
(“C14&P14”) give similar results as the PLS-DA model of the healthy group “C14” vs. 
group “N14”. In both situations the overall correct classification for independent test set 
is 100%. The PLS-DA model of “P10” vs. “P14” is described in the supplementary 
material.  
P10 vs N14 : Peripheral inflammation effect versus neuroinflammation effect 
Based on the experimental design the effect in group “N14” is a combination of 
peripheral inflammation (CFA effect) and neuroinflammation (MBP effect). However, 
considering the conclusion that at Day 14 the peripheral inflammation has vanished, 
group “N14” should show only neuroinflammation. Because group “N10” was is 
heterogeneous in disease onset, we used groups “P10” and “N14” to distinguish 
peripheral inflammation from neuroinflammation. We performed this comparison, 
knowing that groups “P10” and “N14” represent different conditions, i.e. Day 10 for group 
“P10” and Day 14 for group “N14”. This comparison should yield the metabolites 
influenced by peripheral inflammation or neuroinflammation. 
The “P10” vs.”N14” PLS-DA model should carry the information about the metabolites 
differentially profiled in peripherally inflamed and neuroinflamed subjects. The PLS-DA 
model shows perfect prediction ability with an overall correct classification of 100% for 
independent test set. Based on our results these two groups indeed have different 
metabolic profiles. 
 
4.3.3.2 ANOVA-PCA of 1H-NMR CSF data 
To confirm the results from the PLS-DA models we used ANOVA-PCA as a 
corroborative technique to identify metabolites that vary significantly between groups. 
The factors modeled in this study are the factor treatment (CFA, CFA+MBP or no 
treatment), and the different metabolites (the Metabolite factor). The resulting biplots of 
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the ANOVA-PCA are displayed in Figures S2 (a-d), while the group specific metabolites 
are summarized in Table S5 in the supplementary materials. In the next part of this 
paragraph an overview of the results derived from ANOVA-PCA are discussed.  
Except for a few metabolites, the same set of metabolites for peripheral as well as 
neuroinflammation was selected by ANOVA-PCA. ANOVA-PCA showed that the 
metabolic profiles of healthy group, peripheral inflamed and neuroinflamed animals can 
be distinguished. Moreover it showed that groups “C14” and “P14” have similar 
metabolic profiles. 
 
The most discriminating metabolites and their absolute concentrations are presented in 
Table 2; their short biological interpretation is further discussed in the section 
‘Discussion and Conclusion'. 
As a final step, to make the PLS-DA model more robust and generic (i.e. machine 
independent), PLS-DA model was constructed for the absolute concentration of the 
metabolites. This is, however, a time consuming step and therefore we performed it only 
for the “P10” and “N14” groups. The PLS-DA model for group “P10” versus group “N14” 
shows perfect prediction ability with an accuracy of 100% on the independent test set. 
The score plot of this model is shown in the supplementary material (Figure 3S). This 
model is further validated with an independent set of animals, derived from a second 
EAE experiment. 
 
4.3.4 Heat map and correlation network map  
In order to represent the individual differences in metabolites concentrations of healthy 
controls (“C14”), peripherally inflamed (“P10”) and neuroinflamed (“N14”) animals a heat 
map of the metabolomics data was constructed (Figure 3a). The metabolite 
concentrations were standardized with respect to the healthy group “C14”. The 
metabolites included in the heat map correspond to the significant ones shown in Table 
2. The heat map shows that the metabolite concentrations, characteristic for 
neuroinflammation, change significantly in group “N14”. For instance arginine 
concentration is elevated in group “N14” in comparison to healthy and peripherally 
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inflamed controls.  On the contrary alanine is reduced. The intra-individual variations are 
still observable.  
To assess the correlation between metabolites, we calculated Spearman’s correlation 
between relative metabolites concentrations in groups “C14” and “N14”, as well as in 
groups “P10” and “N14”. Those correlations are visualized as a network map (Figure 3b-
3c) to provide an overview of similarities between different metabolites in the considered 
groups. In Figure 3b a correlation network map between metabolites in healthy group 
“C14” and neuroinflamed group “N14” is presented. There are just a few shared 
correlations (indicated with a dashed line), i.e. significant correlations seen in both 
groups. These correlations are thus not influenced by neuroinflammation. Figure 3c 
shows the correlation network map between metabolites in peripherally inflamed group 
“P10” and neuroinflamed group “N14”.  There are only a few correlations present in 
group “P10” (solid, black line) and shared correlations between groups “P10” and “N14” 
are absent. What is particularly noteworthy is the fact that many correlations, present in 
the healthy control, vanished due to neuroinflammation, but also some new correlations 
appeared. 
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Figure 3. (a) Heat map of selected metabolites for groups “C14”, “P10” and “N14”.  Each row 
represents a metabolite, and each column corresponds to an animal from healthy group “C14” or 
peripherally inflamed group “P10”, or neuroinflamed group “N14”.  The relative metabolite 
concentrations were standardized with respect to healthy group. Red and blue colors represent 
elevation or reduction of a given metabolite concentration, respectively. NAA stands for N-
acetylaspartate, while σ indicates the standard deviation of the healthy control. (b) Correlation 
network map between metabolites identified with high certainty: in healthy group “C14” and 
neuroinflamed group “N14”; (c) in peripherally inflamed group “P10” and neuroinflamed group 
“N14”. A solid black line indicates a significant correlation (i.e. correlation > 0.7 and p-value < 
0.05) occurring in the first group (healthy group “C14” or peripherally inflamed group “P10”). A 
dotted line signifies the significant correlation unique for neuroinflamed group “N14”. A dashed 
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line represents a significant correlation seen in each group. The red and blue boxes represent 
elevated or reduced metabolite concentrations in neuroinflamed group “N14”, respectively. NAA 
stands for N-acetylaspartate. 
4.3.5 Prediction of neuroinflammation in an independent set of animals 
To confirm the validity of the discovered disease specific markers for neuroinflammation, 
we used an independent set of samples coming from another EAE experiment, in which 
we want to predict neuroinflammation in an early stage. The absolute concentration of 
our markers was determined for the group with peripheral inflammation at Day 10 (here 
called group “P10-2”) and the group with peripheral and early neuroinflammation at Day 
10 (here called group “N10-2”). All peripherally inflamed animals (group “P10-2”) are 
correctly classified. Animals with peripheral inflammation and early neuroinflammation 
(group “N10-2”) are also correctly classified, except for one animal. The overall correct 
classification for the independent set of samples is 95.8%, with specificity for group 
“P10-2” and group “N10-2” equal to 100% and 91%, respectively. The projection of 
these independent samples on the PLS-DA score plot derived from group “P10” versus 
“N10” is shown in Figure 2f. It is important to note that the misclassified sample is 
located close to the borderline between the two groups.  This result suggests that 
proposed markers have a similar behavior in the second study.  
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4.4 DISCUSSION AND CONCLUSIONS 
Supervised analysis of CSF 1H-NMR data revealed significant changes in biochemical 
composition of the CSF metabolic profile amongst the analyzed groups. PLS-DA and 
ANOVA-PCA have been used to model the metabolic profiles from rat CSF. The small 
differences between PLS-DA and ANOVA-PCA results may arise from the principles of 
the two methods. PLS-DA aims to select a subset of metabolites which gives the highest 
separations between groups. This may imply that not all discriminatory metabolites are 
selected. In the case of ANOVA-PCA the amount of selected variables mostly depend 
on α level Hotelling T2. In addition the two different scaling approaches applied before 
PLS-DA and ANOVA-PCA may have an influence on the selection of metabolites. 
 
Interpretation of PLS-DA models and ANOVA-PCA yielded a set of relevant metabolites, 
which are shown in Table 2. In this section we further discuss their biological 
interpretation 
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Table 2. Average absolute concentration (Cμ) and standard deviation (σ) of metabolites 
important for peripheral inflammation or neuroinflammation selected based on PLS-DA and 
ANOVA-PCA.  
 
Groups 
healthy P10 N10 N14 
Metabolites Cμ [μM] σ [μM] Cμ [μM] σ [μM] Cμ [μM] σ [μM] Cμ [μM] σ [μM] 
NAA* 13.5 2.5 14.8 1.7 16.5 2.3 21.0 3.6 
arginine 39.0 10.5 37.5 8.4 46.2 11.8 62.3 17.8 
lysine 72.5 9.6 68.5 11.6 89.0 15.0 135.6 29.5 
choline 5.6 1.4 5.9 1.2 8.0 1.1 10.6 1.8 
malonate 120.4 17.2 126.6 17.2 122.2 33.2 40.5 10.9 
alanine 51.9 5.1 55.5 7.3 51.8 8.8 34.3 4.6 
citrate 200.2 21.8 143.0 21.2 145.9 37.5 105.4 23.5 
creatine 70.6 9.3 69.1 11.2 80.1 9.1 91.3 8.7 
glutamine 606.4 93.4 531.9 96.4 544.7 71.6 654.3 127.2 
lactate 2660 551.9 2757.3 387.2 3723.0 671.8 2869.3 282.0 
3-hydroxy* 494.4 17.2 430.7 25.8 439.9 33.5 510.8 15.4 
* 3-hydroxy stands for 3hydroxyisovalerate; NAA stands for N-acetylaspartate 
 
Metabolites related to neuroinflammation: Choline, N-acetylaspartate, creatine, lysine, 
arginine, alanine and malonate 
The concentration of choline was elevated in groups “N10” and “N14”. However, the 
choline concentration stayed invariable between two control groups “C10” and “P10”. In 
a previous study, where MScl patients and EAE model in marmoset  were studied by 1H-
NMR spectroscopy, higher choline concentrations have been reported as a marker for 
demyelination in urine.32 This metabolite is required for synthesis of neurotransmitter 
acetylcholine, and phosphatidylcholine. The increase in choline concentration could be 
due to demyelination and/or cell membrane breakdown. 
 151 
Another metabolite found as being highly correlated with EAE-affected groups “N10” and 
“N14” and which enabled to differentiate these groups from the others was N-
acetylaspartate (NAA). This compound is known as a marker of neuronal damage. Its 
concentration was elevated in the “N14” group. In addition this metabolite distinguished 
neuroinflammation from peripheral inflammation in the PLS-DA model. NAA is a free 
amino acid present in neuronal cell and it has been culpably involved in many processes 
of the nervous system: for instance it may be involved in the myelin production, 
regulation of neuronal protein synthesis or the metabolism of several neurotransmitters 
such as aspartate or N-acetyl-aspartyl-glutamate. 
Two other metabolites, creatine and malonate, were found to vary between the two 
EAE-effected groups. Creatine level was found to be up regulated in group “N14”. 
Creatine is considered as one of the principal brain metabolite. Its changes in 
concentration are seen in many other neuro-degenerative disorders and are caused by 
gliosis 33 or scarring of neuron (demyelination). Elevated level of creatine in patients with 
MScl was found in a previous study and has been associated as marker of gliosis.34, 35 36 
Up regulated creatine level could be due to a change in the cellular composition, either 
increased inflammatory cells or glial cells. Malonate level was reduced in neuroinflamed 
group “N14”. Another metabolite found to be reduced in neuroinflamed group “N14” is 
alanine. Reduced level of alanine in patients with MScl in comparison to patients with 
cerebrovascular disease was found in a previous study, where Sinclair et al used NMR 
spectroscopy to evaluate the ability of metabolomics analysis to differentiate 
neurological disease.37 Alanine is used as a source for pyruvate for energy metabolism 
or to synthesis of macromolecules within neural and immune cells.38 Reduction of 
alanine concentration may be connected to energy metabolism, since it might be used 
by invading cells. 
Lysine and arginine were found to have a high correlation with EAE-affected groups 
“N10” and “N14”. Lysine and arginine levels were up regulated in group “N14” compared 
to “N10” and in “N10” compared to “P10”. This indicates their relation to 
neuroinflammation. Lysine and arginine are metabolites which may differentiate 
peripheral inflammation from neuroinflammation. Arginine is used to synthesize nitric 
oxide (NO). Elevated levels of NO oxidation products in the CNS have been shown in 
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bacterial meningitis in cerebral lupus erythematosus. Recently it was demonstrated that 
increased levels of NO oxidation plays a part in the generation of MScl symptoms.39 
Inhibition of NO synthesis may suppress40 or emphasis EAE.41 However, the precise 
role of NO in EAE and MScl still remains elusive and unclear. Qureshi and cowworkers 
have studied a role of neurotransmitters amino acids in CSF of MScl patients. 42 They 
have reported increased level of lysine in CSF in MScl patiens. 
 
Metabolites related to peripheral inflammation: citrate, glutamine, lactate and  
3-hydroxyisovalerate 
Citrate is a key metabolite to differentiate the healthy group “C10” from the peripherally 
inflamed group, “P10” but also the peripherally inflamed group from the EAE affected 
group “N14”. Reduced citrate is in line with a previous study of Sinclair and coworkers.37 
The difference in citrate level is larger between the peripherally inflamed and 
neuroinflamed group than between the healthy control and the peripherally inflamed 
group. The citrate level may indicate the degree of inflammation. Citrate is released to a 
larger extent from astrocytes than from neurons. This metabolite is an intermediate in 
tricarboxylic acid cycle (TCA). In the study of Smith and coworkers43 the metabolic 
activity of proteins from myelin and non-myelin fractions of spinal cords of Lewis rats 
with EAE was investigated using [1-14C]leucine as a protein precursor.  In this study they 
showed that the decreased activity of the TCA cycle exists. However, the implication of 
the citrate alternation is unclear although it was already noted in Alzheimer’s and in MScl 
disease.37, 44  
Glutamine is an amino acid, which plays an important role in brain metabolism. This 
metabolite is involved in energy metabolism. It was shown that glutamine is a necessary 
nutrient for cell proliferation, serving as a specific fuel for inflammatory cells and 
enterocytes and, when present in appropriate concentrations, enhancing cell function. 
During inflammatory states, glutamine consumption may outstrip endogenous production 
and a relative glutamine deficiency state may exist.45  
A higher level of lactate was found in group “N10” in comparison to group “N14”. 
Predominant lactate peaks have already been reported in inflammatory CNS diseases. 
The amount of CSF lactate depends largely on production from CNS glycolysis. 
 153 
Increased lactate production by immune cells is observable in the presence of 
inflammation. Although elevations in CSF lactate may occur because of many different 
processes, for instance hypoxia of inflamed tissues, reduced blood flow from cerebral 
edema, and granulocyte and bacterial metabolism.46 In addition elevated lactate levels 
have been identified in vitreous.  
The reduced level of 3-hydroxyisovalerate was established for group “N10” and group 
“P10” when compared with the healthy group. This suggests that this metabolite is 
involved in peripheral inflammation. However this result deserves more attention since a 
previous publication demonstrated an increase in 3-hydroxyisovalerate level in some 
MScl patients.47   
Conclusions 
We investigated the effect of neuroinflammation and peripheral inflammation on the 
metabolic state of CSF in the rat EAE model, a mimic of the neuroinflammatory aspect 
of the early stage of MScl. In the animal study untargeted and unbiased biomarker 
discovery approach consisting of high-field 1D 1H NMR combined with multivariate data 
analysis was employed.  
CSF is demonstrated as a valuable biofluid for the investigation of neurological disorders 
in the CNS. We found that 1H-NMR is a powerful technique capable of providing 
information for the identification and quantification of a large number of metabolites in 
CSF. 
The use of two statistical techniques (PLS-DA and ANOVA-PCA) contributes 
significantly to the reliability of the results. The two methods are corroborative, because 
the overall results obtained by PLS-DA and ANOVA-PCA were found to be coherent.  
The CSF metabolic profile for neuroinflammation is distinct from that of healthy and 
peripheral inflammation and characterized by changes in concentrations of metabolites 
such as creatine, arginine and lysine. Peripheral inflammation was only seen at Day 10 
and absent at Day 14. A further interesting observation was that the correlation network 
map is much more complex for the healthy group than for the groups affected by 
peripheral inflammation or neuroinflammation. Disappearance of correlation between 
metabolites in peripherally inflamed and neuroinflamed animals might be related to 
change of penetrability of the blood-brain-barrier (BBB). Under standard physiological 
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circumstances BBB controls the homeostasis of the interstitial cerebral fluid.48 It is 
known that during EAE changes in the BBB function occur.  It causes disruption in the 
BBB and affects the saturable transport system of substances involved in disease 
process.49 Injection of CFA can itself lead to increased BBB permeability to small 
molecules and even certain serum proteins.50 These disturbances might then cause 
changes in metabolites flux across BBB and relations between them. For instance the 
correlation might become more non-linear or weaker and therefore be absent in disease 
stage under selected threshold. In addition in EAE there is a strong increase in 
infiltration of the BBB by monocytes and activated lymphocytes which is bound to 
change the metabolite profile of the fluids. Not only a disrupted BBB leads to "leakage", 
but activated immune cells crossing the BBB and entering the interstitial fluid and the 
CSF produce metabolites that change the overall profile of the fluids they are in. 
Interestingly some markers of neuroinflammation have been connected to demyelination 
and neuronal damage. In EAE model induced with MBP demyelination is missing or 
limited to the ventral root exit and dorsal root entry zone of the spinal cord. In the case of 
Lewis rats primary demyelination is restricted to occasional perivenous myelin sheaths. 
In general, demyelination is more distinct when addition of other CNS antigens to the 
MBP results in pronounced demyelination. In addition, some demyelination was 
observed in guinea pig EAE model incorporated with MBP inoculums utilized for 
sensitization.51 However the presence of demyelination in the EAE model induced with 
MBP is a matter of debate. Therefore we believe that it needs additional investigations. 
In current study the presence of demyelination could be investigated by for instance 
repeating the EAE model and then performing histology studies or electron microscopy 
of spinal cord. Another possibility would be to use Magnetic magnetic resonance 
imaging to study the pathology of rats’ brain and spinal cord. These steps could 
demonstrate the presence or absence of demyelination. 
By using an independent set of animals, i.e. coming from another EAE experiment, we 
demonstrated that this model and ipso facto the disease specific markers have ability to 
predict neuroinflammation in its early stage with high accuracy. Thus, these animal-
model based markers may be used to diagnose the early stage of neuroinflammation. 
 155 
Further developments will include the investigation and translation of our results to a 
clinical context, i.e. how these results can be used to predict MScl.  
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ABSTRACT 
Cerebrospinal fluid (CSF) is the biofluid in closest interaction with the central nervous 
system. Therefore it holds promise as a reporter on neurological disease such as 
Multiple Sclerosis (MScl). To characterize the metabolomics signature of the 
neuroinflammation aspects of this disease we studied an animal model of MScl: the 
Experimental Autoimmune/Allergic Encephalomyelitis (EAE). CSF also exchanges 
metabolites with blood via the blood-brain-barrier. Therefore, malfunctions occurring in 
the CNS may be reflected in the biochemical composition of blood plasma. The 
combination of blood plasma and CSF provides more complete information about the 
disease. Both biofluids can be studied using NMR spectroscopy.   It is then necessary to 
perform a combined analysis of the two different datasets. In consequence mid-level 
data fusion was applied to blood plasma and CSF datasets. Firstly, the relevant 
information is extracted per biofluid dataset using linear support vector machine 
recursive feature elimination. The selected variables per dataset are concatenated in 
order to be analyzed jointly by Partial Least Squares Discriminant Analysis (PLS-DA). 
The combined metabolomics information from plasma and CSF allows for a more 
efficient and reliable discrimination of the onset of the EAE. Secondly, we introduce 
Hierarchical Models Fusion, in which previously developed PLS-DA models are 
hierarchically combined. We show that this approach allows one to distinguish 
neuroinflamed rats (even on the day of onset) from either healthy or peripherally 
inflamed rats. Moreover, the progression of EAE can be investigated thanks to the 
model separating the onset and the peak of the disease.  
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5.1 INTRODUCTION 
Multiple Sclerosis (MScl) is an inflammatory, presumably autoimmune disease of Central 
Nervous System (CNS) in which the fatty myelin sheaths which surround the axons of 
the brain and spinal cord are damaged, leading to demyelization1. MScl is one of the 
most common neurological disease affecting young adults and it has enormous effect on 
the health system and economy of different countries. The cause of MScl is still elusive. 
However it is believed that it is a combination of genetic and environmental factors with 
a possible infectious origin. Signs of MScl can be observed not only in CNS but also in 
the peripheral nervous system (PNS) 2. 
Diagnosis of MScl still remains challenging, especially in its early stage. Currently the 
diagnosis of MScl is mostly based on clinical evidence complemented with laboratory 
investigations, like the presence of lesions in the brain and/or spinal cord (visualized by 
magnetic resonance imaging (MRI)). However, lesions have been found in other 
neurological diseases, like Guillain-Barré syndrome 3, as well as in non-neurological 
diseases such as systematic vasculitis 4  or sarcoidosis 5.  Furthermore, brain lesions 
have been found in healthy individuals 6. Therefore, brain lesions are not specific 
enough for proper, early diagnosis. In order to improve diagnosis of MScl it is necessary 
to combine the information from Cerebrospinal fluid analysis, MRI results and all clinical 
symptoms.  
 In order to fingerprint MScl at the molecular level the biological samples have to be 
analyzed. Since CSF is the biofluid in direct contact with the brain and spinal cord, it is 
the most suitable choice for fingerprinting MScl. The investigation of biochemical 
composition of CSF may indicate the abnormal status of the brain. The CSF is absorbed 
into the blood via a semi-permeable membrane, the blood-brain barrier (BBB). 
Therefore, effects of CNS diseases can potentially also be seen in the biochemical 
composition of blood plasma. Obviously, cross-over effects from the plasma to the CSF 
may also cause changes in biochemical composition of the CSF. In MScl, the BBB is 
often damaged causing “leakage” 7. This suggests that plasma may contain predictive 
information about the disease. Therefore we propose to study the metabolic profiles of 
both CSF and plasma. These types of samples are relatively difficult to obtain in humans 
and interesting information is very often obscured by other factors, like genetic, 
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environmental and dietetic backgrounds. Thus we opt for the possibility of using samples 
from designed and controlled experiments in rodents. 
The animal model of MScl, the Experimental Autoimmune/Allergic Encephalomyelitis 
(EAE) model has become an important tool to study the neuroinflammatory aspect of 
MScl 8, 9. EAE is a cell-mediated experimental autoimmune disorder of the CNS and 
shares its clinical expression and pathological picture with that of MScl. EAE is used as 
a pre-clinical model of a single episode of MScl. Similar to MScl, in EAE a strong 
increase in infiltration of the BBB occurs, which leads to increased exchange between 
CSF and plasma.  
In this study we have extracted CSF and plasma samples at two time points of the 
disease progression, namely at the onset and the peak; these samples were obtained 
for healthy, immune booster (a group of animals injected with Complete Freund Adjuvant 
emulsion, CFA) and EAE (resembling MScl) Lewis rats. The metabolic profile of the CSF 
and plasma was measured using the untargeted and unbiased technique of high-field 
1D proton Nuclear Magnetic Resonance (1H-NMR). This method allows one to analyze 
both biofluids with very similar measurements protocol. The 1H NMR data of each 
biofluid can be analyzed separately or the two complementary NMR data sets can be 
combined (fused) in the analysis. In this work CSF and blood plasma NMR spectra were 
used in a mid-level data fusion. The metabolite information extracted for each biofluid 
can be directly translated into relative concentrations for each biofluid and compared.  
To obtain such information from the individual or combined data sets several analysis 
challenges have to be solved. First, the disease must be distinguished from the healthy 
condition but also from other diseases such as peripheral inflammation. This means that 
we need to construct a multi-class classifier. Second, even if well controlled the 
experiment still carries additional variances unrelated to the study, i.e. biological and 
experimental variations. Thirdly, the number of variables recorded by NMR is much 
larger than the number of samples which implies specific statistical problems. Moreover 
most of these variables are probably unrelated to the studied problem or redundant. To 
solve these problems we propose the following architecture for the data analysis. Linear 
support vector machine recursive feature elimination (SVM-RFE) is used as variable 
selection technique for both data sets. The selected variables are fused and analyzed 
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using either one multi-class Partial Least Squares Discriminant Analysis (PLS2-DA) 
model or multiple 2 classes PLS-DA models. The latter using a novel approach where a 
hierarchical structure permits to introduce prior knowledge. We introduce this method as 
Hierarchical Models Fusion (HMF). We show that by using HMF, EAE affected rats can 
be distinguished from either healthy or peripherally inflamed rats at the day of onset 
(when no physical symptoms of neuroinflammation are present) with a 100% correct 
classification rate. In addition the progression of EAE can be described. In summary, 
HMF allows one to characterize all studied groups simultaneously without applying 
multiclass classifier. 
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5.2 MATERIALS AND METHODS 
5.2.1 Experimental design of EAE models 
The Experimental Autoimmune/Allergic Encephalomyelitis (EAE) is the common animal 
model for studying the neuroinflammation aspect of the autoimmune disease of Multiple 
Sclerosis (MScl). The experimental setup was as previously described by Smolinska et 
al. and/or Hendricks 10, 11. Here, we briefly summarize the main points. Three sets of 
male Lewis rats (Harlan Laboratories B.V., the Netherlands) were inoculated on Day 0.  
First, a set of 30 animals was injected with  guinea pig myelin basic protein (MBP), 
Complete Freund Adjuvant H37 RA (CFA, Difco Laboratories, Detroit, MI) and 
Mycobacterium tuberculosis type H37RA (Difco). Another group of 30 animals was 
injected with CFA only. Next to these MBP and CFA challenged rats, referred to as the 
EAE group and peripherally inflamed group, respectively, a healthy group undergoing 
anesthesia only (healthy control) was included.  In each group, half of the animals were 
sacrificed to collect both CSF and plasma on Day 10 (onset of disease in EAE group) 
and the other half on Day 14 (peak of disease in EAE group). The typical progression of 
the disease is shown in Figure 1S in the supplementary material, while the details of the 
design of the EAE experiment are summarized in Table 1. 
 
Table 1. Experimental design of EAE model; “n” indicates a number of rats; p – indicates a 
number of common samples between CSF and plasma.   
Group Inflammation type Day 10 Day 14 
Healthy None 
C10 
n = 15 
p= 14 
C14 
n = 15 
p=14 
CFA Peripheral 
P10 
n = 15 
p= 14 
P14 
n = 15 
p=15 
CFA+MBP Peripheral& neuroinflammation 
N10 
n = 15* 
p=14 
N14 
n = 15** 
p=11 
* 1 sample from CSF was discarded due to blood contamination and one from blood plasma due to 
sampling 
** 3 samples from CSF was discarded due to blood contamination and two from blood plasma due to 
sampling and preparation 
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5.2.2 CSF and plasma sampling, sample preparation and data acquisition 
On Day 10 and 14, animals were euthanized with CO2/O2 and blood and CSF were 
collected. Sampling, sample preparation and data acquisition of CSF NMR spectra was 
as previously described 11. The blood was sampled intravenously with a Heparin-treated 
syringe. Next, every blood sample was centrifuged for 10 minutes at 4°C with a relative 
centrifugal force of 2000g in order to extract plasma. After centrifugation the 
supernatants were stored at -80qC for further analysis.  
For the NMR measurements, an aliquot of 50 μL of the stored frozen plasma was left at 
room temperature for thawing. Next, the plasma sample was diluted into 200 μL of water 
and then proteins were removed by centrifugation for 30 minutes at 2000g (filter 10 kDa 
Centrisart I 13239-E, Sigma Aldrich, St. Louis, MO, USA) 12. After protein removal, the 
supernatant was lyophilized. Prior to NMR measurements the lyophilized plasma 
samples were re-dissolved in 50μL of water, after which  550 μL of buffer solution was 
added  to obtain sufficient volume for NMR measurement. The buffer solution consisted 
of 2.85 mM TSP-d4 (Sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4) (99 atom %D), 6.92 
mM Sodium-azide (NaN3), 42.08 mM Sodium Phosphate dibasic dehydrate 
(Na2HPO4·2H2O) and 7.30 mM HCl solvated in a H2O:D2O (99.96 atom %D) mixture 
(7.93:1). The final TSP concentration in each plasma sample was equal to 2.61 mM. 
The 1H-NMR spectra of the 86 plasma samples were acquired on an AVANCE III 
(Bruker BioSpin, Bruker Inc., Billerica (MA), USA) 500 MHz system equipped 5mm 
cryoprobes, CPTCI (1H-13C/15N/2H + Z-gradients) (Bruker BioSpin, Bruker Inc., 
Billerica (MA), USA). Water suppression was achieved using pre-saturation. For each 
1D 1H NMR spectrum 256 scans were accumulated with a spectral width of 10273 Hz 
resulting in a total of 18K points. The acquisition time for each scan was 3.2s. Between 
scans, a 4s relaxation delay was employed. Prior to spectral analysis, all acquired Free 
Induction Decays (FIDs) were zero-filled to 32K data points, multiplied with a 0.3 Hz line 
broadening function, Fourier transformed, manually phased and the TSP internal 
reference peak was set to 0 ppm - by using ACD/SpecManager software version 12.0 13. 
All 86 rat CSF spectra were acquired and preprocessed as described in 11. However, 
due to high line broadening of the internal standard (TSP) four spectra from CSF and 
plasma were not included in the spectral analysis. Ultimately, 82 CSF spectra and 86 
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plasma spectra were transferred to Matlab (version 7.9, Mathworks Inc., Natick (MA), 
USA) for further analysis, of which 82 samples showed overlap between both CSF and 
plasma spectra (see Table 1).  
 
5.2.3 Preprocessing of CSF and plasma NMR spectra  
The 1H NMR spectral data was preprocessed in Matlab, which typically involved 
baseline correction, alignment, binning, normalization and scaling. For 4 samples (out of 
the 86) only plasma 1H NMR spectra were available. Therefore these four spectra were 
not used in the pre-processing and analysis process. Baseline correction of NMR 
spectra was performed by applying Asymmetric Least Square method 14.  Fluctuation in 
chemical shift variations were removed by applying improved parametric time warping (I-
PTW)15. Each CSF and plasma spectrum was normalized to a total area-under-curve 
(AUC) of 1, to correct for potential differences in sample concentration. In order to 
reduce the high dimensionality of the data, binning was performed by means of adaptive 
intelligent binning 16. This procedure led to 409 bins for CSF and 478 for plasma, which 
can be considered as relative metabolites concentrations. The absolute quantification of 
metabolites in CSF and plasma samples was not performed and used. Data analysis 
was performed on binned data, i.e. on relative metabolites concentrations. The final step 
of preprocessing consisted of autoscaling. 
 
5.2.4 Data analysis 
Explorative analysis by means of robust-Principal Component Analysis (R-PCA) was first 
used to control the presence of outliers in both datasets 17. The strategy for supervised 
data analysis consisted of data division into a training set (75% of samples per class) 
and an independent test set (25% of samples per class) by using the Duplex algorithm 
18, variable selection by Support Vector Machine Recursive Feature Elimination (SVM-
RFE) for linear kernels 19 performed on each dataset (CSF and plasma) separately and 
discriminant analysis by PLS-DA 20 employed on both individual and fused datasets. For 
data fusion so called mid-level data fusion architecture was employed 21. In this 
approach the two data sources are first pre-processed and analyzed separately to 
extract relevant information and next they are fused and analyzed as unique dataset. 
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We used this method, since it was shown that it eliminates variables redundancy. 
Particular steps of this type of data fusion are described in sections 4.1 and 4.2. In this 
fusion approach every data source is treated separately for pre-processing, scaling and 
variable selection. Next, the most optimal set of variables is combined into a single set 
and analyzed with PLS-DA. In the last step of data analysis the approach for cumulative 
fusion by means of Hierarchical Models Fusion (HMF) was carried out. This method, 
proposed for the first time in this paper, is described in detail in the section 4.2. The 
results of this method are compared to PLS2-DA, a variation of PLS-DA which allows 
more than 2 groups to be analyzed simultaneously (see 4.2).  
 
5.2.4.1 SVM-RFE  
SVM-RFE was originally proposed by Guyon et al. 19 and applied to a microarray 
dataset in a cancer study. The method is based on the binary classification method 
SVM. This technique first maps objects into a feature space using kernel transformation 
and then tries to find a hyperplane which separates the data into two classes 22. From all 
separating hyperplanes, SVM looks for the one that gives the biggest separation 
between the borderline training samples of the two classes. The borderline training 
samples are called support vectors. All support vectors have an alpha value, indicating 
how supporting this object is for the position of the hyperplane. Non-supporting objects 
have alpha value equal 0, while alpha equal to 1 indicates the highest support. RFE is a 
backward elimination algorithm, which ranks features based on the weights of linear 
SVM. The algorithm starts with a full training set to train a linear SVM. Next, the 
variables are ranked by sorting in descending order the square of the SVM’s weights 
{wj2} 
 
wj2=(∑i=φαiyixij)2          (1) 
 
where ࣐ contains the indexes of support vectors, αi are alpha values and yi are the class 
labels. A variable with smallest weight wj is then removed. Indeed the smaller the weight 
of a variable is, the less it contributes to the size of the margin between classes. The 
remaining variables are used to train another linear SVM and all the process is repeated 
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until all variables have been eliminated. In our paper, one variable is removed in each 
iteration. 
We have used a Leave-One-Out (LOO) Cross-Validation (CV) approach to select the 
optimal set of variables per data sets. In this procedure one sample from the training set 
is left out and a variables ranking is obtained based on the remaining objects. The 
procedure is repeated until every object is left once. The final ranking was obtained by 
sorting the variables based on the amount of times it was selected in the LOOCV 
procedure. The variables selected median+1 times made up the optimal set.  The 
complete scheme for LOOCV can be found in the supplementary material. 
 
5.2.4.2 Classification of individual and fused plasma and CSF datasets 
After selecting an optimal set of variables, the features of both data sets are 
concatenated and autoscaled. Subsequently, the variables of the fused sets were 
ranked by SVM-RFE. Classification of fused sets was made by PLS-DA, a well-known 
method used in many omics fields 20, 23. PLS-DA uses the group information to maximize 
the separation between groups of observations. It is currently widely used in 
metabolomics because of its ability to cope with high correlations between variables. In 
PLS-DA a linear model is constructed according to equation 2: 
 
y=Xb + r    (2) 
 
Where, X is a dataset matrix, y a vector of group memberships, b a vector of regression 
coefficient (i.e. weights of individual variable) and r a vector of model residuals. The 
regression coefficients reflect the relative importance of the variables in the PLS-DA 
model. PLS2-DA is a variation of PLS-DA, where the response “y” is not a vector but a 
matrix, which allows more than 2 groups to be analyzed simultaneously.  
The optimal complexity (i.e. number of latent variable (LV)) for all individual as well as 
fused models was determined by LOOCV performed on training sets. The optimal 
number of LV was selected based on the minimal error of the root mean square error of 
cross-validation (RMSECV).  For all individual as well as fused models the optimal 
model complexity was determined to be one LV. All PLS-DA models were validated with 
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an independent test set. A PLS-DA model is considered statistically valid if it shows 
good prediction ability.  After validation, a final model is then reconstructed using all 
available samples. The model can be visualized in a score plot. The importance of all 
variables on the predictive model can be investigated by means of the regression 
coefficients 24.   
After the individual two-class (binary) models are optimized they can be used for HMF.  
 
5.2.4.3 Hierarchical Models Fusion  
In this paper, we propose a new approach Hierarchical Models Fusion, HMF, which uses 
hierarchically multiple simple 2-class classification models to represent individually 
certain parts of the inter-class variation. This approach uses, as any supervised method, 
a priori knowledge of the classes (for instance, type of inflammation) and establishes 
commonalities between them. 
The use of simple two-class models makes the results easier to interpret. The method 
proposed here aims to describe the relevant differences gradually instead of explaining 
all variation from all classes at once. This gradual process becomes possible by 
applying statistically optimized binary models to the data at each step and then to 
combine the outcomes.  Since it fuses the outcome of all earlier optimized models it 
describes and shows all the relevant differences in the data. By using this approach it is 
possible to visualize separation between studied classes and relation between objects 
without applying multiclass classification models (like PLS2-DA or Linear Discriminant 
Analysis (LDA)).   
Data
Model 1 (effect 1 
vs. non-effect)
Non-effect
Effect 1 Effect 2
Xscore
Yscore
Combining Xscore
and Yscore
Model 2 (effect 1 
vs. effect 2)
Xscore
Ys
co
re
Non-effect
Effect 1
Effect 2
 
Figure 1. A graphical representation of Hierarchical Models Fusion. 
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To demonstrate the HMF approach let’s consider a dataset with three classes: non-
effect (i.e. healthy), effect 1 (e.g. peripheral inflammation) and effect 2 (e.g. 
neuroinflammation).  First individual binary PLS-DA models of interest have to be 
optimized (i.e. model 1 and 2 from Figure 1). A graphical representation of HMF is 
shown in Figure 1. These models can then be hierarchically applied to the data in 
accordance to a priori knowledge (here experimental design). For example having data 
containing three classes, i.e. effect 1, effect 2 and non-effect, it is possible to apply HMF 
to separate all three classes. In the first step, model 1 (effect 1 versus non-effect) is 
used to obtain a new score for all samples in data matrix X. This new score (here called 
Xscore) separates non-effect objects from objects belonging to group effect 1 and group 
effect 2. In the next step, another model (model 2: effect 1 versus effect 2) can be 
utilized on matrix X to assess and distinguish these two effects. In that way a second 
score is obtained for all samples in data matrix X (here called Yscore). At each step, a 
new score is obtained by multiplying data matrix X with PLS-DA weights. These two new 
scores (Xscore and Yscore) can then be combined and used to visualize the relationship 
between studied groups.  When the new scores are orthogonal they can be represented 
as usual (i.e. with perpendicular axis). 
Because HMF is based on a hierarchical structure, the complexity of the studied 
problem is reduced by describing every difference on a different level (i.e. step). It 
decomposes the difficulty of multi-class separation into simpler, solvable two-class 
problems. Indeed, the representation of HMF as a decision tree (see Figure 1) is similar 
to the Classification and Regression Trees (CART) 25. However, in HMF at each step 
(node) not a single variable but a PLS-DA model is used to separate objects. In order to 
represent the usefulness of HMF for analyzing multiple classes, simulated data were 
created. The results are shown in the supplementary material. 
Obviously, the presented method can be used not just for visualization of relations 
between samples but also for prediction of new samples (e.g. coming from an extra 
experiment). Moreover, information about variables significant for discrimination is 
associated with PLS-DA weights. Therefore biological interpretation is feasible as well.   
Any results obtained by predictive methods must be validated before drawing any 
conclusions. In HMF the validation is twofold. First all the individual PLS-DA models are 
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validated using independent test sets. Second, the complete HMF structure is also 
validated. Moreover to reduce the possibility of random classification we performed 
permutation test for HMF. 
 
5.2.5 Metabolite identification  
Metabolite identification of the most relevant set of variables was carried out by using 
the 800 MHz library (for CSF) and 500 MHz library (for plasma) of metabolite NMR 
spectra from the Chenomx NMR Suite 7.0 (Chenomx Inc., Edmonton (AD), Canada).  
The libraries of metabolite spectra were obtained based on a database of pure 
compound spectra acquired using a particular pulse sequence and acquisition 
parameters, namely, the noesy-presaturation pulse sequence with 4s acquisition time 
and 1s of recycle delay 26. The Chenomx NMR Suite software fits the spectral signatures 
(singlets, doublets, triplets etc), i.e. the peak shapes, of a compound from an internal 
database of reference spectra to the experimental NMR spectrum. 
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5.3 RESULTS 
5.3.1 Explorative analysis of the CSF - and plasma datasets  
The 82 NMR data of plasma and the 82 NMR data of CSF were each pre-processed as 
described in Materials and Methods. Examples of plasma and CSF spectra are shown in 
Figure 2. As can be noted the intensities of many metabolites (normalized to TSP signal, 
only for visualization purpose), like alanine, arginine, in the plasma spectrum are higher 
in plasma than in CSF. Most metabolites present in CSF can be observed in plasma. A 
few volatile metabolites are not visible in plasma, because of lyophilisation. Some 
metabolites are detected only in plasma, for instance glutamate or phenylalanine. This is 
mostly due to low concentration of these metabolites in CSF. The NMR spectra of CSF 
were divided into 409 bins, which contain resonances of 33 identified metabolites and 
some unidentified signals. In the case of plasma, the NMR spectra were divided into 478 
bins, which correspond to resonances of 50 identified metabolites and some unidentified 
signals.  
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Figure 2. Section of the 800 MHz 1H NMR spectrum of CSF (blue) and 1H 500 MHz NMR 
spectrum of plasma (red).  
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After pre-processing, explorative analysis was performed by means of R-PCA and PCA.  
Initially, R-PCA was applied to the autoscaled spectra of 82 rat CSF and plasma 
samples, to check for outliers. No outliers were detected. Figures 3a-3b show the PCA 
score plots of the plasma and CSF NMR spectra, respectively.  These figures show that 
the samples belonging to group “N14” are clearly separated from the others samples 
along PC2 for plasma data and along PC4 for CSF data. In both situations PC1, which is 
the main source of variance, does not show any group information. This indicates that a 
large source of variance in the data does not correspond to the available groups. . No 
clear grouping is present since most of the groups overlap. It is important to mention that 
further PC’s did not show groupings either.   
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Figure 3. PCA score plot of: (a) plasma NMR spectra; (b) CSF NMR spectra.  
 
5.3.2. Supervised analysis 
The most straightforward approach for separating the 6 groups present in CSF and 
plasma data simultaneously is to apply a multi-class method, for instance PLS2-DA. The 
two datasets can be analyzed separately by PLS2-DA. Alternatively, the CSF and 
plasma data can be fused and PLS2-DA can be applied to the fused data. However, 
PLS2-DA has to describe all group-related variations at the same time. This might lead, 
on the one hand, to worse results in comparison to multiple binary PLS-DA models and 
on the other hand, to difficulties in the biological interpretation. One can apply binary 
PLS-DA models to handle individual biological platforms (CSF and plasma) and the 
(mid-level) fused data sets. This implies that for a full description many binary PLS-DA 
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models have to be constructed and optimized. Therefore, we propose and present a 
new approach, namely HMF. In HMF, a limited number of multiple binary PLS-DA 
models are employed to still fully describe the fused CSF and plasma data. The fusion 
was achieved using the approach described in Materials and Methods (section 4.1 and 
4.2). Binary PLS-DA models were applied to the fused datasets to extract information on 
the metabolic effects of the different group treatments shown in Table 1 and to establish 
the variables significance. All optimal binary PLS-DA models were constructed using 
only 1 LV.  Next these optimized binary PLS-DA models are used in HMF.  Below, we 
first present the results of PLS2-DA, subsequently the binary PLS-DA models, and 
finally those of HMF. The outcomes of HMF are compared with PLS2-DA of the fused 
datasets. 
 
PLS2-DA – complete EAE model for plasma data, CSF data and fused sets 
We applied PLS2-DA to separate simultaneously all 6 groups of the CSF dataset and of 
the plasma dataset. The variables included in the PLS2-DA model are selected by linear 
SVM-RFE. The number of LV’s in the PLS2-DA model was optimized by cross 
validation. The correct classification rate for an independent test set was equal to 57.1% 
for plasma data and 56% for CSF data (the correct classification per class is included in 
Table 1S in the supplementary material). It is interesting to note that better results are 
obtained for the binary PLS-DA models (at least for the binary PLS-DA models 
considered) than for PLS2-DA.However, it is important to mention that PLS2-DA has a 
more difficult problem to solve (i.e. separate 6 classes at once) than PLS-DA.  
A similar situation is encountered for fused datasets. The correct classification for an 
independent test set is equal to 65% for PLS2-DA (correct classification per class can be 
found in the supplementary material, Table 1S). This result is much worse than multiple 
PLS-DA models. PLS2-DA performance (64 % classification) is in turn still much better 
than a random classifier (correct classification 17 %) but still insufficient for a proper 
diagnostic. However, one should notice that some groups are completely classified 
correctly (100 % e.g. “C10”), while some are totally misclassified. 
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PLS-DA models for plasma data, CSF data and for mid-level fused sets: the onset of 
neuroinflammation  
We present the results of PLS-DA obtained for the group “P10” versus “N10”, as this 
represents the interesting case of early onset of neuroinflammation. Binary PLS-DA 
models were derived for the separate CSF and plasma data sets as well as for mid-level 
fused data sets. The predictive models for the problem “P10” vs. “N10” are displayed as 
PLS-DA score plots in Figures 4a, 4b, and 4c. These 1 LV score plots are presented as 
the density distribution of the entire group. The PLS-DA model of CSF is constructed 
based on 87 variables. The PLS-DA model of CSF alone has no prediction ability, as 
follows from the 50% correct classification for an independent test set. Accordingly the 
groups “P10” and “N10” (for CSF) are not separated in Figure 4a. For plasma, the PLS-
DA model separates the classes somewhat better, as follows from the classification for 
independent test sets of 75%. However, there is still quite some overlap and the groups 
of points are still mixed, as can be seen on the horizontal axis of Figure 4b.   
 
Since the individual analysis did not bring satisfactory results, we decided to fuse the 
selected variables from plasma and CSF data. The SVM-RFE carried out on the fused 
sets, led to 11 variables (out of the 112 firstly selected variables). The resulting PLS-DA 
model of fused datasets is shown in Figure 4c. The correct classification for independent 
test set is equal to 100%, demonstrating the statistical adequacy of this model. As can 
be seen from Figure 4c, there is a clear separation.  Figure 4d shows the regression 
coefficients of this PLS-DA model. Interestingly, the fusion model consists of 6 CSF and 
5 plasma variables. This suggests that both biofluids contribute significantly to the group 
separation.  
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Figure 4. Density distribution of PLS-DA scores of: (a) “P10” vs. “N10” for CSF data, the amount 
of y variance for 1 LV is equal 77.5%; (b) “P10” vs. “N10” for plasma data, the amount of y 
variance for 1 LV is equal 63.5%; (c) “P10” vs. “N10” for fused data, the amount of y variance for 
1 LV is equal 61.3%; (d) Regression coefficients of fused PLS-DA model. 
 
Table 2 summarizes the results of the PLS-DA models for P10 versus N10, and for two 
other pairs of groups, namely “C10” vs. “P10”, and “N10” vs. “N14”. These models were 
used in the HMF. Table 2 displays, apart from the degree of correct classification for 
independent test sets, also the number of selected variables by RFE-SVM used in PLS-
DA models for the fused data. We find that the binary PLS-DA model for “P10 vs. N10” 
(early onset of neuroinflammation) results in a 100% correct classification. The same 
holds for “N10” vs. “N14” (progression of neuroinflammation), while for “C10” vs. “P10” a 
93 % correct classification is achieved. The score plots and regression coefficients of 
models “C10” vs. “P10” and “N10” vs. “N14” are shown in Figures 5Sa-5Sd in the 
supplementary material.  
179 
 
In Table 2 only a few of many possible pairs of groups for PLS-DA have been presented. 
Nevertheless, in Table 2S in the supplementary material the correct classification rate 
for the independent test set obtained for individual analysis of plasma data, CSF data 
and fused datasets by PLS-DA for different pairs of groups can be found. To achieve a 
full or nearly full description of the fused data set, without having to use all pairs of 
groups, we apply the hierarchical data fusion model, HFM in the next section.     
 
Table 2. Correct classification rates for an independent test set obtained for fused datasets, 
number of variables coming from plasma and CSF used in a PLS-DA model and number of 
samples in training set and test set. 
PLS-DA 
model 
Correct 
classification 
# variables in PLS-DA 
model 
# samples  
Plasma CSF training test 
C10 vs. P10 93% 4 13 20 8 
P10 vs. N10 100% 5 6 20 8 
N10 vs. N14 100% 8 3 18 7 
 
 
5.3.3 Hierarchical Models Fusion 
The predictive power of the individual PLS-DA models is by itself already satisfactory 
(see Table 2 and in the supplementary material Table 2S). At this point one could stop 
the analysis and start the biological interpretation of the results. However each PLS-DA 
model only looks at two groups at a time and therefore is not able to predict a completely 
unknown sample. Thus, it is necessary to combine the different models. The idea of 
HMF is to join them in a meaningful order.   To perform the HMF on the datasets of CSF 
and plasma, we used the PLS-DA models of “C10” vs. “P10”, “P10” vs. “N10” and “N10” 
vs. “N14” (shown in Table 2). They characterize, respectively, the effect of peripheral 
inflammation, neuroinflammation and progress of neuroinflammation. They are therefore 
consistent with the experimental design shown in Table 1. The HMF approach used in 
this paper is represented in Figure 5. Note that we present here HMF on the fusion of 
two datasets but the same principle could be applied on a single dataset. As explained 
in Materials and Methods, the HMF is validated in two ways. First, all individual PLS-DA 
models were statistically validated with independent test sets. Secondly, the complete 
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scheme of HMF was validated with a set including all test sets used in the binary PLS-
DA models from Table 2 and additionally, some samples belonging to classes “C14” (4 
samples in test set and 10 in training set) and “P14” (5 samples in test set and 10 in 
training set). The graphical representation of HMF for training and test set samples is 
shown in the supplementary material in Figure 5S. As can be seen all test samples are 
correctly predicted. Additionally the permutation test was performed for all 6 classes as 
extra check. The p-value for 40000 permutations was equal to 0.0006. 
 
Data (all groups)
Peripheral inflammation model
Peripheral 
inflammation
Neuroinflammation  model
Neuroinflammation
Neuroinflammation 
progression model
Neuroinflammation at 
peak
N14
Neuroinflammation at 
onset
N10
No 
neuroinflammation
P10 & P14
No inflammation
C10 & C14
Step 1 Xscore
Step 2 Yscore
Step 3 Zscore
*
“C10” vs. “P10”
“P10” vs. “N10”
“N10” vs. “N14”
 
Figure 5. Representation of hierarchical models fusion for fused plasma and CSF NMR 
datasets. * Note that the “P14” is classified as control (the inflammation is gone, see section 
below). 
 
We started with the PLS-DA model of peripheral inflammation, i.e. “C10” vs. “P10” 
(shown in Figure 5 as step 1). This allows one to separate healthy objects, i.e. the one 
without any type of inflammation (see Table 1) from all those with peripheral 
inflammation. The latter also includes groups which have undergone neuroinflammation, 
because in accordance with the experimental design shown in Table 1 these groups 
were injected with CFA. This step enables creating a first new score (i.e. Xscore) for all 
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samples in the data. In other words, this model separates the healthy groups from the 
ones presenting any form of inflammation (neuro- or peripheral).  
In a second step, we used a PLS-DA model of “P10” vs. “N10”, shown in Figure 4d. This 
model distinguishes peripheral inflammation from neuroinflammation at the onset of 
EAE. Therefore, by using this model we are able to separate neuroinflamed animals 
from animals that were only peripherally inflamed (i.e. “P10” and “P14” see Figure 5 step 
2).  Similar to step 1, a second score is generated, the Yscore. At this level, we have 
separated samples belonging to groups with peripheral inflammation (i.e. “P10” and 
“P14”) from the neuroinflamed groups (“N10” and “N14”).  
The last step (number 3) considers the separation of the onset of the disease from the 
peak of EAE. In order to achieve this separation, we applied the PLS-DA model of “N10” 
vs. “N14”, i.e. the model describing the severity of neuroinflammation. At this level, a 
third new score is created, the Zscore. After iterative application of these simple 1LV 
models to fused plasma and CSF datasets, we can integrate the three new scores, i.e. 
Xscore, Yscore and Zscore. They are then used to visualize the outcome. They 
represent the relation between the groups and their separation. The corresponding 
graph is shown in Figure 6. As can be observed, full separation of the different groups is 
achieved.  It is worthwhile to mention that samples belonging to healthy groups “C10” 
and “C14” mostly overlap. However, there is a small shift along the x-axis observable, 
probably due to sampling time (Day 10 vs. Day 14). As can be noticed samples 
belonging to group “P14” overlap with healthy groups, which is in agreement with our 
previous finding, that peripheral inflammation has vanished by day 1411. 
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Figure 6. Graphical representation of HMF applied to fused data of plasma and CSF.  
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5.4 DISCUSSION AND CONCLUSIONS 
Using a mid-level fusion architecture we were able to identify a set of metabolites that 
revealed significant changes in plasma and CSF of neuroinflamed animals. Based on 
the regression coefficients of the PLS-DA model of fused datasets (see e.g. Figure 4d 
and supplementary materials) the importance of the individual metabolites in each PLS-
DA model as well as a direction of elevation/reduction of concentration can be 
evaluated. Based on this information the biological interpretation of these metabolites 
and their connection to EAE, neural inflammation and/or MScl can be performed. 
Therefore, the first aspect to be discussed is the nature of the selected metabolites. It 
should be mentioned that the main aim of the paper is not to provide a biological 
explanation, but to present the methodology for fusion and analysis of 1H NMR 
metabolomics datasets. Therefore biological conclusions are not stressed.   
One can notice that many amino acids (mostly neutral ones) were found to be 
discriminatory for EAE groups and therefore we focus on them. The transport of neutral 
amino acids through BBB is significant for the overall regulation of cerebral metabolism 
and neurotransmitters production 27. BBB amino acids transport plays an important role 
in the regulation of several pathways of brain amino acids metabolism. It is known that 
EAE affects the BBB.  It causes disruption in the BBB and affects the saturable transport 
system of substances involved in the disease process 28. Injection of CFA can itself lead 
to increased BBB permeability to small molecules and even certain serum proteins 29. 
 
We found that tyrosine concentration is reduced in plasma of groups “P10”, “N10” and 
“N14”. It has been reported previously that tyrosine has a role in BBB permeability 30. In 
accordance with our results Monaco et al. detected a reduced level of plasma tyrosine in 
Mscl 31. Another neutral amino acid related to EAE groups is alanine. This metabolite 
was found as a relevant metabolite in both plasma and CSF. Its concentration is 
reduced in CSF and plasma of EAE groups in comparison to healthy controls and 
peripheral inflamed group “P10”. Alanine is associated with energy metabolism and is 
known to be used as a source for pyruvate for energy metabolism and macromolecules 
within neural and immune cells 11.  Similarly, lysine concentration was elevated in CSF 
and plasma related to neuroinflamed groups “N10” and “N14”. Qureshi and co-workers 
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in a study on the role of neurotransmitters amino acids in CSF of MScl patients have 
reported increased levels of lysine in CSF and plasma of MScl patients 32.  
We found the combination of glutamate and proline signals in plasma decreased in the 
EAE groups compared to the other groups. In a previous study a change of glutamate 
concentration in CSF was reported in a clinical study of MScl 33.  Glutamate is a very 
important neurotransmitter and the most abundant free amino acid in the brain. A 
metabolite that is closely interconnected with glutamate is glutamine. This metabolite 
was found in plasma as discriminatory for groups injected with immune booster (i.e., 
“P10” and “N10”) when compared to the healthy groups and its concentration was 
elevated in these groups. Additionally, it was found as discriminatory when comparing 
“P10” and “N10” groups.  In CSF, its level was found to be down regulated in group 
“P10” in comparison to healthy controls. This metabolite is involved in energy 
metabolism. It was shown that glutamine is a necessary nutrient for cell proliferation, 
serving as a specific fuel for inflammatory cells and enterocytes and, when present in 
appropriate concentrations, enhancing cell function 34. The last amino acid that is 
discussed here is phenylalanine. This metabolite was diminished in EAE groups. This 
metabolite is the precursor to Tyrosine, it is necessary in the function of catecholamine 
neurotransmitters epinephrine, norepinephrine, dopamine and tyramine. In the previous 
study by Monoco et al. a reduced level of phenylalanine in MScl was found.31   
 
One aspect which was not emphasized is the importance of a proper preprocessing. 
Here the use of AI binning ensures that one bin corresponds to one peak, therefore 
preventing signals of different metabolites to be mixed within one bin. Normalization is 
the second important preprocessing aspect. We compared the influence of the classical 
total area normalization to the probabilistic quantum normalization. No strong differences 
were observed (data not shown) therefore we decided to use the simplest approach. 
However one should be aware that the total area normalization could be suboptimal due 
to the large influence of highly abundant multiplets (e.g. glucose). 
The third aspect to be discussed is connected to the data analysis strategy used in this 
manuscript, i.e. mid-level data fusion and HMF. Firstly, the approach of mid-level data 
fusion performed here enabled individual variable selection and thus to discard irrelevant 
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information. Secondly, the HMF method, shown in this paper, represents a novel, simple 
strategy for multi-class analysis. Each PLS-DA model only looks at two groups at a time 
and therefore a single model is not able to predict a completely unknown sample. This is 
a minor advantage of HMF over multiple PLS-DA models. One should keep in mind that 
the outputs of this method are statistically accurate, since they are based on validated 
binary predictive models. Moreover, the complete scheme of HMF was validated as well. 
The output of HMF (i.e. new scores) can be used for visualization or prediction of new 
samples. However, it is good practice to check if these new scores are orthogonal.   
When comparing HMF and PLS2-DA, it is important to mention that it is possible that if 
some groups do not behave in accordance to experimental design, the optimal solution 
for class separation can be flipped. In other words, if one or more groups cannot be 
distinguished, PLS2-DA still tries to separate them, which may affect the solution for the 
whole PLS2-DA model. In the case of EAE datasets, there are two groups (i.e. “N10” 
and “P14”) that are characterized with behaviour different than was assumed by 
experimental design. In case of the “N10” group we have shown previously, that animals 
are heterogeneous regarding to disease response 11. Further, the second group “P14” 
was not (or no longer) peripherally inflamed at day 14. This causes the results obtained 
by PLS2-DA to be sub-optimal for groups “N10”, “C14” and “P14”.  In the method 
proposed here, HMF, the situation described for PLS2-DA cannot happen. HMF leads to 
the optimal solution, because it includes relevant sources of variance between groups 
individually rather than all at the same time. This suggests that if two groups are not 
separable this can be easily detected during the HMF and does not influence the 
separation between other groups.   
 
In our study the HMF was shown for fused plasma and CSF NMR datasets. However 
this approach can be also used for one platform (as shown in the supplementary 
material). Obviously, the individual PLS-DA models can be developed for any platform 
and then HMF can be applied.  
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Conclusions 
In this study, we have demonstrated the feasibility of fusion of metabolomics 1H NMR 
datasets from different biofluids. From the data analysis point of view multiple challenges 
had to be addressed. One of them had to do with the biological variation usually 
encountered in omics experiments. Another issue was linked to the number of variables 
recorded by NMR, which first is greatly superior to the number of samples and secondly 
most of them are probably unrelated to the studied problem or redundant. We 
successfully solved these problems using a new architecture for data fusion, where 
SVM-RFE is used as variable selection method and PLS-DA to focus on the information 
of interest through a training procedure.  
We analyzed CSF and plasma metabolomics data of the EAE model for MScl using mid-
level data fusion. The procedure was represented by constructing predictive model for 
neuroinflamed group “N10”, i.e. before physical symptoms have appeared, versus 
peripherally inflamed group “P10”. Prediction models based on either CSF or plasma 
metabolomics data alone could not separate the immune booster and EAE groups at 
day 10, whereas the predictive model using a fused set of variables from CSF and 
plasma managed to separate the two groups with a 100% correct classification rate for 
the independent test set. One should be aware that these results do not imply that all 
new samples will be always correctly classified. However validation with the independent 
test set and the permutation test set indicate that the results are meaningful.  This shows 
that by using bio-molecular information (metabolomic data), a diagnosis can be made 
before physical symptoms arise. Our results also demonstrate that plasma can play a 
significant role in diagnosis of neuroinflammation. Therefore, we believe that plasma 
should be considered when investigating neuroinflammation. 
Finally, we have introduced a new multi-class method HMF, which aims to describe 
relevant sources of variance connected to groups’ description by fusing individual binary 
models. We have shown that by using HMF we are able to separate groups in our data 
by using simple, easily interpretable, one-component predictive models. 
From a biological point of view, the selected metabolites appears to be relevant, 
because the metabolites described in this study were previously found in relationship to 
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the EAE and/or Mscl. Therefore, they provide a biological validation for the fusion of data 
from two different biofluids.  
Further research will focus on the deeper interpretation and absolute quantification of 
newly detected metabolites in plasma and CSF and their relation to BBB. These two 
steps are time consuming but would bring more insights on disease mechanism. The 
pattern and concentrations defined by these variables could also be studied by 
themselves and put into a systems biology context. Absolute quantification would be 
crucial for obtaining advanced biological conclusions and conformation using completely 
different analytical method (e.g. Mass Spectrometry)  
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ABSTRACT 
Background: In the last decade data fusion has become widespread in the field of 
metabolomics. Linear data fusion is performed most commonly. However, many data 
display non-linear parameter dependences. The linear methods are bound to fail in such 
situations. We used proton Nuclear Magnetic Resonance and Gas Chromatography-
Mass Spectrometry, two well established techniques, to generate metabolic profiles of 
Cerebrospinal fluid of Multiple Sclerosis (MScl) individuals. These datasets represent 
non-linearly separable groups. Thus, to extract relevant information and to combine 
them a special framework for data fusion is required.  
Methodology: The main aim is to demonstrate a novel approach for data fusion for 
classification; the approach is applied to metabolomics datasets coming from patients 
suffering from MScl at a different stage of the disease. The approach involves data 
fusion in kernel space and consists of four main steps.  The first one is to extract the 
significant information per data source using Support Vector Machine Recursive Feature 
Elimination.  This method allows one to select a set of relevant variables. In the next 
step the optimized kernel matrices are merged by linear combination. In step 3 the 
merged datasets are analyzed with a classification technique, namely Kernel Partial 
Least Square Discriminant Analysis. In the final step, the variables in kernel space are 
visualized and their significance established.   
Conclusions: Conclusions: We find that fusion in kernel space allows for efficient and 
reliable discrimination of classes (MScl and early stage). This data fusion approach 
achieves better class prediction accuracy than analysis of individual datasets and the 
commonly used mid-level fusion. The prediction accuracy on an independent test set (8 
samples) reaches 100 %. Additionally, the classification model obtained on fused 
kernels is simpler in terms of complexity, i.e. just one latent variable was sufficient. 
Finally, visualization of variables importance in kernel space was achieved. 
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6.1 INTRODUCTION 
Currently, due to the increasing amount of data generated from different analytical 
platforms for a single studied system, for instance in fingerprinting a disease in the 
metabolomics and proteomics fields, optimal data concatenation, or data fusion, has 
become an issue that needs to be addressed. Each analytical technology demonstrates 
different strengths and limitations regarding its capability to distinguish between different 
biological conditions, depending upon factors such as sensitivity, sample preparation, 
analytical stability, and analytical reproducibility. The jointed use of two or more 
analytical technologies gives then a more robust strategy for data analysis than the use 
of a single platform 1. 
Data fusion is widely applied in the pattern recognition field 2. For example, in chemistry, 
biology, medicine and many others fields linear techniques are used to construct a 
mathematical model that relates spectral responses from different techniques to analyte 
concentrations 3-6. In the omics related fields, data fusion is performed in different ways 
and on different data levels 7. To date, data fusion methods are organized in three 
levels: low-level, mid-level and high-level fusion 8, 9. In low-level fusion, different data 
sources are concatenated at the data level. In the mid-level fusion, data from different 
sources are combined at the data level by selection of variables or at the latent variables 
level. In high-level data fusion, different model responses (for instance prediction for 
each available data set) are joined to produce a final response. Currently, several linear 
techniques, such as Principal Component Analysis (PCA) or Partial Least Squares 
Discriminant Analysis (PLS-DA), are used for the above mentioned types of data fusion. 
These different linear data fusion approaches have been applied with good success in 
recent times in the different omics fields, including metabolomics 8, 10-12. To our 
knowledge non-linear methods have not been applied to data fusion in for instance 
metabolomics. However, some chemical systems and problems are inevitably non-linear 
and reveal characteristics in a non-linear fashion. The assumption of a linear response is 
then incorrect and non-linear description is appropriate 13. Of course, to follow Occam’s 
razor principle, it is common practice to first apply linear methods and only if they fail to 
move to non-linear techniques like kernel-based methods. Kernel-based methods 
transform the data to a high dimensional feature space by means of a kernel function. 
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This generates a new data matrix, which can be viewed as a similarity matrix. The kernel 
function takes relationships that are implicit in the data and makes them explicit, so that 
patterns are easier to detect. Moreover, they have been designed to deal with datasets 
where many variables are present. Kernel-based methods have already been 
demonstrated to form powerful tools and therefore are widely applied to various 
statistical problems due to their flexibility and good performance 14, 15. A major 
disadvantage of these Kernel-based methods has been that information on the 
importance of variables is lost. However, recently an approach has been proposed for 
representing the importance of variables in kernel space, a method based on the 
principles of so-called pseudo samples 16, 17.  
Nowadays, proton Nuclear Magnetic Resonance (1H-NMR) and Gas Chromatography-
Mass Spectrometry (GC-MS) are well-established powerful analytical methods for 
generating metabolomics profiles. For analysis of complex, biological samples like those 
from Cerebrospinal fluid (CSF) both techniques have their advantages and 
disadvantages. For instance, 1H-NMR requires limited sample preparation, is 
quantitative, non-destructive and unbiased. 1H-NMR may detect compounds that are too 
volatile for GC, while metabolites without proton (phosphoric acid) are not detected by 
1H-NMR. GC-MS requires derivatization and thus more time consuming sample 
preparation. On the other hand, GC-MS yields a higher sensitivity than NMR and 
therefore may detect metabolites that are present in a concentration below the detection 
limit of 1H-NMR. Therefore, these analytical platforms give wide and complementary 
views of the studied system. To obtain the maximum/optimal amount of relevant 
information about the complex biological system, the data from these powerful analytical 
techniques need to be combined and analyzed with advanced multivariate statistical 
tools.  
This paper presents a novel framework for integrating data from different analytical 
sources by applying non-linear kernel-based statistical learning methods. We 
demonstrate this non-linear kernel fusion approach on 1H-NMR and GC-MS 
metabolomics datasets obtained from CSF of patients with Multiple Sclerosis (MScl) 18. 
These data display non-linear response characteristics. The proposed approach for non-
linear Kernel-based data fusion consists of four steps. The first step aims to extract 
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relevant variables from both datasets separately.  Variable selection is performed by 
means of Support Vector Machine Recursive Feature Elimination (SVM-RFE) for non-
linear kernels 19. The second step is designed to fuse the relevant information of both 
datasets by using linear combinations of kernel matrices 20. This kernel fusion falls 
outside the range of the classical low-, mid- and high-level fusion. The next step (step 3) 
consists of applying PLS-DA on the fused kernels as classification method. In step 4, the 
visualization of the relative contribution of each variable to K-PLS-DA model (variable 
importance) was achieved by applying and extending the recently developed pseudo 
samples principle 16, 17.  Consequently, in our approach the importance of variables is 
visualized. The variables can then be interpreted in terms of the underlying biology of 
system. Application of our non-linear Kernel-based data-fusion methodology to the 1H-
NMR and GC-MS metabolomic datasets from samples of CSF of MScl individuals and 
individuals in the early stage of the disease enabled better classification than using the 
data from the two sources separately. More importantly, the biological interpretation can 
now be done based on the joined data from the two platforms. The approach proposed 
here can be extended to other types of datasets such as to MS or NMR data from 
proteomics or data from microarrays and Liquid Chromatography. The number of 
samples used to study the progression of MScl is relatively small. Therefore, some 
limitations with respect to biological interpretation as well as prediction of future samples 
may exist, e.g. due to biological variation. In order to use the findings in the clinic they 
should be validated in a new cohort with a larger number of samples. This issue will be 
further addressed in the discussion section. 
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5.2 MATERIALS AND METHODS 
5.2.1 CSF sampling and patients 
The CSF patients involved in this study were all followed by the Rotterdam Multiple 
Sclerosis Center and the department of Neurology at Erasmus University Medical 
Center (Rotterdam, The Netherlands). The Medical Ethical Committee of Erasmus 
University Medical Centre in Rotterdam, The Netherlands, approved the study protocol 
and all study patients gave written consent. All CSF samples were specifically collected 
from patients that were not under any drug treatment. 
All CSF samples were taken from patients via lumbar puncture. Immediately after 
sampling, the CSF samples were centrifuged to remove cells and cellular elements (10 
minutes at 3000 rpm). Subsequently, a fraction of the CSF samples were used for 
diagnosis purpose and the remaining amounts were aliquoted and stored at -800 C.  
The CSF samples were classified into two groups. The first group consisted of CSF 
samples collected from patients diagnosed with MScl. The second group of CSF 
samples was taken from patients who were diagnosed with clinically isolated syndrome 
of demyelination (CIS), which represents an early stage of MScl. It is worthwhile to 
mention that all patients diagnosed with CIS have later developed MScl. The overview of 
the available CSF samples for NMR and GC-MS is presented in Table 1, while clinical 
information is described in the supplementary material. It is important to mention that the 
set of samples analysed by NMR and GC-MS only partly overlap (Table 1).  
 
Table 1. The number of samples included in a training and independent test set. 
Group 
No. samples NMR No. samples GC-MS Overlap NMR and GC-MS 
Training Test Total Training Test Total Training Test Total 
MScl 19 7 26 18 6 24 7 5 12 
CIS 15 5 20 10 4 14 7 3 10 
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5.2.2 NMR samples preparation and data acquisition 
The CSF samples of the CIS and MScl classes were prepared as follows. An aliquot of 
20μL of the stored frozen human CSF sample (-80 °C) was thawed at room 
temperature. Subsequently, 200 μL D2O was added to biofluid in order to obtain 
sufficient sample volume for NMR measurements. We used 3-(Trimethylsilyl)propionic-
2,2,3,3-d4 acid sodium salt (TSP-d4 99 at.%D) as internal standard for chemical shift 
reference (δ 0.00 ppm) and metabolite quantification. For this and buffering, 70μL of 
buffer solution was added to the 220 μL of human CSF sample. The buffer solution 
solvated in a mixture of water and D2O consists of 2,85mM TSP, 6.92 mM sodium azide 
(NaN3) and 42.08 mM sodium phosphate dibasic dehydrate (Na2HPO4•2H2O).  The 
addition of mixture solution to 220 μL of CSF sample leads to a final concentration of 
0.66 mM TSP-d4 and corresponding concentrations of buffer solution components. The 
pH of the CSF NMR sample was adjusted to around 7 (7.0 – 7.1) by the buffering 
capacity of the phosphate in the buffer solution. The final CSF NMR sample (290 μL) 
was transferred to a SHIGEMI microcell tube for NMR measurements. 
All spectra were recorded by using a standard pulse sequence (1D-NOESY; recycle 
delay-90°-t1-90°-tm-90°) at a temperature of 25 °C. The water suppression was achieved 
by presaturation during the relaxation delay (8 s) and mixing time (100 ms). All 1H NMR 
spectra were acquired at 600 MHz Bruker NMR Spectrometer equipped with cryo-cooled 
probe. For each 1D 1H NMR spectrum 256 scans were accumulated with a spectral 
width of 7200 Hz resulting in a total of 16K data points. The acquisition time for each 
scan was 2.2s. Prior to spectral analysis, all Free Induction Decays (FIDs) were 
multiplied with a 0.3 Hz line broadening function, Fourier transformed and manually 
phased. In addition, the TSP internal reference peak was set to 0 ppm. This initial 
processing was done  using ACD/SpecManager software version 12.02 21. 
All 46 human CSF spectra were acquired and pre-treated as described above and 
subsequently, transferred to Matlab, version 7.6 (R2008b) (Mathworks, Natick, MA) for 
further analysis. 
 
200 
 
5.2.4 Preprocessing of NMR spectra  
The NMR spectral data of human CSF was pre-processed, which typically involves 
baseline correction, alignment, binning, normalization and scaling.  Asymmetric Least 
Square method was used for baseline correction of NMR spectra 22. Next, in order to 
remove variations in peak position, NMR spectra were aligned by using correlation 
optimized warping 23. A further problem is the high dimensionality of the data (circa 
15000 variables). To reduce the number of variables associated with the NMR spectra, 
we performed binning via adaptive intelligent binning 24. Before binning data were 
normalized to total area. The chemical shift ranges of G 0.75 – 4.15 and G 8.65 – 8.85 
were used for the binning procedure. The binning procedure led to 233 bins in total. In 
the final step of preprocessing data were scaled to unit variance. 
 
5.2.5 GC-MS samples preparation and data acquisition 
The GC-MS method applied here is a non-targeted GC-MS method which uses  a 
derivatization step that has frequently been applied for metabolomics studies 25. With 
this method it is possible to analyse simultaneously various classes of (polar) 
metabolites, e.g. amino acids, organic acids, fatty acids, sugars.  
Human CSF samples (100 μL) were deproteinized by adding 400 μL methanol and 
subsequently centrifuged for 10 min at 10000 rpm. The supernatant was dried under N2 
followed by derivatization with methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) in 
pyridine similar to Koek et al.25. During the different steps in the sample work-up, i.e. 
prior to deproteinization, derivatization and injection, different (deuterated) internal 
standards were added at a level of circa 20 ng/μL. The end volume was 135 μl and 1 μl 
aliquots of the derivatized samples were injected in splitless mode on a HP5-MS 30 m x 
0.25 mm x 0.25 mm capillary column (Agilent Technologies, Palo Alto, CA) using a 
temperature gradient from 70 °C to 320 °C at a rate of 5 °C/min. GC-MS analysis was 
performed using an Agilent 6890 gas chromatograph coupled to an Agilent 5973 
quadrupole mass spectrometer. Detection was carried out using MS detection in 
electron impact mode and full scan monitoring mode (m/z 15-800). The electron impact 
for the generation of ions was 70 eV. 
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A total of 38 human CSF samples were analysed by GC-MS. The samples were 
randomly distributed over batches and each sample was injected once. A pooled CSF 
sample was prepared from the study samples for quality control (QC). Aliquots of this 
QC sample were analysed in sextuplicate in each batch according to the procedure 
described by van der Greef et al. 26.  
Data-pre-processing was performed by composing target lists of peaks detected in the 
samples based on retention time and mass spectra. Peaks were characterized by 
retention time and m/z ratio and identified by comparison with a spectral database. 
These peaks were integrated for all samples. The peak areas were subsequently 
normalized using internal standards and corrected for intra- and inter-batch effects using 
the QC samples according to the procedure described by Verheij et al. 27. The final step 
of preprocessing was unit variance scaling. 
 
5.2.6 Data analysis 
5.2.6.1 Explorative analysis 
The first step of our data analysis strategy consists of a data exploration by means of 
Robust – Principal Component Analysis (R-PCA) 28 and PCA. R-PCA was employed on 
the autoscaled data to detect the outliers in both datasets. To extract and display the 
systematic variation in the two datasets PCA was also carried out on the autoscaled 
data.  
5.2.6.2 Selection of training set and independent test set 
In order to validate the performance of the classifier an independent test set was used. 
Dividing the data into training and test sets is a widely accepted approach for this 
purpose 29, 30. The commonly used leave-one-out cross-validation (LOOCV) is biased to 
assess the predictive ability of the classification model. External validation using test 
sets provides a means to establish a more reliable predictive performance of the 
classification model 31-33. 
The training set and an independent test set were selected separately for NMR and GC-
MS datasets using the Kennard-and-Stone algorithm 34 in such a way that the number of 
samples in the test set in every group (i.e. MScl or CIS, see Table 1) was equal to 25% 
of the total number of samples in a group). The training sets were used for all 
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optimization steps and for developing a classifier, while the independent test was utilized 
to assess the predictive ability of the classification model. The Kennard-and-Stone 
algorithm is one of many possible approaches for data division 32, 35, 36. The use of 
Kennard-and-Stone algorithm for data division is justified by the advantage of obtaining 
representative training set and the reproducibility of the selection. Nevertheless, since it 
is Euclidean based algorithm it might be influenced by noisy variables. Therefore, in 
addition the training and independent test sets were selected randomly. The results of 
presented fusion approach for random division is shown in the supplementary material. 
The number of samples included in the training set and independent test set is shown in 
Table 1. Since the number of overlapping samples between NMR and GC-MS is 
relatively low (22) this puts limitations on the accuracy of the predictions when using a 
relatively small independent test. Therefore, as an additional check of the 
meaningfulness of the classification model, a permutation test with 10000 permutations 
was performed. Using a permutation test, we checked if the assessment of the 
classification of objects into the original classes is significantly better than any random 
classification in two arbitrary classes. 
 
5.2.6.3 Supervised analysis: linear and non-linear approaches 
The supervised analysis is carried out in order to extract class related information. 
Below, we briefly describe the overall strategy. First, the supervised data analysis 
involving linear methods is described followed by the proposed kernel based non-linear 
methods. In the next sections detailed information on specific technical aspects of the 
supervised data analysis strategy is provided.  
The most straightforward approach in data analysis is to first use a linear method. 
Therefore, the linear method by means of the cross model validation (CMV) PLS-DA is 
applied 37. In this technique, two cross validation procedures are included in the variable 
selection procedure based on jack-knifing. This approach enables removal of irrelevant 
variables and optimizes the model for accurate prediction of group memberships. This 
technique was first applied to individual datasets and then the selected variables were 
fused and analysed by the linear classifier.  
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Next, if the considered classification problem is suspected to be non-linear (e.g. when 
prediction accuracy of linear model is low), more sophisticated algorithms can be 
applied. Here, a non-linear technique based on kernel methods was utilised. The 
strategy is shown in Figure 1. The steps 1 and 2 were carried out on the training set. 
The first step consists of a variable selection method, which aims to obtain meaningful 
information from each individual data set. We used SVM-RFE for the non-linear kernel 
as variable selection method 19. For both datasets the radial basis function (rbf), i.e. a 
Gaussian function, is used to map the original input data into a feature space 38. The 
choice of kernel function is performed both by means of visual inspection of PCA score 
plot and using the root mean square error of cross validation (RMSECV).  
RMSECV= 
n
YYn
i ii
2
1¦  ¹¸·©¨§   
 Here, Y is a real class label, while 

Y is the predicted class label; n indicates the number 
of observations. 
The kernel parameter sigma (σ) is optimized by LOOCV. More specifically, in each 
iteration, one object from the training set is removed and a model is constructed on the 
remaining objects for different values of σ. This is repeated until each object has been 
removed once. The RMSECV is calculated for each iteration. The optimal σ value is 
selected based on the first minimum in the RMSECV. SVM-RFE is performed for both 
datasets separately. Only the selected variables are then used in the subsequent steps. 
In the final part of step 1 (see Figure 1), the data with only significant variables are 
analysed by K-PLS-DA, which is an alternative to the SVM technique. This part is 
employed to tune the kernel parameters and to estimate the classification accuracy of 
the separate datasets. The optimal model complexity (i.e. number of latent variables 
(LV’s)) was selected based on RMSECV. Note that the selected variables per dataset 
can be concatenated in classical mid-level fusion and analysed with K-PLS-DA.8 In our 
procedure, SVM-RFE was selected as variable selection and K-PLS-DA as classification 
method. The use of SVM-RFE it justified by the fact that it is a well-established method, 
able to find significant variables in non-linear space. The binary classifier (PLS-DA) is a 
popular alternative to SVM. Our choice was guided by the fact that SVM offers sparse 
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solutions based on a limited number of observations, i.e. the support vectors. Since the 
obtained hyperplane can be based on outlying objects, this brings a question about the 
robustness of SVM 38. The main benefits of K-PLS-DA are its efficiency and simplicity. In 
addition, it has convenient visualisation options in the latent variable space. 
Nevertheless, as it will be shown latter, in terms of prediction K-PLS-DA and SVM 
perform similarly (see Data fusion by MKL).In the second step (see Figure 1), the 
kernels of the individual datasets are concatenated by linear combination of their kernel 
matrixes. In step 3 the combined kernels are analyzed with K-PLS-DA. The accuracy of 
the K-PLS-DA model is validated by the independent test set and by the permutation 
test. In order to obtain more robust classification model in the final step (number 4) the 
K-PLS-DA model is reconstructed using all available samples (i.e. both training and test 
sets) and all previously optimized parameters, namely number of variables, sigma for rbf 
kernel, coefficients μ and nr. of LV’s  (see later). Moreover in this step variable 
importance in kernel space is evaluated and visualized. 
 
5.2.7 Variable selection by SVM- RFE 
The first step of our approach (Figure 1) consists of extracting the most relevant 
information from the datasets by using SVM- RFE variable selection. SVM is a powerful, 
supervised method and since this technique is extensively discussed in the literature we 
do not focus on its description 39.  SVM- RFE is an application of RFE in the SVM 
algorithm and was introduced by Guyon 19. RFE is a backward elimination algorithm that 
ranks variables on the basis of the smallest change in a cost function minimized in the 
SVM algorithm. In the specific case of a non-linear kernel, used in this manuscript, the 
cost function to be minimized takes the form: 
1)2/1( TTJ DDD  H         (1)  
Here, H is a matrix with elements yiyjK(xi,xj), K is a kernel function, yj and yj denotes the 
class labels, α’s are the Lagrangian multipliers and 1 is a vector of ones. The algorithm 
begins by using all training data to train SVM. The matrix H is than recomputed for every 
variable being removed, while the α’s values remain unchanged. The elimination of the 
input variable “i” causes the change in cost function, J. The change in the cost function 
is calculated according to equation 2: 
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Here, H(-i) indicates the matrix H calculated when the input component “i” is removed. 
All the ∆J(i) is calculated  and the values are sorted accordingly. A subset of variables 
corresponding to the end of the sorted list of ∆J (i.e. those with small ∆J) is then 
removed. In our case, the subset is formed by only one variable in each iteration.  
In order to select an optimal set of variables LOOCV approach is used. We used RFE 
with cross-validation since it increases the likelihood that relevant variables are selected. 
Averaging over cross-validation iterations ensures that the variables that were significant 
in each run are selected. This gives a better estimation of the important variables than 
performing variable selection only once using all training samples. Moreover, using a 
variable selection procedure with cross-validation, overly optimistic results (solely valid 
for the training models) can be avoided. In LOOCV in each iteration, one object of the 
training set is left out and a ranking is obtained.  Next, the total ranking is obtained by 
sorting the variables based on the amount of times it is selected in the LOOCV. All 
variables that appear twice or more in the “top ten” of the rankings are selected. 
Although the number ten is somewhat arbitrary, exploration of other options (e.g. “top 
fifteen” or median +1 of the amount it is selected in the LOOCV) did not affect the 
outcome. 
 
5.2.8 Data fusion by Multiple kernel learning  
The second step of our approach (step 2, Figure 1) aims to combine the kernels. This is 
done  by means of Multiple Kernel Learning (MKL), which was pioneered by Lanckriet et 
al. 40and Bach et al. 41 as extension of single kernel to integrate multiple kernels in SVM. 
They integrated multiple kernels in classification problems. The essence of MKL is to 
combine kernel matrices into a single kernel using basic algebraic operations such as 
addition or multiplication. For example, given two (positive semi-definitive) kernels K1 
and K2 it is possible to define the new kernel K, which is a parameterized linear 
combination of K1 and K2. In particular, given a set of kernels K it is possible to combine 
them by linear combination according to equation 3: 
KK i
m
i
i¦  1 P   (3)  
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Here m is a number of kernels and coefficients μ are non-negative to assure positive 
semi-definiteness of K: μi ≥0. Note that the dimensions of the kernels have to be equal 
(i.e. the number of samples in the datasets has to match). The coefficients μi in equation 
3 can be tuned to weight the importance of the different kernels. The weights can be 
obtained in multiple ways, i.e. by applying different regularization method such as the L1 
or L2-norm. L1 regularization on the kernel coefficients corresponds to the requirement 
that the sum of μi equals one (||μi||1=1). L1 regularization can lead to sparse optimal 
solution and diminishing one of the platforms.. In the current problem of deriving 
metabolite profiles from NMR and GC-MS datasets both datasets are relevant and 
complementary (the sets of measured metabolites are partially different). In order to 
avoid the possibility of shrinking the importance of any platform the L2-norm was used as 
regularization parameter. In the L2-norm approach, different constraint on the 
coefficients are used, i.e. the sum of squares of μi equals one (||μi||2=1). The L2-norm 
yields a non-sparse solution and it distributes the coefficients over  multiple kernels 20. 
Using the L2-norm MKL we try to find the best separation between classes by solving the 
objective as follows: 
1||||
,...,1,0
;
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The weights μi were optimized by LOOCV performed on the training set. The optimal 
weights were selected based on the minimal error of the root mean square error of 
cross-validation (RMSECV).   
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5.2.9 K-PLS-DA and variables visualisation  
In the non-linear architecture presented in Figure 1, the fused kernels are analyzed with 
a classification method, K-PLS-DA (step 3). This means that PLS-DA is applied on to the 
combined kernel matrix.  
 
 
 
Figure 1. Conceptual flowchart of kernel-based data fusion. X1 and X2 are two blocks of data. * 
Note that all optimized parameters, i.e. number of variables, sigma for the rbf kernel, coefficients 
μ and nr. of LV’s are kept during the model reconstruction using all available samples. The 
particular steps are described in sections data analysis. 
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The classification model is statistically validated, i.e. it is based on the prediction 
accuracy of the K-PLS-DA model, on the independent test and on the permutation test. 
Therefore, in the final fourth step of the approach shown in Figure 1 K-PLS-DA is first 
reconstructed using all available samples and next variables importance is established. 
 
To represent the importance of the original variables, the pseudo samples principle, 
recently proposed by Krooshof et al. 16 and based on the non-linear plot principle 
described by Gower 42, was applied (step 4; Figure 1). As shown in Figure 2a, the matrix 
X (with n number of objects and p number of variables) is mapped by the kernel function 
K(xi,xj) (where xi and xj are samples from matrix X). The obtained kernel matrix K is a 
square matrix of size “n x n” (where n is a number of samples). The application of PLS-
DA on the kernel matrix leads to a linear model, i.e. y=Kb+r, where y a vector of group 
memberships, b regression coefficients and r a model residual. It is possible to obtain 
predicted ŷ-values for all training samples of matrix X, but the information about the 
variables (i.e. metabolites) involved in the discrimination is lost. In our approach every 
original variable is represented as a set of pseudo samples. The pseudo samples are 
artificial samples constructed as follows: every pseudo sample contains a certain value 
(e.g. 1) for only one variable and zeros for all the others. It is possible to check the 
influence of these pseudo samples in a K-PLS-DA model by predicting their 
corresponding ŷ-values or projecting them into latent variable space.  
The graphical representation of the pseudo samples principle is shown in Figure 2b. It is 
possible to construct for each original variable a series of pseudo samples containing 
different values. These different values permit to describe a complete trajectory for each 
variable. In that way, for every variable a matrix of size “k x p” (where k is the number of 
pseudo samples used to span the complete range of the original variable and p the 
number of original variables) is created. From now on, we call this set of pseudo 
samples describing a single original variable a pseudo samples matrix. For data matrix X 
(shown in Figure 2a) “p” pseudo samples matrices are created, each of size “k x p”. 
Once all pseudo samples matrices are constructed, one can apply the K-PLS-DA model 
to estimate the influence of the original variables. The pseudo samples are first mapped 
into the kernel space in relation to the original data matrix X using the same kernel 
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function as derived for data matrix X (Figure 2a), i.e. K(xi,psj) where xi is an object of 
matrix X and psj is one pseudo sample. This leads to “p” kernel pseudo samples 
matrices (Figure 2b). Next the ŷ-values of pseudo samples can be estimated using 
regression vector “b” of K-PLS-DA model or they can be projected into LV space using 
loading vector of K-PLS-DA model. It has been shown that for linear kernel predicted ŷ-
values of pseudo samples can be directly related to the regression coefficient of the 
original variables 17. The projections of pseudo samples into the regression vector “b” of 
K-PLS-DA model from now on will be called “regression coefficient”; while the projection 
of the pseudo samples in the LV space will be referred to as a loading plot.  
 
Figure 2. Representations of the a) kernel mapping of data matrix X into kernel space; b) 
pseudo samples principle in K-PLS-DA. k indicates the range of pseudo sample values 
(uniformly distributed); * Note that  there are “p” pseudo sample matrixes and “p” kernel pseudo 
samples matrixes. **The ŷ-values can be projected into latent variable space.  #Note that for 
kernel pseudo samples the loading and b vector of K-PLS-DA model are used.  *** These ŷ-
values can be represented as “regression coefficients” shown later in Figure 4 or loading plot 
shown in Figure 5. 
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The first graphical representation (Figure 3a) permits one to investigate how the original 
variables evolve as a function of the studied response as well as their global and local 
importance in the model. As described above, the kernels pseudo samples (see Figure 
2b) are projected into the K-PLS-DA model to visualize the importance and behaviour of 
the original variables. A schematic example is provided in Figure 3a.  The “regression 
coefficients” of four variables trajectories are displayed, each one illustrating a different 
case. If the influence of a given variable to the model is linear the corresponding pseudo 
samples trajectory should form a straight line, as variable 1 in Figure 3a. Variable 2 
behaves linearly in the low variable range but becomes non-linear in the high range as 
can be observed from the corresponding curvature. Variable 3 represents a more 
complex sigmoid shape. This variable has big importance in the model in the low range 
and in high range but less in intermediate range. Note that in the high range variable 3 
shows a plateau, which indicates that after passing a certain concentration value its 
importance stays constant. Finally, the last variable shown in Figure 3a, variable 4, has 
very little influence on the model. Note that, if the optimal K-PLS-DA model complexity is 
one LV, information contained in the regression coefficient and the loading vector 
(obtained from K-PLS-DA model) is equivalent. Therefore it is possible to use the 
loading vector instead of the regression vector “b” for obtaining the predicted ŷ-values of 
pseudo samples (the y-axis of Figure 3a represent 1LV). This kind of plot in linear PLS-
DA is called loading plot. Therefore, in the rest of paper it will also be called loading plot. 
Another piece of information delivered from Figure 3a, is the change of variable value 
between studied groups. Positive predicted ŷ-values of pseudo samples indicates group 
A and a negative indicates group B. For instance the value of variable 1 increases from 
group A to group B, while the value of variable 2 decreases from group A to group B.  
Figure 3b is an enhanced version of the figure presented in reference 17. It allows direct 
visualisation of the importance of each variable on the K-PLS-DA model. Figure 3b is 
constructed as follows: the absolute value of the maximal “regression coefficients” (i.e. 
predicted values of pseudo samples) is used as the relative importance of each variable. 
Note that this approach can be used when the original variables are scaled to unit 
variance. Note further, an alternative to estimate/visualize the relative importance would 
be by taking the absolute value of the difference between maximum value and minimum 
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value. The result can be graphically represented using the traditional regression plot 
obtained in any regression method 8. Note that the importance of the variables can be 
also directly read off from Figure 3a, i.e. from the absolute max values along the 
horizontal axis. The 4 variables in Figure 3b correspond thus to the ones shown in 
Figure 3a.   
 
Figure 3.  (a) A schematic example of “regression coefficients” of original variables trajectories 
plotted versus their range; (b) The maximum absolute value of “regression coefficients” of 
original variables trajectories shown in a. 
 
 
5.2.10 Data 
Every NMR spectrum of CIS and MScl groups was divided into 233 bins, corresponding 
to relative metabolites concentrations. These bins are equivalent to approximately 50 
identified metabolites and some unidentified resonances. The GC-MS data consists of 
66 metabolites and their corresponding relative concentrations. It is important to mention 
that 20 metabolites were measured by both NMR and GC-MS. Some metabolites are 
identified only by NMR (e.g. methanol) or only by GC-MS (e.g. urea) 43.   
These two datasets are used as case study to represent the proposed architecture for 
non-linear data analysis and fusion. After variables selection by SVM-RFE the NMR data 
and GC-MS data are reduced to 47 bins and 29 metabolites, respectively. In case of 
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NMR these 47 informative bins correspond to 20 identified metabolites and some 
unidentified resonances.  
It is important to keep in mind that σ, i.e. the parameter controlling the smoothness of 
the function, has to be tuned correctly, since it impacts the model performance. The σ 
parameter used for rbf kernel function is optimized separately for NMR dataset and GC-
MS dataset and again before kernel fusion. An overview of σ parameters optimized in 
particular steps in Figure 1 is summarized in Table 2.  
 
Table 2. Summary of σ parameter for rbf kernel function. 
σ parameter at: NMR GC-MS 
Step 1 (variable selection) 0.5 0.55 
Step 3 (kernel fusion) 0.3 0.3 
 
 
5.2.11 Metabolites identification  
After selection and visualization of the most important variables, the corresponding 
metabolites were identified (NMR). Metabolite identification for NMR data was carried 
out by using the 600 MHz library of metabolite NMR spectra from the Chenomx NMR 
Suite 7. The library of metabolite spectra is obtained based on a database of pure 
compound spectra acquired using particular pulse sequence and acquisition 
parameters, the tn-noesy-presaturation pulse sequence with 4s acquisition time and 1s 
of recycle delay 44.  
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6.3 RESULTS 
6.3.1Linear methods 
The analysis of the data can be first performed per analytical method. This is particularly 
significant not only during exploratory phase but also during supervised analysis, where 
relevance of individual sets is investigated. Both datasets were first analyzed with R-
PCA and PCA for presence of outliers and to detect potential trends. In total 4 NMR 
spectra and 3 GC-MS samples were detected as outliers and removed from further 
analysis. Since PCA score plots did not reflect any groupings and the variations did not 
separate according to groups CIS and MScl, the results of this analysis are not shown. 
Next, the linear method, CMV-PLS-DA, was employed on separate platforms and on 
fused datasets in mid-level fashion. In our case, the application of linear methods 
provided disappointing results for the separate datasets as well as for the datasets fused 
in the mid-level fashion. The degree of correct classification for a validation set obtained 
for the individual data-set analysis and for the concatenated sets can be seen in Table 3 
and the corresponding figures are shown in the supplementary material (Figure 2Sa-
2Sc).  
 
Table 3. An overview of prediction accuracy for the validation set using linear methods, non-
linear methods and MKL.   
 
Correct classification rate 
NMR GC-MS fusion (NMR +GC-MS) 
Linear method 61% 63% 65% 
Non-linear method 93% 85% 89% 
MKL   100% 
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6.3.2 Non-linear analysis 
Since linear methods did not lead to satisfactory results (see Table 3), we used more 
sophisticated methods (i.e. non-linear) to find differences in metabolic profiles of CSF of 
CIS and MScl groups. As pointed out previously (see Materials and Methods), our 
approach is based on four steps. The first one consists of a variable selection performed 
on each dataset. We used SVM-RFE in order to get good predictive group membership 
ability and a meaningful interpretation of the model. After the first step, we analysed the 
separate datasets by K-PLS-DA. After variable selection every dataset can be assessed 
in terms of complexity and prediction accuracy. The overall correct classification for 
independent test sets, left out during model optimization and construction, is 93% for 
NMR data and 85% for GC-MS data, respectively (Table 3). Both K-PLS-DA models 
were constructed for 2 latent variables (LV’s). These results suggest that both data 
sources hold relevant information concerning discriminating CIS and MScl groups. The 
overview of the prediction of each K-PLS-DA model is presented in Table 3. 
The most straightforward approach for data fusion is to analyse the two datasets 
together by simply concatenating the selected variables from two data sources together 
(mid-level fusion). It is expected that the two types of information from the NMR and GC-
MS datasets should complement each other and improve the class separation. 
However, this mid-level fusion provides very similar results in terms of complexity of the 
K-PLS-DA model and correct classification (i.e. 2LV’s and 89% correct classification, 
see Table 3).  
 
6.3.3 Data fusion by Multiple Kernel Learning  
Since the analysis of both sets as unique matrices does not provide a better separation 
of the groups, we decided to apply kernel-based fusion by MKL (Materials and 
Methods). Note that this kernel fusion architecture, as applied by us here, falls outside 
the range of the classical low-, mid-, or high-level fusion. It uses the specific property of 
the kernel matrix in the data fusion, i.e. its dimensions and its nature comparable to a 
similarity matrix.   
The MKL approach used here is composed of optimizing weights for each kernel matrix. 
The optimized weights were equal 0.75 for NMR and 0.661 for GC-MS. This indicates 
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that both datasets are almost equally important. After weighted kernel-based fusion, the 
newly formed kernel matrix can by analysed by PLS-DA. The kernel fusion leads to 
correct prediction of 100% on the independent test set (versus 89% for mid-level fusion, 
see Table 3). The K-PLS-DA model was constructed by using 1 LV. As an additional 
check, we performed a permutation test. The p-value for 10000 permutations was equal 
to 0.0013. The accuracy of K-PLS-DA was further compared to SVM. The correct 
prediction was as well 100% on the independent test set.  
 
Since the model shows good predictive ability on the independent test set, we consider it 
as statistically validated and as shown in Figure 1 (step 4) the K-PLS-DA model is then 
reconstructed using all available samples. The resulting model can be graphically 
assessed using a score plot (here not shown). Obviously, this kind of plot is the normal 
visual representation of kernel method.  
Variables importance visualization 
As shown in Materials and Methods, it is possible to visualize the original variables in 
discriminating the groups. For that purpose the maximum absolute value of the predicted 
values of pseudo samples was calculated. The obtained values are shown in Figure 4. 
This figure demonstrates that there are several variables having very high importance. 
For instance, variables number 67 (sucrose), 76 (urea) and 50 (3-methyl-2-
hydroxybutanoic acid) have the highest values of the predicted values of pseudo 
samples, demonstrating the relevance of these variables. There are just few variables 
seen as less significant, for example variable 57 (glycerol) or 63 (phenylalanine). The 
complete list of names of metabolites corresponding to variable number is given in the 
supplementary material (Table 1S).  
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Figure 4. The maximum absolute value of “regression coefficients” of original variables. 
 
 
As was explained in Materials and Methods, to investigate the relation between 
individual variables and changes of metabolite concentration (i.e. elevation or reduction) 
the trajectory of predicted values of pseudo samples (representing individual variables) 
can be studied. Since the optimal model complexity is 1LV we used loading vector 
delivered from K-PLS-DA model to project the pseudo samples into LV1. The obtained 
trajectories are shown in Figure 5. Because presenting trajectories for all variables 
makes the plot unreadable, in Figure 5, only a few of them are given. Trajectories for all 
variables are given in the supplementary material (Figure 1S). 
 
Besides showing the importance of variables in discriminating, Figure 5 also reveals the 
linear or non-linear trend and/or monotonicity of the variables in certain concentration 
ranges. A variable which shows a non-linear trend is glutamine and is derived from 
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NMR. Valine is characterized by linearity and monotonicity in its low range, and non-
linearity in its high range. Urea and sucrose demonstrate linearity over the whole 
concentration range. 
 
 
Figure 5. Loading plot of pseudo samples trajectories for selected variables. Numbers in the 
brackets correspond to variable numbers in Figure 4.   
 
As mentioned before the change in metabolite concentrations across groups can be 
assessed. The horizontal axis in the Figure 5 represents the range of every original 
variable (scaled to its min to max value). The levels of lactate and of valine both 
increase, while the concentration of glutamine and citrate is reduced with disease 
progression. To make the change of metabolite concentrations more evident we 
included the direction of groups along vertical y-axis. More specifically, the negative 
values of the predicted values of pseudo samples correspond to CIS and the positive 
values to MScl. 
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At this point one should remember that some metabolites were measured both by NMR 
and GC-MS. It is therefore interesting to check how the corresponding variables 
compare with each other. For instance, pseudo sample trajectories for glutamine derived 
from NMR and GC-MS reveal very similar evolution upon disease progression.  
Correspondingly, pseudo sample for lactate, glucose and citrate measured by NMR and 
GC-MS display comparable trajectories along concentration range.  This suggests that 
even after non-linear transformation the same variables measured by two different 
analytical methods are correlated and demonstrate their akin behaviour. 
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6.4 DISCUSSION 
In this paper we have described a procedure for kernel-based data fusion. We have 
demonstrated an application of the proposed procedure to the classification problem of 
metabolomics datasets of CIS and MScl individuals. We have proposed a framework 
based on four steps, where the first one is focused on optimization of individual 
datasets. This is relevant, since we want to make sure that accurate information 
extracted from both data sources is included in fusion. We applied the L2 MKL 
framework, demonstrated by Yu et al. for SVM, to K-PLS-DA, since it is characterized by 
the non-sparse integration of multiple kernels. Indeed, the optimization of the L2 norm 
showed that both datasets, i.e. NMR and GC-MS, are valuable for discriminating CIS 
and MScl individuals. 
The application of SVM-RFE allowed one to reduce both datasets significantly and 
select a set of informative variables. The classification performance of K-PLS-DA 
performed on fused kernels was better than single analysis and common mid-level 
fusion. Additionally, the K-PLS-DA model was simpler in terms of complexity, i.e. just 
one LV was sufficient to obtain optimal classification model.  
The visualization of the variables relative contribution to K-PLS-DA model was achieved 
by applying and extending the pseudo samples approach demonstrated by 16, 17. This 
allowed us to show that even after non-linear kernel transformation two different 
analytical methods are consistent with the results. The pseudo samples trajectories of 
the same variable measured by NMR or GC-MS demonstrate very similar trends.  
 
Several potential challenges remain in the proposed framework. One possibility is to 
apply it to larger datasets with more different sources, for instance lipids and 
metabolites.   
Since the number of available samples was limited, the potential impact of over-fitting of 
statistical model must be considered. We used here an independent test set and 
permutation test, which yielded results that clearly show that over-fitting, is highly 
unlikely.  Note that in individual analysis the total number of samples was larger than in 
the fused set.  
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Classification with different types of non-linear functions in the original space can be 
achieved using diverse types of kernels.  Of course, the choice of kernel function has to 
be done beforehand.  A correct selection of kernel function has a significant influence on 
classification accuracy. However, no rules can be defined. In our experiment different 
kernel functions were tried. The Gaussian kernel was chosen as the one to fit the data 
properly.  If the sigma value is too small over-fitting can easily occur. It has also 
influence on pseudo samples trajectories. Small sigma value (e.g. 0.1) might lead to 
very non-linear and hardly interpretable trajectories.  
The case study described here represents indeed a non-linearly separable problem. As 
was shown, linear methods gave poor classification performance. The class separation 
was possible after application of a non-linear kernel function and PLS-DA. Non-linearity 
is also visible in the pseudo samples trajectories. There are several variables that are 
characterized by curved trajectories. The curvatures of the trajectories illustrate the 
effect of the original data. Importantly, even if these trajectories are non-linear, they are 
still simple enough to be interpretable.  
 
The example given on the metabolites analysis of CSF gave very interesting results. 
However the number of used samples was relatively low. It should then be pointed out 
that due to this small number of samples, this study may have several limitations. 
Obviously, the size of the training and testing sets has an influence on the accuracy 
assessment of the classification method. Small sample size may result in detecting only 
the largest differences. Indeed the data size and classification rate are correlated.  
The bigger the groups size the more representative and robust the results become. It 
has been shown 45 that as the sample size is increased prediction accuracy overcomes 
local minima and next stabilizes and therefore become more reliable and accurate. 
Obviously classification performance of a classifier is influenced by the natural difficulty 
of the studied problem, however there are possibilities where the performance of a 
classifier is degraded because of small training cases. Therefore one should be aware 
that results (with 100% correct prediction on test set) shown here do not imply that all 
new samples will be always correctly classified (due to e.g. biological variance). Hence, 
more studies involving a larger cohort will be necessary to fully establish and assess the 
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findings. However, despite the drawbacks of the study, it seems that validation with the 
independent test set and the permutation test set attest that the results are meaningful. 
In general the accuracy of the classification of objects into the original classes is 
significantly better assessed than any random classification in two arbitrary classes (p-
value of 0.0013). Additionally the random division of data to training and test set was 
performed, showing that the average correct prediction over 10000 different runs 
supports our results. 
From a biological point of view the metabolites having a relatively high contribution in the 
K-PLS-DA model, e.g. urea, glutamine, lactate, citrate, valine, are consistent with 
biological knowledge. These metabolites, described in this study, were previously found 
in relationship to the MScl 6. They, therefore, provide a biological validation for the fusion 
of data. However, the full interpretation of the presented models in terms of biology still 
remains to be made.   Therefore, future work will focus on the interpretation of newly 
detected metabolites and on highlighting pathways involved in the MScl disease 
process. The pattern defined by these variables must also be studied by itself and put 
into context in a system biology approach. 
The kernel fusion approach presented in this paper assumes the dimensionalities of the 
kernels to be equal, i.e. the samples present in each dataset have to come from the 
same subjects at the same time points. Although, extending our method for missing 
values appears valuable and would be an interesting subject for further research.  
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SUMMARY 
In this thesis we investigated the metabolomics of biofluids by Nuclear Magnetic 
Resonance (NMR) in combination with chemometrics analysis. Apart from the 
development of new methods, the main aim was to identify potential metabolomic 
biomarkers of Multiple Sclerosis (MScl).  
MScl is a disease of the Central Nervous System (CNS) and is characterized by a 
combination of many factors, such as inflammation, demyelination, remyelination and 
axonal damage, most probably caused by a disturbance of the autoimmune system. It is 
the most common chronic disease in young adults. Since the early 20th century, constant 
research has been performed to understand the origin and the pathology of the disease, 
to set up diagnostic criteria and to come up with a cure for this disease. However, the 
cause(s) of MScl still remains unknown. Moreover, a cure has not yet been found. MScl 
is a very heterogeneous disease and thus it is difficult to diagnose especially at an early 
stage. Therefore, there is still a need for new molecular biomarkers, which would allow 
an early diagnosis and consequently improve preventative action. Since MScl is a CNS 
disorder, analyzing Cerebrospinal fluid CSF is the most suitable and interesting 
compartment, because of its proximity to the brain, besides the brain itself. Therefore, 
our main focus was to investigate the metabolic profile of CSF. Nevertheless, we also 
examined blood plasma in the animal model of MScl and we showed that not only CSF, 
but blood plasma as well contains significant information about neuroinflammation.  
In this thesis four main aspects are covered and discussed, namely: (i) sample 
treatments and measuring by NMR, (ii) data preprocessing of NMR data, (iii) 
chemometric analysis of NMR metabolomics data, and (iiii) data interpretation in 
biomarker discovery of MScl disease. The joint analysis of NMR of biofluids and pattern 
recognition methods has driven forward the relevance of metabolomics in biomarker 
discovery field. In chapter 1 a review is given of the data acquisition and multivariate 
analysis of NMR-based metabolomics data, with particular emphasis on CSF and MScl. 
We demonstrate recent developments in biofluid sample handling and measuring, 
crucial steps in preprocessing of NMR spectra, i.e. baseline correction, alignment, 
binning and scaling, and different approaches in multivariate data analysis. Moreover, 
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the application of current developments of NMR and chemometrics methods in 
metabolic biomarker discovery for MScl is addressed.  
A proper biomarker search first requires standardization in sample handling. Several 
aspects, such as sample collection, sample storage and time between collection and 
storage can influence the results. Therefore, in order to obtain reliable results and avoid 
false biomarker candidates the stability of metabolites identified by NMR was 
investigated. The metabolites that were identified in human CSF by NMR showed 
negligible changes in concentration when left at room temperature for 30 and 120 
minutes before freezing and storing the samples at -80oC.  The results are presented in 
chapter 2 of the thesis.  
Investigating the biological and analytical variations in metabolite concentrations in CSF 
of “healthy” (i.e. with no neurological disease) individuals is brought up in the third 
chapter of the thesis. The knowledge of inter-individual variation of metabolite 
concentrations in CSF of “healthy” humans is essential for evaluating a potential up-
regulated/down-regulated metabolite when confronted with CSF samples of subjects 
with a disease. The results clearly showed that variations in metabolite levels range from 
circa 8% to 53% for majority, while the analytical variation was found to be less than 9%. 
Moreover, using Principal Component Analysis no clear relation between variation in 
metabolite concentrations and gender and age range was found.  
In biomarker discovery studies, it is a common approach to start the investigation of a 
certain disease with a control experiment, i.e. an animal model. Animal models allow a 
better understanding of the underlying (molecular) processes in a disease. As presented 
in chapter 4, we first investigated MScl by means of Experimental Autoimmune 
Encephalomyelitis (EAE), an animal model which mimics a certain aspect of MScl, 
namely neuroinflammation. In this study, we found that by using NMR spectra of rat CSF 
in combination with state of the art pattern recognition methods (PLS-DA and ANOVA-
PCA), a set of metabolites relevant for neuroinflammation can be established. We 
demonstrated that the CSF metabolic profile of neuroinflamed animals is distinct from 
that of healthy and peripherally inflamed individuals. Moreover, we have shown that 
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neuroinflamed animals at the onset of the EAE are heterogeneous regarding to the 
disease response. More importantly, our findings were validated with a second 
independent set of animals, showing the relevance of the metabolites specific for 
neuroinflammation.  
Our first study involving CSF of EAE affected rats indicated that it is difficult to 
distinguish neuroinflamed rats from peripherally inflamed animals at the onset of the 
disease. This was mostly due to heterogeneous response of neuroinflamed animals to 
disease. For this reason metabolic profiles of blood plasma and CSF were combined by 
the mid-level-fusion strategy. In chapter 5, the combined analysis of blood plasma and 
CSF of EAE models is detailed. It describes that the combined metabolomics 
information from blood plasma and CSF enables a more efficient and reliable 
discrimination of the onset of the EAE. Several metabolites in blood plasma are relevant 
in discriminating neuroinflammation at its onset. At this point new chemometric 
developments were required. Therefore, we present and introduce a new chemometric 
method: Hierarchical Models Fusion (HMF). This approach hierarchically combines 
previously developed classification two-class models. We show that HMF allows one to 
distinguish neuroinflamed rats also on the day of onset from either healthy or 
peripherally inflamed rats as well as to investigate the progression of EAE.  
Following the studies of the two previous chapters we investigated the metabolic profile 
of MScl in humans. Recently, a number of studies aiming to identify metabolic 
components of MScl pathology have been published. However, in most of these studies 
a single metabolomic analytical platform (e.g. NMR or Gas Chromatography-Mass 
Spectrometry (GC-MS)) is used to find metabolic patterns characteristic for MScl. In 
chapter 6, we discuss a novel approach for data fusion, which is subsequently applied 
to CSF metabolic profiles of patients suffering from MScl and obtained by NMR and GC-
MS. Due to complexity of these datasets, new challenges needed to be tackled. The 
data fusion architecture involves fusion in kernel space, which permits one to establish 
non-linear discrimination models. Using this approach we were able to study the 
progression of MScl in humans. We unveiled that fusion of datasets in kernel space 
provides more efficient discrimination between MScl individuals and patients 
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representing early stage of MScl in comparison to mid-level fusion approach and 
analysis of individual datasets. Moreover the visualization tools implemented for this 
method open the gate for a thorough biological interpretation. It is important to point out 
that the main focus was the statistical approach not the biological interpretation and 
translation. Nevertheless, the majority of metabolites specific for neuroinflammation 
found in CSF of EAE-affected rats, were also significant for describing progression of 
MScl in human CSF.  
 
Conclusively, the metabolic biomarker discovery of MScl disease was investigated in 
different species (humans and rats) as well as in different biofluids (CSF and plasma). 
The thesis also presents new analytical/statistical methods for the metabolics research, 
methods which are able to improve the metabolic biomarker discovery. We found that 
the metabolic profile of MScl in an early stage can be recognized for humans and in a rat 
model. We also found that the majority of MScl related metabolites in rats are similar to 
those in humans. This is very interesting since it suggests that the results found on rats 
could be transmitted to humans. However for a good “translation” study further research 
is needed. Another interesting observation was the strong similarity of the metabolic 
profile in blood plasma and CSF of EAE rats, which suggest that the plasma metabolites 
could be used as a source for biomarker discovery of MScl instead of CSF. However, 
the similarity between blood plasma and CSF of EAE rats had only been cursory 
glanced, so in the future a detailed comparison has to be made to validate these results.  
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 FUTURE PERSPECTIVES 
The metabolomics analysis of biofluids by means of Nuclear Magnetic Resonance 
(NMR) and chemometrics in the investigation of neurological diseases is presented. The 
main focus was metabolomic biomarker search in Multiple Sclerosis (MScl) disease. 
Several aspects connected to suitable biofluids sampling and prior measurement 
samples handling, data pretreatment and data preprocessing, and proper analyzing are 
brought up, described and presented.  Consequently, as it was pointed out in the 
introduction and summary, this thesis highlights four main points: coefficient  
(i) analytical, i.e. samples handling and NMR measuring 
(ii) preprocessing of NMR metabolomics data 
(iii) data analysis of NMR metabolomics data 
(iiii) interpretation of findings and their biological relevance 
Obviously, each of these aspects opens doors for future research. However, the synergy 
between them is potentially more interesting. The most straightforward step is the 
validation of the findings on larger cohort of individuals, because the amount of samples 
is very crucial for precise statistical multivariate analysis. The larger the groups, the 
more representative and accurate the analysis becomes. Unfortunately, in many animal 
and human studies large study groups are difficult to reach and thus uncommon, e.g. 
due to ethical reasons. In biomarker discovery studies the number of individuals is 
generally low, because of the explorative nature of this type of research. To compensate 
for this pitfall, our statistical approaches were always validated with an independent test 
set. When it was possible, an extra validation was performed with additional subjects 
coming from an independent experiment. Nevertheless, the validation on the target 
population using hundreds or thousands of samples ensures the validity and reliability of 
discovered markers. Besides that, this kind of validation is mandatory if a biomarker is 
going to be used as diagnostic tool.  
In parallel to validation on large population one could use these putative biomarkers to 
define drugs targets or effects. This is the basic concept behind  
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pharmacometabonomics. This is currently the new field where drug efficiency and/or 
toxicity are predicted from the metabolic profile of an individual prior to treatment. 
Concretely, the biomarkers could be utilized to study the pharmaceutical effects of 
different drugs in e.g. rats or mice using EAE model. The metabolite profiles would be 
used to predict a response to potential drug treatment.  In that way the quantitative 
pharmaceutical properties of drugs could be measured. The concept of investigating the 
pharmaceutical effects can be extended into personalization of drug treatments, so 
called personalized medicine, which combines pre-dose metabolite profiling and 
chemometrics to model and predict the responses of individual subjects. From a 
chemometrics point of view it would be interesting to combine the information present in 
the covariance matrix to the information in the network analysis. Information contained in 
the network might be used directly to weight the covariance matrix, for instance if two 
metabolites share a reaction it can be assumed that they should be correlated. This 
could bring together two approaches, the usual bottom up approach of chemometrics 
(starting from data to build hypotheses) and the top down approach generally used in 
biochemical modeling. This would allow reaping the benefits of both concepts.   
1D NMR spectra are very rich in information and completely untargeted. Therefore, one 
can expect to obtain a complex biomarker pattern based on multiple metabolites. Some 
of these metabolites can be straightforwardly assigned, while others remain challenging 
in terms of identification. Moving to higher dimensional NMR would be beneficial by 
reducing signals overlap and thus entail that more metabolites can be assigned. The 
application of homonuclear techniques like COSY and TOCSY could help in identifying 
unknown resonances in complex biofluid mixtures. Moreover, improving the sensitivity of 
NMR by applying recent developments in the area of hyperpolarization are potentially 
very useful in metabolomics. Finally, improved applications of so-called pure-shift NMR, 
in which NMR spectra are simplified by removing the resonance splittings due J-
couplings, may considerably improve the spectral resolution. These advances in 
combination with higher magnetic fields open the doors for considerably better coverage 
of the metabolome of biofluids by means of NMR.   
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Once all signals have been assigned, the next step of the metabolomics analysis is to 
investigate the relationships between the metabolites. This allows finding others 
metabolites involved in a disease and consequently, to improve our understanding of a 
disease. In this respect, the integration of metabolomics with others ‘omics’ data, i.e. in a 
systems biology approach, is essential to come to a better understanding of the multi-
factorial interactions of causes and effects of a disease.  Such an approach will provide 
system-wide properties of a studied disorder. For this point, developing further data 
fusion methods is essential. One of the major problems in fusion methods is the aspect 
of missing values. This aspect would be of particular interest to explore in non-linear 
space. 
In this thesis MScl was studied metabolomics in two different systems, namely in rats 
and in humans. Fortunately, in comparison to other ‘omics’ fields, metabolomics is far 
less species dependent. Therefore, it has potential to relatively easily perform translation 
from animals to humans. However, there is at present little known about direct 
comparison between metabolic profiles of animals, e.g. rats (used so often in animal 
models), and humans.  It has been shown that there is still considerable difference in 
metabolite composition between human and rat urine. This is most probably triggered 
not only by dissimilarity in metabolic pathways in humans and rats, but as well by 
nutritional and food source differences. Therefore, an interesting issue would be to first 
investigate the qualitative and next quantitative difference in metabolic profile of humans 
and e.g. rats CSF.  This would simplify the translation studies. The next step forward 
would consist of translating the results found in pre-clinical study into humans. In the 
EAE studies we have discovered candidate markers in CSF and blood plasma that are 
related to neuroinflammation. In our research metabolic profile of CSF of humans 
affected with MScl was also examined. It was necessary to develop novel chemometric 
approach, since the standard available ones did not fully enable to extract class-related 
variance. It ought to be mention that therefore the focus was the statistical approach not 
the biological interpretation and translation. Nevertheless, metabolites found previously 
in EAE model were identified in human CSF as disease related. However, still more 
exhaustive translation study is necessary. 
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The philosophy of translation does not apply only between species but also between 
different biofluids. CSF is in closest interaction with the brain therefore it is the obvious 
choice for analyzing CNS disorders. The biochemical composition of CSF may indicate 
the malfunction occurring in the brain and more generally the abnormal status of the 
brain. However, the collection of CSF requires a lumbar puncture, which is invasive and 
might result in clinical complications. Moreover the total volume of CSF is far lower than 
the total volume of blood, so this circumscribes the amount that can be sampled. 
Therefore the detection of markers in blood would be more optimal. The CSF 
metabolites are absorbed into the blood via the blood-brain barrier (BBB) and thus 
effects of CNS disorders can presumably also be detected in the biochemical 
composition of blood. Since BBB is often damaged in MScl causing “leakage”, this 
presumes that that blood may comprise significant information about the disease. In our 
research blood plasma was investigated in an animal model of MScl, namely EAE. We 
demonstrated the usefulness of blood plasma for discriminating the early onset of EAE. 
However an in depth investigation of relation between markers found in CSF, plasma 
and vice versa has not been done. Therefore the translation of markers found in CSF 
into blood is a possibility of future research.  
For any translation study the chemometrics approach is essential. One can imagine 
adapting the calibration transfer methods to adjust a model constructed for rodents into 
a model suitable for humans, or a model for CSF to plasma. 
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In dit proefschrift worden metabolomics studies beschreven van lichaamsvloeistoffen 
waarin de data gemeten zijn met behulp van Nucleaire Magnetische 
KernspinResonantie (NMR) en geanalyseerd met behulp van chemometrie. Naast het 
ontwikkelen van nieuwe methoden, was het identificeren van potentiële metabole 
biomarkers voor Multiple Sclerose (MScl) een van de belangrijkste doelstellingen. 
Multiple Sclerose is een aandoening van het centrale zenuwstelsel en wordt 
gekenmerkt door een combinatie van verschijnselen, zoals ontstekingen, beschadiging 
van het myeline en aantasting van de axonen, waarschijnlijk voorzaakt door een 
verstoring van het immuun systeem. Bij jong volwassenen is het de meest 
voorkomende chronische ziekte. Sinds het begin van de 20e eeuw wordt onderzoek 
gedaan naar het het ontstaan en de pathologie van de ziekte. Ook wordt onderzoek 
gedaan om te komen tot betere criteria voor het diagnosticeren van de ziekte. Dit alles 
gericht op het ontwikkelen van een behandeling van de ziekte. Hoewel het duidelijk is 
geworden dat MScl een auto-immuun ziekte is, blijft het nog altijd niet geheel duidelijk 
waardoor MScl wordt veroorzaakt en, vooral, is er nog geen effectieve behandeling 
gevonden. MScl kan zich bovendien heel verschillend uiten, vooral in de beginstadia, en 
is dan ook moeilijk te diagnosticeren in een vroeg stadium. Daarom is er nog altijd een 
grote behoefte aan nieuwe moleculaire biomarkers die een vroege diagnose mogelijk 
maken en dientengevolge preventief handelen kunnen verbeteren. Omdat MScl een 
aandoening is van het centrale zenuwstelsel, is, naast onderzoek naar de hersenen 
zelf, het analyseren van hersen vloeistof-  oftewel cerebrospinale vloeistof (CSF) - het 
meest voor de hand liggende en interessantste gebied. Daarom hebben wij ons 
onderzoek vooral gericht op het metabole profiel van CSF. Daarnaast hebben we ook 
bloed plasma van het dierlijke MScl model onderzocht en konden we aantonen dat niet 
alleen hersenvloeistof (CSF) maar ook bloed plasma belangrijke informatie over 
inflammatie van het centrale zenuw stelsel bevat. 
Vier belangrijke aspecten worden in dit proefschrift beschreven en bediscussieerd, te 
weten: (i) behandeling van monsters en meten met behulp van NMR, (ii) bewerken van 
NMR data zodat deze bruikbaar worden voor de volgende stap, te weten: (iii) 
chemometrische analyse van NMR metabolomics data, en (iiii) interpretatie van data bij 
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het zoeken naar biomarkers voor MScl. Dit proefschrift laat via de combinatie, NMR 
metaboliet spectra van lichaamsvloeistoffen en analyse daarvan met patroon 
herkennings methoden,het grote belang en potentie van metabolomics zien en heeft 
daarmee metabolomics op het gebied van de ontdekking van biomarkers een impuls 
gegeven. In hoofdstuk 1 wordt een overzicht gegeven van de data acquisitie en de 
multivariate analyse van de op NMR gebaseerde metabolomics gegevens, waarbij de 
nadruk wordt gelegd op CSF en MScl. We laten recente ontwikkelingen op het gebied 
van het behandelen en meten van monsters van lichaamsvloeistoffen de revue 
passeren, behandelen de cruciale stappen in het voorbehandelen van NMR spectra, 
zoals basislijncorrectie, alignment, binning en schaling van data. Daarnaast worden 
verschillende moderne methodes voor de multivariate data analyse beschreven. Verder 
wordt ook de toepassing van actuele ontwikkelingen van de NMR en chemometrische 
methoden bij het zoeken naar metabolische biomarkers voor MScl belicht. 
Een goede zoektocht naar biomarkers vraagt allereerst om standarisatie in de 
behandeling van monsters. Verschillende aspecten, zoals het verzamelen en opslaan 
van de monsters, en de tijdsduur tussen verzameling en opslag, kunnen de resultaten 
beïnvloeden. Om betrouwbare resultaten te krijgen en valse biomarker kandidaten te 
vermijden, is daarom de stabiliteit van door NMR geïdentificeerde metabolieten 
onderzocht. De metabolieten die door NMR in menselijk CSF werden geïdentificeerd, 
lieten verwaarloosbare veranderingen in concentratie zien als ze tussen 30 en 120 
minuten aan kamertemperatuur werden blootgesteld alvorens de samples in te vriezen 
en op te slaan bij -80˚C. Deze resultaten worden in hoofdstuk 2 van dit proefschrift 
gepresenteerd. 
Onderzoek naar de biologische en analytische variaties in metaboliet concentraties in 
het CSF van “gezonde” (d.w.z. zonder neurologische aandoeningen) individuen wordt in 
het derde hoofdstuk van dit proefschrift gepresenteerd. Kennis van de variatie van 
metaboliet concentraties in het CSF van en tussen “gezonde” mensen is van groot 
belang om de verhoging of verlaging van de concentratie van een metaboliet op zijn 
waarde te kunnen schatten wanneer men wordt geconfronteerd met CSF samples van 
zieke subjecten. De resultaten geven duidelijk aan dat de variatie in metabole niveaus 
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verschillen van ongeveer 8% tot 53% voor de meerderheid, terwijl voor de analytische 
variatie werd aangetoond dat deze kleiner dan 9% is. Door gebruik van 
hoofdcomponentenanalyse (PCA) werd bovendien zichtbaar dat er geen relatie is 
tussen variatie in metabole concentraties enerzijds en geslacht en leeftijd anderzijds. 
Bij onderzoek naar biomarkers is het gebruikelijk het onderzoek naar een bepaalde 
ziekte te starten met een controle experiment, b.v.  via een diermodel. Diermodellen 
maken het mogelijk tot een beter begrip van onderliggende (moleculaire) processen bij 
een ziekte te komen. Zoals gepresenteerd in hoofdstuk 4, hebben we MScl eerst 
onderzocht met behulp van Experimentele Auto-immune Encephalomyelitis (EAE), een 
diermodel dat een bepaald aspect van MScl, te weten neuro-inflammatie, nabootst. In 
dit onderzoek ontdekten we dat door het gebruik van NMR spectra van het CSF van 
ratten in combinatie met ‘state-of-the art’ patroon herkennings methoden (PLS-DA en 
ANOVA-PCA), een set van metabolieten relevant voor neuro-inflammatie kon worden 
vastgesteld. We toonden aan dat het metabole CSF profiel van dieren met neuro-
inflammatie verschilt van dat van gezonde dieren en van dieren met perifere 
inflammatie. Ook toonden we aan dat de groep dieren met neuro-inflammatie bij de start 
van de EAE een heterogene reactie op de ziekte heeft. Van belang is dat onze 
resultaten zijn gevalideerd door een tweede onafhankelijke groep dieren, die de 
relevantie van metabolieten specifiek voor neuro-inflammatie liet zien. 
Ons eerste onderzoek op het gebied van CSF van met EAE aangetaste ratten liet zien 
dat het moeilijk is om in de beginfase van de ziekte een onderscheid te maken tussen 
enerzijds ratten met neuro-inflammatie en anderzijds ratten met perifere inflammatie. Dit 
was vooral te wijten aan de heterogene respons op de ziekte van de neuro-
geїnflammeerde dieren. Daarom hebben we de metabole profielen van bloed plasma en 
CSF gecombineerd met behulp van zogenaamde ‘mid-level’ data fusie. In hoofdstuk 5 
wordt de gecombineerde analyse van metabolite data van bloed plasma en CSF van 
EAE modellen gedetailleerd beschreven. Hieruit komt naar voren dat de gecombineerde 
metabolomics informatie uit bloed plasma en CSF een meer efficiënte en betrouwbare 
bepaling van de start van de EAE mogelijk maakt. Verschillende metabolieten in bloed 
plasma blijken van betekenis voor het bepalen van neuro-inflammatie in de beginfase. 
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Om tot dit resultaat te kunnen komen moest een nieuwe chemometrische methode 
worden ontwikkeld, namelijk Hierarchical Model Fusion (HMF). In HMF worden eerder 
ontwikkelde twee-groeps classificatie modellen hiërarchisch gecombineerd. We laten 
zien dat HMF het mogelijk maakt neuro-geїnflammeerde ratten vanaf het begin te 
onderscheiden van zowel gezonde als perifeer geїnflammeerde ratten. Op deze manier 
kan men de progressie van EAE volgen en onderzoeken vanaf een vroeg stadium. 
Volgend op het onderzoek in de twee voorafgaande hoofdstukken, onderzochten we het 
metabole profiel van MScl bij mensen. Recentelijk is een aantal onderzoeken 
gepubliceerd waarin wordt geprobeerd de metabole componenten van de MScl 
pathologie te identificeren. In de meeste van deze publicaties wordt echter een 
enkelvoudig metabolomics platform (zoals NMR of Gas Chromatografie-Massa 
Spectrometrie (GC-MS)) gebruikt om de voor MScl karakteristieke metabole patronen te 
vinden. In hoofdstuk 6 bespreken we een nieuwe aanpak van data fusie, welke wordt 
toegepast op door NMR en GC-MS verkregen metabole profielen van het CSF van 
MScl patiënten. Vanwege de complexiteit van deze verzamelingen van gegevens 
(datasets), moesten nieuwe analyse methoden worden onwikkeld, i.h.b. nieuwe data 
fusie methodes, namelijk in data fusie en analyse in kernel ruimte. Deze datafusie 
architectuur in de kernel ruimte, maakt het mogelijk om niet lineaire verbanden 
zichtbaar te maken. Dankzij deze kernelruimte (niet-lineaire) benadering konden we de 
progressie van MScl bij mensen onderzoeken. We laten zien dat fusie van datasets in 
de kernelruimte een effectieve methode is om onderscheid te maken tussen MScl 
patienten in een vroeg en later stadium, dwz tussen MScl patienten (laat MScl stadium) 
en CIS patienten (Clinically Isolated Syndrome; vroeg MScl stadium). Deze kernel fusie 
methode werkt aanzienlijk beter dan de mid-level fusie benadering en de analyse van 
individuele datasets. De visualisatie handvaten die voor deze methode zijn 
geïmplementeerd effenen het pad voor een diepgaande biologische interpretatie. Wij 
benadrukken dat in dit onderzoek de nadruk lag op de ontwikkeling van de statistische 
analyse methoden en niet op de biologische interpretatie en translatie. Desalniettemin 
was de meerderheid van de metabolieten, die karakteristiek waren voor neuro-
inflammatie in het CSF van EAE ratten, ook significant voor het beschrijven van de 
progressie van MScl in menselijk CSF. 
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Dit proefschrift beschrijft een zoektocht naar metabole biomarkers voor MScl in 
verschillende lichaamsvloeistoffen (CSF en plasma) bij mens en dier (rat, EAE model). 
Het proefschrift presenteert ook nieuwe analytische/statistische methoden op het 
onderzoeksgebied van de metabolics, methoden die kunnen helpen bij deze zoektocht. 
Deze nieuwe methoden kunnen een impuls geven aan de verdere ontwikkeling van het 
veld van de metabolomics. Het is gevonden dat metabolite profiel MScl in een vroeg 
stadium is te herkennen in mensen en in een rat model (Hoofdstuk 5). Het is verder 
gevonden dat de meerderheid van aan de MScl-ziekte gerelateerde metabolieten in 
ratten overeenkomt met die in mensen. Dit is zeer interessant omdat dit suggereert dat 
resultaten gevonden voor ratten overdraagbaar zijn naar mensen. Voor een volledige 
‘translatie’ studie moet evenwel een uitgebreidere en diepere analyse worden 
uitgevoerd. Een andere interessante observatie is de sterke overeenkomst in het 
metabole profiel van bloed plasma en CSF van EAE ratten (ratten die door EAE zijn 
beïnvloed). Dit suggereert dat het plasma metaboloom gebruikt zou kunnen worden als 
bron voor biomarkers voor MScl diagnostiek in plaats van de veel minder makkelijk 
toegankelijke CSF. Echter, de overeenkomst tussen bloed plasma en het CSF van met 
EAE aangetaste ratten is maar kort besproken in Hoofdstuk 4 en een gedetailleerde 
vergelijking moet in de toekomst worden uitgevoerd om dit punt te valideren.  
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Table S1. Peptide isotope standards used for SRM quantification 
Protein 
(accession number) 
Peptide Modification Mass difference 
 (Da) 
Concentration 
(mg/L) 
Albumin (P02768) 427FQNALLVR434 L-Arg-13C6, 15N4 10 27.7 
Cystatin C (P01034) 52ALDFAVGEYNK62 L-Lys-13C6, 15N2 8 6.6 
 
Table S2. Settings used for SRM quantification.1  
Peptide Q1 mass Q3 mass Fragment ion Collision energy (V) 
FQNALLVR 480.8 685.4 y6 23.1 (2+ ion) 
ALDFAVGEYNK 613.8 709.4 y6 35.0 (2+ ion) 
ALDFAVGEYNK 613.8 780.3 y7 35.0 (2+ ion) 
 
Table S3. Cystatin C concentrations measured by SRM MS2 
 Cystatin C concentration (mg/l) 
Sample t = 0 
minutes 
t = 30 minutes t = 120 
minutes 
H 1 2.71 2.96 2.98 
H 2 2.91 2.77 3.15 
H 3 2.41 2.55 2.19 
H 4 5.24 6.08 5.83 
H 5 2.32 2.17 2.60 
H 6 2.28 2.30 2.40 
Average 2.98 3.14 3.19 
 
Table S4. Albumin concentrations measured by SRM MS3 
 Albumin concentration (mg/l) 
Sample t = 0 
minutes 
t = 30 minutes t = 120 
minutes 
H 1 195.40 187.47 193.93 
H 2 240.04 232.62 239.81 
H 3 227.30 222.02 213.57 
H 4 225.62 232.52 218.75 
H 5 214.44 208.08 219.13 
H 6 192.38 197.57 192.63 
Average 215.87 213.38 212.97 
                                                          
 
1 For all peptides the dwell time was set to 100 ms, entrance potential was set to 10 V and declustering 
potential was set to 66.2 V. 
2 No significant differences were observed between the time points (paired t-test, t = 0 vs. t = 30: p = 0.34, 
t = 0 vs. t = 120; p = 0.11, and t = 30 vs. t = 120: p = 0.71). 
 
3 No significant differences were observed between the time points (paired t-test, t = 0 vs. t = 30: p = 0.40, 
t = 0 vs. t = 120; p = 0.32, and t = 30 vs t = 120: p = 0.92). 
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PC1
PC2
PC3
 
Figure S1. Score plots for PCs 1-3 of the NMR spectral data using vast scaling and 
meancentering per patient (0 min: o; 30 min: +; 120 min: ×). Total variance explained per first 
three PCs was 21%, 18% and 13%, respectively. 
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These figures all illustrate the lack of clustering of the different subgroups in a PCA 
analysis, indicating that the total variation is not unevenly influenced by one of these 
subgroups. 
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Figure S1. PCA plots proteomics ESI-Orbitrap, gender effect (Male vs. Female); (a), 
PC1 vs. PC2; (b) PC1 vs. PC3 ; (c) PC2 vs. PC3. 
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Figure S2. PCA plots proteomics ESI-Orbitrap, age effect (1 = <35, 2 = >35 and < 50, 3 
= >50); (a) PC1 vs. PC2; (b) PC1 vs. PC3; (c) PC2 vs. PC3. 
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Figure S3. PCA plots metabolomics GC-MS, gender effect (Male vs. Female);(a) PC1 
vs. PC2; (b) PC1 vs. PC3; (c) PC2 vs. PC3. 
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(c)  
 
 
Figure S4: PCA plots metabolomics GC-MS, age effect (1 = <35, 2 = >35 and < 50, 3 = 
>50); (a) PC1 vs. PC2; (b) PC1 vs. PC3; (c) PC2 vs. PC3. 
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(c)  
 
 
Figure S5. PCA plots metabolomics NMR, gender effect (Male vs. Female); (a) PC1 vs. 
PC2; (b) PC1 vs. PC3; (c) PC2 vs. PC3. 
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(c)  
 
Figure S6. PCA plots metabolomics NMR, age effect (1 = <35, 2 = >35 and < 50, 3 = 
>50); (a) PC1 vs. PC2; (b) PC1 vs. PC3; (c) PC2 vs. PC3. 
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(c)  
Figure S7. PCA plots metabolomics LC-MS/MS, gender effect (Male vs. Female); (a) 
PC1 vs. PC2; (b) PC1 vs. PC3; (c) PC2 vs. PC3. 
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(c)  
 
 
PCA plots metabolomics LC-MS/MS, age effect, age effect (1 = <35, 2 = >35 and < 50, 
3 = >50), (a) PC1 vs. PC2; (b) PC1 vs. PC3; (c) PC2 vs. PC3. 
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Original samples information 
Sample Gender age Protein (g/L) Albumin (g/L) 
61454 M 59 0.45 0.244 
61525 M 30 0.25 0.118 
61281 M 44 0.4 0.221 
61430 M 51 0.62 0.403 
61435 M 57 0.4 0.173 
61349 M 62 0.33 0.179 
61373 F 72 0.46 0.241 
61378 M 57 0.31 0.097 
61607 F 27 0.26 0.171 
AVG 7M/2F 51 0.3867 0.2052 
STDV 14.849 0.1162 0.0897 
AVG Male 51.4 0.39 
STDV Male 11.1 0.12 
AVG Female 49.5 0.36 
STDV Female 
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Validation samples information 
Sample 
number  Gender 
protein concentration 
(g/L) 
SFG01 F 64 0.32 
SFG02 M 44 0.38 
SFG07 M 43 0.34 
SFG09 M 49 0.44 
SFG10 M 40 0.65 
SFG12 M 52 0.34 
SFG14 F 76 0.4 
SFG15 M 27 0.33 
SFG17 F 17 0.21 
SFG18 F 34 0.38 
SFG20 F 74 0.48 
SFG21 M 42 0.49 
SFG26 F 49 0.19 
SFG27 F 54 0.32 
SFG28 F 42 0.35 
SFG29 M 42 0.54 
SFG30 M 39 0.35 
SFG31 M 34 0.56 
SFG32 M 36 0.45 
SFG46 F 39 0.31 
SFG47 F 50 0.29 
SFG49 F 35 0.19 
SFG53 M 32 0.36 
SFG55 F 22 0.33 
SFG56 M 62 0.23 
SFG58 F 64 0.3 
SFG59 F 29 0.28 
SFG60 F 54 0.46 
AVG 13M/15F 44 0.3668 
STDV 14.513 0.1112 
AVG Male 41.7 0.42 
STDV Male 9.1 0.12 
AVG Female 46.9 0.32 
STDV Female 17.9 0.09 
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Experimental samples information metabolomics 
GC-MS MALDI-FT-ICR MS Gender Diagnosis Age 
protein concentration 
(g/L) 
2 171 M PP MS 51 0.41 
4 199 M CIS 41 0.36 
5 163 M RR MS 62 0.47 
6 198 M RR MS 36 0.31 
7 186 M OIND 24 0.44 
8 192 F OIND 39 0.24 
11 197 F PP MS 60 0.29 
12 120 M OND 44 0.29 
14 182 M PP MS 36 0.44 
15 200 F CIS 29 0.24 
17 159 F CIS 27 0.27 
18 161 M OND 56 0.63 
20 162 F OND 46 0.36 
22 150 M CIS 22 0.29 
23 148 M OIND 62 0.77 
24 147 F RR MS 41 0.4 
26 140 M PP MS 50 0.62 
27 103 F PP MS 49 0.29 
28 138 F OIND 46 0.31 
30 98 M RR MS 16 0.53 
31 125 F RR MS 44 0.28 
33 89 M OIND 70 0.44 
35 106 M OND 40 0.27 
36 87 F OND 76 0.29 
37 92 F PP MS 48 0.35 
40 57 M RR MS 39 0.63 
41 105 F RR MS 38 0.33 
42 102 F OND 39 0.23 
43 107 F CIS 50 0.4 
44 101 F RR MS 46 0.33 
45 50 M PP MS 36 0.45 
46 97 M CIS 57 0.39 
49 62 F CIS 26 0.24 
50 54 M CIS 30 0.28 
51 A261 M RR MS 41 0.43 
52 60 F OND 57 0.4 
53 68 M OIND 36 0.27 
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56 64 F OIND 54 0.42 
59 69 M OND 54 0.53 
61 A66 M RR MS 37 0.44 
62 40 F RR MS 36 0.19 
63 129 M PP MS 37 0.35 
AVG 23 M/19 F 43.5 0.38 
STDV 12.8 0.13 
  
AVG 
Male 42.5 0.44 
STDV 
Male 13.6 0.13 
  
AVG Female   
  
44.8 0.31 
STDV Female 12.1 0.07 
 
 
Experimental samples information proteomics 
Sample 
number Gender Age 
Protein 
concentration(g/L) 
Albumin 
concentration(g/L) Diagnosis 
42 F 25 0.27 0.154 Headache 
106 M 40 0.27 ? Headache 
126 F 55 ? ? Headache 
128 F 34 0.36 ? Headache 
195 M 42 0.35 ? Headache 
A69 M 40 0.22 ? Headache 
A82 M 41 0.24 0.149 Headache 
C1063 M 36 0.51 ? Headache 
C1111 M 46 0.6 ? Headache 
C1117 M 27 0.44 ? Headache 
C1210 F 21 0.35 0.229 Headache 
92 F 48 0.35 0.211 PP MS 
103 F 49 0.29 0.159 PP MS 
197 F 60 0.29 0.186 PP MS 
A4 M 52 0.44 0.169 PP MS 
A5 F 60 0.29 0.186 PP MS 
A24 M 36 ? 0.314 PP MS 
A91 M 37 0.35 0.163 PP MS 
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A134 F 51 0.49 0.337 PP MS 
A146 F 55 ? 0.271 PP MS 
A169 M 50 0.62 0.477 PP MS 
A179 M 51 0.41 0.238 PP MS 
C1251 F 51 0.49 0.337 PP MS 
47 F 31 0.33 0.2 RR MS 
91 F 36 0.61 0.405 RR MS 
100 F 38 0.41 0.259 RR MS 
105 F 38 0.33 0.2 RR MS 
115 F 29 0.2 0.12 RR MS 
122 F 33 0.45 0.196 RR MS 
125 F 44 0.28 0.154 RR MS 
147 F 41 0.4 0.245 RR MS 
155 F 30 0.34 0.2 RR MS 
163 M 62 0.47 ? RR MS 
A102 F 39 0.35 0.189 RR MS 
A167 F 22 0.3 0.116 RR MS 
C1222 F 52 ? 0.26 RR MS 
AVG 13M/23F 41.722 0.378125 0.2268   
STDV 10.841 0.110173983 0.0858   
  
  
  
  
  
  
  
  
  
AVG 
Male 43.1 0.41 
STDV 
Male 9.0 0.13 
  
AVG 
Female 41.0 0.36 
STDV 
Female 11.9 0.09 
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Variation analysis proteomics 
9 Original samples 
Name RSD (%) 
Analytical 
error (%) 
Av SD 
Complement C4-A 18 25 27138450 4866115 
Complement factor H 18 19 1700013 312547 
Complement C3 19 24 87009580 16659566 
Antithrombin-III 20 21 4526377 906119 
Alpha-2-HS-glycoprotein 20 27 14545015 2928096 
Insulin-like growth factor-binding 
protein 6 
20 21 866435 174989 
Tetranectin 21 24 323073 67465 
Complement C1q subcomponent 
subunit B 
24 26 399373 95186 
Gelsolin 24 26 33507052 8044402 
Alpha-2-macroglobulin 24 19 27648642 6694200 
Complement C1s subcomponent 24 20 216100 52462 
Ceruloplasmin 25 23 17944231 4425677 
Serotransferrin 25 28 369677777 91474621 
Clusterin 25 18 55161172 13968349 
Apolipoprotein D 25 24 14147657 3602011 
Ig gamma-1 chain C region 25 25 96127790 24489601 
Alpha-1-antichymotrypsin 26 17 24319660 6224496 
Cathepsin D 26 17 759239 194412 
Ig kappa chain C region 26 18 82086700 21228205 
Prothrombin 26 24 654402 172085 
Plasma protease C1 inhibitor 26 24 1996211 524950 
Beta-2-microglobulin 27 26 1332327 353236 
Alpha-1B-glycoprotein 28 16 5949602 1581320 
Epididymal secretory protein E1 29 26 12728294 3426895 
Vitamin D-binding protein 29 24 12170699 3418187 
Ganglioside GM2 activator 29 23 193682 56813 
Hemopexin 29 22 32879169 9684949 
Beta-2-glycoprotein 1 30 18 2313020 697871 
Fibronectin 30 23 5098155 1539160 
Mimecan 30 26 865639 261395 
Apolipoprotein A-I 31 15 7056838 2185665 
Transthyretin 32 24 26458600 8343161 
Vitronectin 32 18 3310278 1065162 
Plasminogen 33 15 870518 285846 
Ig lambda chain C regions 34 26 26621885 9039823 
Extracellular superoxide dismutase 35 17 302183 104416 
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[Cu-Zn] 
Fibrinogen beta chain 35 22 829886 289591 
Apolipoprotein A-IV 35 15 462888 162289 
Chromogranin-A 35 29 13666560 10277369 
Fibrinogen alpha chain 35 23 1069593 377280 
Apolipoprotein E 36 28 21931476 7818894 
Angiotensinogen 36 26 39827610 14414312 
Insulin-like growth factor-binding 
protein 7 
36 28 819068 297200 
Complement factor B 37 28 1206238 441960 
Zinc-alpha-2-glycoprotein 37 18 2710354 995077 
Secretogranin-1 37 29 13441778 4976916 
Complement component C7 37 24 336342 125909 
Galectin-3-binding protein 38 26 459980 173737 
Apolipoprotein A-II 39 20 197709 76502 
Alpha-1-antitrypsin 39 24 67673227 26229891 
Serum albumin 39 23 4381612279 969042168 
Inter-alpha-trypsin inhibitor heavy 
chain H4 
39 24 286511 112307 
Alpha-2-antiplasmin 40 21 51774 20609 
Kallikrein-6 40 29 7760011 3115900 
Complement C1r subcomponent 40 27 314186 126650 
Prostaglandin-H2 D-isomerase 40 21 422446514 170728098 
Cystatin-C 41 20 95242329 39101877 
Histidine-rich glycoprotein 41 29 2399445 986981 
Calsyntenin-1 41 24 1093188 451402 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 
family member 2 
41 28 2441554 1008732 
Ig gamma-3 chain C region 41 22 7832786 3245788 
Pigment epithelium-derived factor 42 29 20021202 8428956 
Ribonuclease pancreatic 42 24 1660649 701515 
Biotinidase 43 24 83830 35754 
Ig gamma-4 chain C region 44 19 9375918 4169811 
Neural cell adhesion molecule 1 45 28 3438240 1560063 
Ig kappa chain V-III region SIE 46 25 1449706 662829 
Afamin 46 23 59458 27186 
Osteopontin 46 23 6064788 2800927 
Kininogen-1 47 26 927469 435902 
Carboxypeptidase E 47 25 698574 328487 
Peptidyl-glycine alpha-amidating 
monooxygenase 
47 27 155663 73622 
Alpha-1-acid glycoprotein 1 48 18 13926929 6654663 
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Alpha-1-acid glycoprotein 2 48 29 3470429 1664010 
Inter-alpha-trypsin inhibitor heavy 
chain H1 
49 20 210609 103093 
Chitinase-3-like protein 1 49 17 250984 123304 
Dickkopf-related protein 3 50 24 17936224 8987787 
Pyruvate kinase isozymes M1/M2 50 15 187792 94322 
Amyloid beta A4 protein 50 18 2207802 1109417 
Lumican 51 27 243809 123767 
Beta-Ala-His dipeptidase 51 24 6140453 3134697 
Ig gamma-2 chain C region 51 26 30692062 15691973 
Neuroendocrine protein 7B2 52 16 723035 377600 
ProSAAS 52 28 1453298 760500 
Inter-alpha-trypsin inhibitor heavy 
chain H2 
53 23 598461 315987 
Fibrinogen gamma chain 54 20 698561 377501 
Amyloid-like protein 1 54 19 5115411 2775572 
Brevican core protein 55 23 749172 412662 
Cartilage acidic protein 1 56 29 1589651 888129 
Procollagen C-endopeptidase enhancer 
1 
56 21 163431 91350 
Protein FAM3C 57 17 1526470 875357 
Collagen alpha-1(VI) chain 59 28 566701 337022 
N-acetyllactosaminide beta-1,3-N-
acetylglucosaminyltransferase 
60 30 4212554 2513146 
Insulin-like growth factor-binding 
protein 2 
60 23 30120 18025 
Cadherin-2 60 27 488433 295467 
Major prion protein 61 27 1525232 924607 
Reelin 61 28 26557 16274 
Secretogranin-3 62 28 4392667 2729659 
Protein kinase C-binding protein 
NELL2 
63 22 141105 89249 
Neural cell adhesion molecule 2 65 22 252609 163981 
SPARC-like protein 1 65 26 7946151 5169792 
Tyrosine-protein phosphatase non-
receptor type substrate 1 
66 19 84342 55393 
Ubiquitin 68 25 224325 151670 
Neuronal cell adhesion molecule 69 22 5730668 3957629 
Superoxide dismutase [Cu-Zn] 71 18 535106 378451 
Cell adhesion molecule 3 71 30 220836 157002 
Secretogranin-2 72 27 1613520 1155587 
Neuroserpin 72 26 123199 88440 
Thy-1 membrane glycoprotein 74 29 211863 157129 
Neurotrimin 75 26 172232 129000 
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Neural cell adhesion molecule L1-like 
protein 
76 16 2988910 2269783 
Neurosecretory protein VGF 76 23 2497365 1906055 
IgGFc-binding protein 78 20 56777 44510 
Receptor-type tyrosine-protein 
phosphatase zeta 
81 26 27691 22364 
Cadherin-13 82 28 124803 102958 
Limbic system-associated membrane 
protein 
83 29 273267 228088 
L-lactate dehydrogenase B chain 85 27 28031 23767 
Disintegrin and metalloproteinase 
domain-containing protein 22 
86 22 47948 41253 
Neuronal pentraxin receptor 97 19 1531542 1491664 
Seizure 6-like protein 102 21 17922 18231 
Voltage-dependent calcium channel 
subunit alpha-2/delta-1 
103 19 38474 39755 
Ephrin type-A receptor 4 107 19 71103 76301 
Contactin-2 124 19 1740303 2166015 
Basement membrane-specific heparan 
sulfate proteoglycan core protein 
134 24 421578 563833 
Haptoglobin 135 28 21359232 28936658 
Hornerin 148 28 9722 14363 
 
Variation analysis proteomics 
28 validation samples 
Name RSD 
% 
RSD % 
Age >50 
RSD % Age 
>35 & <50 
RSD % 
Age<35 
RSD % 
Male 
RSD % 
Female 
Complement C4-A 14 15 13 13 14 14 
Complement factor H 18 18 20 18 18 19 
Complement C3 15 14 12 17 13 17 
Antithrombin-III 14 16 15 14 14 16 
Alpha-2-HS-
glycoprotein 15 13 15 16 15 16 
Insulin-like growth 
factor-binding protein 6 17 18 19 17 17 18 
Tetranectin 18 17 23 18 42 26 
Complement C1q 
subcomponent subunit 
B 16 16 17 16 17 16 
Gelsolin 19 20 20 16 15 20 
Alpha-2-macroglobulin 20 22 18 20 21 19 
Complement C1s 
subcomponent 20 20 23 21 21 20 
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Ceruloplasmin 19 16 21 20 16 23 
Serotransferrin 18 19 19 21 20 16 
Clusterin 21 18 22 25 22 21 
Apolipoprotein D 20 23 15 16 17 21 
Ig gamma-1 chain C 
region 22 21 26 20 26 19 
Alpha-1-
antichymotrypsin 17 16 17 21 16 18 
Cathepsin D 20 22 19 30 18 22 
Ig kappa chain C region 23 25 25 21 26 16 
Prothrombin 22 21 21 25 21 22 
Plasma protease C1 
inhibitor 23 20 23 25 28 18 
Beta-2-microglobulin 23 24 22 19 28 19 
Alpha-1B-glycoprotein 23 20 26 23 21 26 
Epididymal secretory 
protein E1 25 26 27 21 23 25 
Vitamin D-binding 
protein 21 18 23 22 24 18 
Ganglioside GM2 
activator 26 31 28 19 24 25 
Hemopexin 21 21 23 16 21 21 
Beta-2-glycoprotein 1 24 16 27 26 25 24 
Fibronectin 17 17 20 14 17 18 
Mimecan 21 22 26 19 23 20 
Apolipoprotein A-I 29 32 27 25 29 28 
Transthyretin 24 27 28 20 25 23 
Vitronectin 25 27 23 31 27 24 
Plasminogen 24 20 22 16 17 29 
Ig lambda chain C 
regions 26 33 31 20 28 26 
Extracellular 
superoxide dismutase 
[Cu-Zn] 30 27 26 35 27 35 
Fibrinogen beta chain 29 30 32 28 30 28 
Apolipoprotein A-IV 29 32 29 28 27 29 
Chromogranin-A 32 31 33 26 30 33 
Fibrinogen alpha chain 30 34 32 29 29 31 
Apolipoprotein E 27 29 27 23 25 29 
Angiotensinogen 25 29 24 25 26 23 
Insulin-like growth 
factor-binding protein 7 26 32 28 19 24 27 
Complement factor B 26 22 28 29 23 28 
Zinc-alpha-2-
glycoprotein 26 27 29 24 21 30 
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Secretogranin-1 27 27 32 21 34 23 
Complement 
component C7 28 32 23 33 30 27 
Galectin-3-binding 
protein 27 23 23 35 35 21 
Apolipoprotein A-II 42 46 44 36 39 47 
Alpha-1-antitrypsin 31 33 27 36 28 32 
Serum albumin 30 27 29 32 29 30 
Inter-alpha-trypsin 
inhibitor heavy chain 
H4 27 30 29 24 27 27 
Alpha-2-antiplasmin 36 34 44 35 44 28 
Kallikrein-6 31 28 23 27 31 31 
Complement C1r 
subcomponent 27 21 34 21 30 25 
Prostaglandin-H2 D-
isomerase 28 28 27 29 30 25 
Cystatin-C 30 27 38 32 33 28 
Histidine-rich 
glycoprotein 29 32 38 24 30 28 
Calsyntenin-1 33 23 38 27 35 30 
Ectonucleotide 
pyrophosphatase/phos
phodiesterase family 
member 2 31 28 32 31 21 38 
Ig gamma-3 chain C 
region 32 30 38 27 30 33 
Pigment epithelium-
derived factor 30 26 27 35 27 32 
Ribonuclease 
pancreatic 30 32 32 28 25 36 
Biotinidase 32 32 26 36 27 36 
Ig gamma-4 chain C 
region 34 34 33 35 30 39 
Neural cell adhesion 
molecule 1 32 31 32 33 23 42 
Ig kappa chain V-III 
region SIE 35 34 33 38 32 37 
Afamin 34 27 35 24 33 34 
Osteopontin 35 30 38 32 33 36 
Kininogen-1 31 38 31 24 26 35 
Carboxypeptidase E 26 24 27 25 24 27 
Peptidyl-glycine alpha-
amidating 
monooxygenase 45 50 42 49 43 47 
Alpha-1-acid 
glycoprotein 1 33 37 34 33 33 34 
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Alpha-1-acid 
glycoprotein 2 32 28 31 37 21 43 
Inter-alpha-trypsin 
inhibitor heavy chain 
H1 44 37 45 52 56 32 
Chitinase-3-like protein 
1 33 37 53 28 40 45 
Dickkopf-related 
protein 3 33 33 39 30 31 35 
Pyruvate kinase 
isozymes M1/M2 36 32 46 26 38 33 
Amyloid beta A4 
protein 37 41 39 30 39 36 
Lumican 39 45 34 36 29 48 
Beta-Ala-His 
dipeptidase 40 39 46 33 45 35 
Ig gamma-2 chain C 
region 40 37 40 42 42 37 
Neuroendocrine protein 
7B2 39 41 43 34 39 37 
ProSAAS 39 47 32 39 32 47 
Inter-alpha-trypsin 
inhibitor heavy chain 
H2 43 42 45 36 38 47 
Fibrinogen gamma 
chain 40 36 42 42 35 44 
Amyloid-like protein 1 41 39 47 40 37 45 
Brevican core protein 45 42 50 42 45 43 
Cartilage acidic protein 
1 40 40 46 34 35 45 
Procollagen C-
endopeptidase 
enhancer 1 41 47 35 44 42 41 
Protein FAM3C 42 44 44 41 42 42 
Collagen alpha-1(VI) 
chain 44 47 46 42 37 49 
N-acetyllactosaminide 
beta-1,3-N-
acetylglucosaminyltran
sferase 44 49 44 37 45 43 
Insulin-like growth 
factor-binding protein 2 41 54 38 33 39 43 
Cadherin-2 42 46 47 35 34 50 
Major prion protein 45 45 45 45 32 62 
Reelin 46 46 47 46 46 48 
Secretogranin-3 45 53 45 41 45 46 
Protein kinase C- 47 45 48 46 40 52 
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binding protein NELL2 
Neural cell adhesion 
molecule 2 48 58 43 43 44 51 
SPARC-like protein 1 48 55 48 42 42 55 
Tyrosine-protein 
phosphatase non-
receptor type substrate 
1 35 29 50 22 40 30 
Ubiquitin 51 60 57 37 61 42 
Neuronal cell adhesion 
molecule 51 56 45 48 41 60 
Superoxide dismutase 
[Cu-Zn] 49 56 47 54 49 49 
Cell adhesion molecule 
3 42 38 46 41 31 52 
Secretogranin-2 47 40 54 49 53 42 
Neuroserpin 51 64 47 41 42 62 
Thy-1 membrane 
glycoprotein 52 66 46 46 49 57 
Neurotrimin 56 60 52 56 57 54 
Neural cell adhesion 
molecule L1-like 
protein 52 62 49 47 54 50 
Neurosecretory protein 
VGF 52 63 47 48 49 54 
IgGFc-binding protein 52 55 52 50 46 58 
Receptor-type tyrosine-
protein phosphatase 
zeta 55 65 50 50 47 61 
Cadherin-13 60 58 59 63 61 58 
Limbic system-
associated membrane 
protein 59 60 60 59 53 66 
L-lactate 
dehydrogenase B chain 69 68 69 69 72 67 
Disintegrin and 
metalloproteinase 
domain-containing 
protein 22 68 67 68 68 59 75 
Neuronal pentraxin 
receptor 63 65 61 63 60 65 
Seizure 6-like protein 86 98 84 72 81 92 
Voltage-dependent 
calcium channel 
subunit alpha-2/delta-1 61 64 59 59 56 66 
Ephrin type-A receptor 
4 72 82 67 64 75 68 
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Contactin-2 80 86 82 70 83 75 
Basement membrane-
specific heparan 
sulfate proteoglycan 
core protein 86 102 70 88 80 93 
Haptoglobin 84 91 84 78 74 94 
Hornerin 184 209 156 185 141 228 
 
Variation analysis proteomics 
28 Validation samples 
Name RSD % 
Complement C4-A 79 
Complement factor H 30 
Complement C3 84 
Antithrombin-III 53 
Alpha-2-HS-glycoprotein 47 
Insulin-like growth factor-binding protein 6 49 
Tetranectin 52 
Complement C1q subcomponent subunit B 58 
Gelsolin 39 
Alpha-2-macroglobulin 39 
Complement C1s subcomponent 50 
Ceruloplasmin 50 
Serotransferrin 49 
Clusterin 81 
Apolipoprotein D 54 
Ig gamma-1 chain C region 98 
Alpha-1-antichymotrypsin 62 
Cathepsin D 53 
Ig kappa chain C region 124 
Prothrombin 46 
Plasma protease C1 inhibitor 57 
Beta-2-microglobulin 64 
Alpha-1B-glycoprotein 88 
Epididymal secretory protein E1 81 
Vitamin D-binding protein 55 
Ganglioside GM2 activator 54 
Hemopexin 62 
Beta-2-glycoprotein 1 67 
Fibronectin 65 
Mimecan 70 
Apolipoprotein A-I 70 
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Transthyretin 73 
Vitronectin 84 
Plasminogen 106 
Ig lambda chain C regions 73 
Extracellular superoxide dismutase [Cu-Zn] 66 
Fibrinogen beta chain 89 
Apolipoprotein A-IV 70 
Chromogranin-A 72 
Fibrinogen alpha chain 108 
Apolipoprotein E 64 
Angiotensinogen 69 
Insulin-like growth factor-binding protein 7 69 
Complement factor B 86 
Zinc-alpha-2-glycoprotein 81 
Secretogranin-1 106 
Complement component C7 56 
Galectin-3-binding protein 69 
Apolipoprotein A-II 85 
Alpha-1-antitrypsin 72 
Serum albumin 60 
Inter-alpha-trypsin inhibitor heavy chain H4 73 
Alpha-2-antiplasmin 59 
Kallikrein-6 71 
Complement C1r subcomponent 100 
Prostaglandin-H2 D-isomerase 59 
Cystatin-C 80 
Histidine-rich glycoprotein 98 
Calsyntenin-1 88 
Ectonucleotide pyrophosphatase/phosphodiesterase family 
member 2 73 
Ig gamma-3 chain C region 151 
Pigment epithelium-derived factor 80 
Ribonuclease pancreatic 89 
Biotinidase 94 
Ig gamma-4 chain C region 148 
Neural cell adhesion molecule 1 110 
Ig kappa chain V-III region SIE 126 
Afamin 72 
Osteopontin 71 
Kininogen-1 99 
Carboxypeptidase E 82 
Peptidyl-glycine alpha-amidating monooxygenase 88 
Alpha-1-acid glycoprotein 1 83 
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Alpha-1-acid glycoprotein 2 92 
Inter-alpha-trypsin inhibitor heavy chain H1 104 
Chitinase-3-like protein 1 87 
Dickkopf-related protein 3 94 
Pyruvate kinase isozymes M1/M2 84 
Amyloid beta A4 protein 89 
Lumican 111 
Beta-Ala-His dipeptidase 106 
Ig gamma-2 chain C region 172 
Neuroendocrine protein 7B2 130 
ProSAAS 120 
Inter-alpha-trypsin inhibitor heavy chain H2 107 
Fibrinogen gamma chain 120 
Amyloid-like protein 1 119 
Brevican core protein 92 
Cartilage acidic protein 1 101 
Procollagen C-endopeptidase enhancer 1 68 
Protein FAM3C 115 
Collagen alpha-1(VI) chain 91 
N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 118 
Insulin-like growth factor-binding protein 2 100 
Cadherin-2 96 
Major prion protein 103 
Reelin 119 
Secretogranin-3 99 
Protein kinase C-binding protein NELL2 108 
Neural cell adhesion molecule 2 91 
SPARC-like protein 1 111 
Tyrosine-protein phosphatase non-receptor type substrate 1 85 
Ubiquitin 106 
Neuronal cell adhesion molecule 126 
Superoxide dismutase [Cu-Zn] 112 
Cell adhesion molecule 3 126 
Secretogranin-2 127 
Neuroserpin 134 
Thy-1 membrane glycoprotein 127 
Neurotrimin 145 
Neural cell adhesion molecule L1-like protein 156 
Neurosecretory protein VGF 114 
IgGFc-binding protein 120 
Receptor-type tyrosine-protein phosphatase zeta 134 
Cadherin-13 143 
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Limbic system-associated membrane protein 127 
L-lactate dehydrogenase B chain 126 
Disintegrin and metalloproteinase domain-containing protein 22 159 
Neuronal pentraxin receptor 165 
Seizure 6-like protein 160 
Voltage-dependent calcium channel subunit alpha-2/delta-1 139 
Ephrin type-A receptor 4 161 
Contactin-2 156 
Basement membrane-specific heparan sulfate proteoglycan 
core protein 159 
Haptoglobin 182 
Hornerin 159 
 
 
Variation analysis metabolomics LC-MS 
Original samples 
  
concentration 
(uM) 
Av 
(n=8) 
SD 
(n=8) 
RSD (%, 
n=8) 
Analytical error 
(%) 
pooled CSF 
sample 
alanine 36.2 14.7 40 4 44.9 
arginine 25.1 6.9 28 8 31.6 
asparagine 8.7 3.0 34 4 10.6 
citrulline - - - - - 
glutamine - - - - - 
glycine 10.3 3.2 31 5 12.0 
histidine 21.7 6.9 32 9 27.1 
iso-leucine 5.0 1.7 34 6 6.1 
leucine 17.4 5.0 29 11 22.1 
lysine 35.9 10.9 30 8 43.8 
methionine 4.9 2.3 46 9 6.0 
phenylalanine 12.3 5.0 41 8 17.0 
proline 0.66 0.34 52 7 0.78 
serine 30.3 9.1 30 9 36.2 
threonine 36.3 11.6 32 4 44.5 
tryptophan 2.6 1.2 44 9 3.4 
tyrosine 12.0 5.1 42 7 16.0 
valine 22.5 8.6 38 8 29.0 
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Variation analysis metabolomics LC-MS (Validation samples) 
concentration 
(uM) 
Av 
(n=27) 
SD 
(n=27) 
RSD (%, 
n=27) 
Analytical error 
(%) 
alanine 30.4 9.7 32 1 
arginine 24.8 6.2 25 9 
asparagine 6.7 1.5 22 2 
citrulline 2.1 0.7 34 7 
glutamine 537 77 14 7 
glycine 6.3 1.9 30 5 
histidine 17.2 2.8 16 9 
iso-leucine 6.0 1.8 30 3 
leucine 14.7 4.0 27 2 
lysine 32.6 7.2 22 7 
methionine 3.8 1.3 34 8 
phenylalanine 9.0 2.1 23 8 
proline 1.0 0.5 49 5 
serine 27.0 4.5 17 3 
threonine 30.4 8.1 27 2 
tryptophan 2.3 0.6 24 9 
tyrosine 11.2 3.3 30 6 
valine 18.4 5.2 28 2 
 
Variation analysis metabolomics LC-MS (Validation samples) 
concentratio
n (uM) 
MALE FEMALE 
Av 
(n=13) 
SD 
(n=13) 
RSD 
(%,n=13) 
AV 
(n=14) 
SD 
(n=14) 
RSD (%, 
n=14) 
alanine 32.0 9.3 29 28.9 10.2 35 
arginine 27.9 6.6 24 21.9 4.2 19 
asparagine 7.1 0.9 13 6.4 1.9 29 
citrulline 2.5 0.8 31 1.8 0.5 26 
glutamine 565 74 13 511 73 14 
glycine 6.7 2.2 32 5.8 1.5 25 
histidine 18.1 2.8 16 16.3 2.5 15 
iso-leucine 6.6 1.2 18 5.4 2.2 40 
leucine 16.0 2.6 16 13.4 4.7 35 
lysine 34.3 7.2 21 30.9 7.1 23 
methionine 4.1 1.1 26 3.6 1.5 40 
phenylalanine 9.3 1.8 20 8.7 2.3 26 
proline 1.1 0.6 50 0.8 0.3 40 
serine 25.7 3.8 15 28.1 4.9 17 
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threonine 31.4 6.5 21 29.5 9.4 32 
tryptophan 2.4 0.6 26 2.2 0.4 21 
tyrosine 11.7 2.7 23 10.7 3.9 36 
valine 19.4 4.0 20 17.4 6.0 35 
 
Variation analysis metabolomics LC-MS (Validation samples) 
concentration 
(uM) 
AGE <35 AGE >35  and <50 AGE <50 
Av 
n=8 
SD 
n=8 
RSD 
%, n=8 
Av 
n=10 SD n=10 
RSD 
%, 
n=10 
Av n=9 
SD 
n=9 
RSD 
%, 
n=9 
alanine 24.9 5.0 20 31.1 9.6 31 34.5 
11.5 33 
arginine 23.3 7.5 32 27.2 5.4 20 23.5 
5.5 23 
asparagine 6.4 2.0 31 6.8 1.1 17 6.9 
1.4 21 
citrulline 1.9 0.8 41 2.2 0.5 23 2.2 
0.9 41 
glutamine 504 83 16 557 82 15 545 
63 12 
glycine 5.6 2.5 45 6.3 1.4 22 6.8 
1.7 25 
histidine 17.2 2.2 13 17.1 2.1 12 17.2 
3.9 23 
iso-leucine 5.9 1.8 30 5.9 1.6 28 6.2 
2.2 36 
leucine 13.5 4.0 30 15.2 3.3 22 15.1 
4.8 32 
lysine 32.9 7.0 21 32.8 9.0 27 31.9 
5.9 18 
methionine 3.4 1.5 43 3.8 1.0 25 4.2 
1.4 34 
phenylalanine 8.3 2.4 29 8.9 1.6 18 9.6 
2.3 24 
proline 0.9 0.3 33 0.9 0.6 62 1.0 
0.5 51 
serine 26.7 4.1 16 25.8 4.1 16 28.5 
5.2 18 
threonine 30.9 10.4 34 30.0 6.5 22 30.5 
8.3 27 
tryptophan 2.0 0.6 28 2.4 0.5 22 2.5 
0.5 22 
tyrosine 9.5 3.2 34 11.1 3.0 27 12.8 
3.4 27 
valine 16.8 5.0 30 18.2 3.9 21 19.9 
6.5 33 
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Variation analysis metabolomics NMR (Original samples) 
concentration (uM) Av n=5 SD n=5 RSD %, n=5 
Analytical error 
(%) 
pooled CSF 
sample 
2-aminobutyric acid 3.4 0.6 17 8 3.2 
2-hydroxybutyric acid 21.1 3.4 16 4 19.4 
2-hydroxyisovaleric acid 4.1 1.8 43 8 3.0 
3-hydroxyisovaleric acid 32.6 13.8 42 4 40.2 
3-hydroxybutyric acid 6.2 3.1 50 9 4.7 
Acetic acid 37.2 12.4 33 6 79.0 
Acetoacetic acid 5.1 1.4 27 8 7.0 
Acetone 12.6 2.5 20 4 97.7 
Alanine 21.8 4.1 19 6 25.6 
Aconitic acid 19.6 9.0 46 9 28.4 
Arginine 22.0 2.0 9 5 23.1 
Choline 3.3 0.7 22 9 4.4 
Citric acid 178 33 19 5 186.5 
Creatine 32.8 4.2 13 6 33.7 
Creatinine 42.7 5.2 12 5 49.5 
Dimethylamine 2.3 0.3 15 8 3.1 
Formic acid 18.7 1.5 8 5 21.7 
Fructose 230 68 29 9 262.5 
Galactitol 5.6 0.8 13 7 5.6 
Glucose 1895 308 16 6 2404 
Glutamine 428 86 20 4 424 
Glycine 9.3 3.2 34 9 11.2 
Histidine 8.6 2.0 23 5 9.8 
Isoleucine 3.6 0.7 21 6 4.2 
Lactic acid 848 100 12 4 915 
Leucine 9.1 2.3 26 3 9.5 
Lysine 13.0 4.8 37 9 12.8 
Methanol 36.4 9.9 27 6 39.9 
Methionine 4.4 1.6 37 7 4.4 
1-methylhistidine 5.6 2.8 50 8 6.0 
3-methylhistidine 5.2 1.3 25 7 4.5 
Myo-Inositol 59.1 20.2 34 4 54.2 
Phenylalanine 10.6 2.1 20 5 12.7 
Pyruvic acid 46.3 7.4 16 7 50.9 
Succinic acid 2.9 0.7 23 7 2.7 
Trimethylamine-N-oxide 4.8 1.2 25 9 4.8 
Threonine 21.5 3.6 17 6 25.1 
Tyrosine 7.1 1.6 22 6 9.9 
Urea 2758 1472 53 8 1975 
Valine 11.9 2.1 18 9 14.4 
Xanthine 7.8 2.7 35 8 7.6 
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Variation analysis metabolomics NMR (Validation samples) 
concentration (uM) Av n=27 SD n=27 RSD %, n=27 Analytical error % 
2-aminobutyric acid 3.6 1.0 28 5 
2-hydroxybutyric acid 21.0 6.1 29 4 
2-hydroxyisovaleric acid 4.0 1.2 30 8 
3-hydroxyisovaleric acid 11.5 1.7 15 2 
3-hydroxybutyric acid 7.1 1.0 15 3 
Acetic acid 77.0 39.7 52 2 
Acetoacetic acid 4.9 1.3 26 4 
Acetone 8.7 1.7 20 5 
Alanine 29.7 8.0 27 3 
Aconitic acid 22.6 6.2 28 6 
Arginine 19.1 3.7 19 4 
Choline 1.9 0.5 24 6 
Citric acid 204 31 15 2 
Creatine 38.5 5.9 15 3 
Creatinine 56.8 9.5 17 2 
Dimethylamine 1.9 0.5 25 6 
Formic acid 37.9 7.3 19 5 
Fructose 135 32 24 7 
Galactitol 5.5 1.3 23 4 
Glucose 2621 303 12 8 
Glutamine 399 70 18 2 
Glycine 7.5 1.8 24 2 
Histidine 11.5 1.8 15 3 
Isoleucine 5.1 1.3 25 4 
Lactic acid 1127 155 14 2 
Leucine 12.1 3.1 26 4 
Lysine 18.2 3.0 16 2 
Methanol 47.1 10.0 21 2 
Methionine 3.0 0.9 31 6 
1-methylhistidine 3.9 1.9 49 4 
3-methylhistidine 1.0 1.5 143 8 
Myo-Inositol 122 30 25 9 
Phenylalanine 8.8 1.99 23 5 
Pyruvic acid 62.6 14.4 23 5 
Succinic acid 2.5 0.6 23 9 
Trimethylamine-N-oxide 5.1 0.9 18 3 
Threonine 26.5 5.3 20 4 
Tyrosine 9.5 2.6 27 6 
Urea - - - - 
Valine 16.5 4.6 28 2 
Xanthine 3.4 2.9 86 8 
 
 
287 
 
 
 
Variation analysis metabolomics NMR (Validation samples) 
concentration (uM) 
MALE FEMALE 
Av n=13 
SD 
n=13 
RSD %, 
n=13 AV n=14 SD n=14 RSD %, n=14 
2-aminobutyric acid 3.8 1.3 34 3.3 0.5 16 
2-hydroxybutyric acid 22.4 6.6 29 19.6 5.8 30 
2-hydroxyisovaleric acid 3.7 0.8 22 4.3 1.5 34 
3-hydroxyisovaleric acid 7.3 1.2 16 6.8 0.7 11 
3-hydroxybutyric acid 11.7 1.1 9 11.3 2.2 20 
Acetic acid 82.7 32.8 40 71.0 47.0 66 
Acetoacetic acid 4.7 1.2 25 5.1 1.4 27 
Acetone 9.0 1.7 19 8.3 1.7 20 
Alanine 29.0 8.1 28 30.6 8.2 27 
Aconitic acid 19.0 2.7 14 19.1 2.7 14 
Arginine 2.0 0.5 24 1.8 0.4 24 
Choline 24.7 6.7 27 20.3 4.9 24 
Citric acid 206 37 18 201 25 13 
Creatine 38.7 5.8 15 38.3 6.5 17 
Creatinine 58.6 10.5 18 54.8 8.5 15 
Dimethylamine 1.8 0.5 27 2.0 0.4 23 
Formic acid 39.3 6.9 18 36.3 7.2 20 
Fructose 128 28 22 142 35 25 
Galactitol 5.7 1.3 22 5.2 1.2 23 
Glucose 2487 265 11 2764 279 10 
Glutamine 384 68 18 415 75 18 
Glycine 7.9 2.2 27 7.0 1.1 16 
Histidine 11.5 2.1 18 11.5 1.4 13 
Isoleucine 5.1 1.6 30 5.0 1.0 19 
Lactic acid 1161 186 16 1090 107 10 
Leucine 11.8 2.5 22 12.3 1.6 13 
Lysine 18.1 2.5 14 18.3 3.6 20 
Methanol 47.0 12.7 27 47.1 5.5 12 
Methionine 3.1 1.1 35 2.9 0.7 26 
1-methylhistidine 3.3 2.2 66 4.5 1.4 31 
3-methylhistidine 1.0 1.5 150 1.0 1.5 142 
Myo-Inositol 125 31 25 117 28 24 
Phenylalanine 9.4 1.4 15 8.3 2.3 28 
Pyruvic acid 67.9 13.8 20 56.9 13.4 23 
Succinic acid 2.4 0.6 25 2.6 0.6 23 
Trimethylamine-N-oxide 27.0 6.0 22 25.9 4.4 17 
Threonine 4.9 1.0 19 5.3 0.9 17 
Tyrosine 8.3 1.5 17 10.7 3.0 28 
Urea - - - - - - 
Valine 16.1 5.7 36 17.1 3.3 19 
Xanthine 2.4 3.1 130 4.4 2.3 53 
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Variation analysis metabolomics NMR (Validation samples) 
concentration 
(uM) AGE <35 AGE >35  and <50 
AGE <50 
  
Av 
n=8 
SD 
(n=8) 
RSD %, 
n=8 
Av 
n=10 
SD 
n=10 
RSD %, 
n=10 
Av 
n=9 
SD 
n=9 
RSD %, 
n=9 
2-aminobutyric 
acid 3.9 1.0 26 3.1 0.6 19 3.7 1.3 34 
2-
hydroxybutyric 
acid 18.0 3.5 19 20.6 5.0 24 24.1 8.2 34 
2-
hydroxyisovaler
ic acid 4.5 1.8 39 4.0 0.8 21 3.5 0.7 22 
3-
hydroxyisovaler
ic acid 7.5 1.1 14 6.8 1.0 15 7.0 0.9 13 
3-
hydroxybutyric 
acid 12.4 1.3 10 11.0 2.3 21 11.2 1.0 9 
Acetic acid 90.4 31.9 35 72.3 52.3 72 70.6 30.8 44 
Acetoacetic 
acid 5.4 1.4 26 4.9 1.1 22 4.5 1.3 29 
Acetone 8.8 1.9 21 8.4 1.7 21 8.9 1.7 19 
Alanine 25.5 4.4 17 30.1 9.8 33 33.1 7.2 22 
Aconitic acid 21.8 4.7 22 19.9 5.5 27 26.2 6.9 26 
Arginine 19.3 2.9 15 19.0 2.9 15 18.9 2.5 13 
Choline 1.8 0.4 21 1.7 0.4 22 2.2 0.5 21 
Citric acid 194 21 11 199 18 9 218 45 21 
Creatine 36.4 4.4 12 39.3 6.8 17 39.4 6.6 17 
Creatinine 53.1 8.2 15 55.9 9.0 16 61.0 10.7 17 
Dimethylamine 1.9 0.4 19 1.9 0.5 28 1.9 0.5 28 
Formic acid 38.6 5.8 15 37.4 7.7 21 37.7 8.2 22 
Fructose 136 37 27 127 26 20 142 35 24 
Galactitol 5.2 1.0 19 5.0 1.0 20 6.3 1.4 22 
Glucose 2571 482 19 2636 206 8 2648 201 8 
Glutamine 375 42 11 412 84 20 406 80 20 
Glycine 7.4 2.1 28 7.3 1.9 25 7.7 1.5 20 
Histidine 12.3 1.0 8 11.0 1.2 11 11.3 2.6 23 
Isoleucine 4.6 0.6 13 4.8 0.8 16 5.9 1.8 31 
Lactic acid 1038 76 7 1139 176 15 1193 157 13 
Leucine 12.3 2.0 16 11.9 2.1 17 12.0 2.5 21 
Lysine 19.1 2.3 12 17.5 3.5 20 18.1 3.1 17 
Methanol 48.6 12.5 26 46.0 8.0 17 46.8 9.8 21 
Methionine 3.5 0.8 22 2.5 0.6 24 3.0 1.2 39 
1-
methylhistidine 3.9 1.1 29 3.7 1.8 49 4.1 2.6 64 
3-
methylhistidine 0.6 1.1 194 1.3 1.5 115 1.1 1.7 158 
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Myo-Inositol 106 26 24 132 27 20 124 31 25 
Phenylalanine 8.7 1.3 15 9.5 1.4 15 8.2 2.8 34 
Pyruvic acid 55.5 12.0 22 59.4 13.1 22 72.5 13.6 19 
Succinic acid 2.4 0.5 20 2.4 0.6 26 2.7 0.6 23 
Trimethylamine
-N-oxide 5.1 1.0 19 5.1 1.0 19 5.2 1.0 19 
Threonine 25.1 5.4 22 26.4 5.0 19 27.9 5.5 20 
Tyrosine 9.1 2.5 27 10.1 3.2 32 9.2 2.1 23 
Urea - - - - - - - - - 
Valine 15.6 3.9 25 15.6 4.1 26 18.4 5.7 31 
Xanthine 3.0 2.3 77 3.8 2.8 73 3.1 3.6 116 
 
Biological variation in the validation CSF sample set vs experimental CSF sample set with 
GC-MS 
  Validation sample set Experimental sample set 
 Name RSD (%, n=28) RSD (%, n=420 
1,5-Anhydro-D-Glucitol 7 31 
Arabitol 12   
alanine 12 32 
leucine 13 32 
iso-leucine 13 32 
2-Hydroxybutanoic acid 14 88 
3,4-Dihydroxybutanoic acid 14   
3-Hydroxypropanoic acid 16 43 
Aspartic acid 16 58 
Aminomalonic acid 17 30 
Benzoic acid 17 29 
Myo-inositol 18 38 
Sucrose 19 53 
2-Hydroxypropenoic acid 19 36 
Asparagine 19 36 
Glucose 19 41 
Urea 21   
Glutamic acid 21 36 
Tryptophan 22   
Arabinose 22 36 
Hypoxanthine 22 116 
2-Aminobutyric acid 23 28 
Creatinine 24 56 
Proline 25 94 
Tyrosine 26   
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3-hydroxyisovaleric acid 26 43 
Glycerol 26 34 
Acetoacetic acid 26 42 
Glycerol-galactopyranoside 26   
C18:1 fatty acid 28 33 
Cysteine 28 89 
Inositol 28 36 
Erythronic acid 28   
Quinic acid 28 36 
sn-Glycerol-3-Phosphate 30 45 
5,6-dihydrouracil 30 44 
C18:0 Fatty acid 30 40 
Cholesterol 30 52 
phenylalanine 31   
C16:0 Fatty acid 31 32 
Gluconic acid 33 38 
2-Oxo-butanoic acid 33 56 
Ribitol 34 64 
1-Monostearoylglycerol 35 28 
Glyceric acid 35 72 
C14:0 Fatty acid 36 31 
Mannitol 36 36 
Serine 38   
2,3-dihydroxybutanoic acid 38 39 
Fructose 38 104 
2-hydroxyisovaleric acid 43 34 
Methionine 45 47 
Xylonic acid 45   
3-Hydroxyhexanoic acid 46 42 
Uric acid 47   
Fucose 48 67 
2,4-Dihydroxybutanoic acid 54 129 
N-Acetylaminomalonic acid 57 47 
Phosphoric acid 58   
Amino-butyric acid isomer 63 29 
Valine 64   
Threonic acid 68 71 
Myo-inositol-1,2-cyclicphosphate 69 63 
Xylose 82  - 
Uridine 90  - 
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Phosphorylethanolamine 106 106 
Threonine 113   
Inositol related compound 214 120 
 
Concentrations comparison 
 
Validation sample 
set Wishart et al. (13) 
Literature values 
referred to by 
Wishart et al. (13) 
concentration (uM) 
Av 
(n=27) SD (n=27) 
Av 
(n=35) 
SD 
(n=35) Av SD 
1-methylhistidine 3.9 1.9 ND ND ND ND 
2-aminobutyric acid 3.6 1.0 ND ND ND ND 
2-hydroxybutyric acid 21.0 6.1 40 24 35 24 
2-hydroxyisovaleric 
acid 4.0 1.2 8 6 7 7 
3-hydroxybutyric acid 7.1 1.0 34 31 46 24 
3-hydroxyisovaleric 
acid 11.5 1.7 4 2 ND ND 
3-methylhistidine 1.0 1.5 ND ND ND ND 
Acetic acid 77.0 39.7 58 27 100 30 
Acetoacetic acid 4.9 1.3 12 14 6 6 
Acetone 8.7 1.7 20 21 67 24 
Aconitic acid 22.6 6.2 ND ND ND ND 
Alanine 29.7 8.0 46 27 37 7 
Arginine 19.1 3.7 ND ND ND ND 
Choline 1.9 0.5 3 1 8 5 
Citric acid 204 31 225 96 176 50 
Creatine 38.5 5.9 44 13 ND ND 
Creatinine 56.8 9.5 43 12 65 25 
Dimethylamine 1.9 0.5 2 1 ND ND 
Formic acid 37.9 7.3 32 16 ND ND 
Fructose 135 32 160 91 240 20 
Galactitol 5.5 1.3 ND ND ND ND 
Glucose 2621 303 2960 1110 5390 1650 
Glutamine 399 70 432 204 444 80 
Glycine 7.5 1.8 ND ND ND ND 
Histidine 11.5 1.8 14 8 12 2 
Isoleucine 5.1 1.3 7 5 8 3 
Lactic acid 1127 155 1651 626 1590 330 
Leucine 12.1 3.1 16 9 19 4 
Lysine 18.2 3.0 29 13 28 8 
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Methanol 47.1 10.0 44 36 ND ND 
Methionine 3.0 0.9 5 4 6 3 
Myo-Inositol 122 30 84 40 133 20 
Phenylalanine 8.8 1.99 15 13 18 7 
Pyruvic acid 62.6 14.4 53 42 71 30 
Succinic acid 2.5 0.6 3 2 29 5 
Threonine 26.5 5.3 30 12 28 5 
Trimethylamine-N-
oxide 5.1 0.9 ND ND ND ND 
Tyrosine 9.5 2.6 12 9 10 4 
Valine 16.5 4.6 19 13 24 7 
Xanthine 3.4 2.9 13 7 5 1 
Av Average 
SD Standard deviation 
RSD Relative standard deviation 
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List of metabolites identified in rat CSF by 1H-NMR 
Metabolites 
3-Hydroxyisovalerate  
Acetate 
Acetoacetate 
Acetone 
Alanine 
Arginine 
Butyrate 
Choline 
Cis-aconitate 
Citrate 
Creatine 
Creatinine  
Dimethylamine 
Formate 
 Fructose 
Glucose 
Glutamine 
Glycerol 
Lactate 
Lysine 
 Malonate 
Methanol 
Methylmalonate 
N-acetylaspartate 
Ornithine 
Pantothenate 
Propylene glycol 
Pyruvate 
Succinate 
Threonine 
Valine 
myo-Inositol 
N-acetylcompounds 
 
 
Sample preparation and data acquisition of CSF samples from the second EAE 
experiment 
10μL of rat CSF were thawed at room temperature and 210 μL D2O (99.96 at.%D) were 
added to the biofluid. TSP-d4 (Sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4 ) (99 
at.%D) was used as internal standard for chemical shift reference (δ 0.00 ppm). For the 
latter, 70μL of buffer solution was added to 220 μL of rat CSF. The buffer solution 
solvated in a mixture of water and D2O consists of 2,85mM TSP, 6.92 mM Sodium azide 
(NaN3) and 42.08 mM sodium phosphate dibasic dehydrate (Na2HPO4•2H2O).  The 
addition of buffer solution to 220 μL of CSF sample leads to a final concentration of 
0.66mM TSP. The pH of the CSF was adjusted to around 7 (7.0 – 7.1) by phosphate 
buffer in buffer solution. The final CSF NMR sample (290 μL) was then transferred to a 
SHIGEMI microcell tube for measurements. 
The 1D 1H NMR spectra of rat CSF samples were acquired on a 600 MHz Bruker with a 
5 mm CPTCI z-gradient cold probe.  Suppression of water was achieved by using 
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presaturation. For each 1D 1H NMR spectrum 512 scans were accumulated with a 
spectral width of 7000 Hz resulting in a total of 16K points. The acquisition time for each 
scan was 2.2s. Between scans, a 8s relaxation delay was employed. Prior to spectral 
analysis, all acquired Free Induction Decays (FIDs) were zero-filled to 32K data points, 
multiplied with a 0.3 Hz line broadening function, Fourier transformed, manually phased, 
the TSP internal reference peak was set to 0 ppm and baseline corrected by using 
ACD/SpecManager software version 12.02. All 44 rat CSF spectra were acquired and 
preprocessed as described above and subsequently transferred to Chenomx NMR Suite 
7.0 for metabolites quantification.  
 
Table 1S. Groups description of the second EAE experiment; “n” indicates number of rats 
(samples) for each group.  
Treatment 
Day 0 
Group description Day 10 
CFA Peripheral inflammation P10-2
* 
n=15 
CFA+MBP Neuroinflammation + peripheral inflammation 
N10-2** 
n=15 
*2 sample were discarded due to blood contamination 
**4 samples were discarded due to blood contamination 
 
PLS-DA of 1H-NMR CSF data 
C10 vs. P10: Effect of peripheral inflammation  
Figure S1 presents the score plot of the PLS-DA model for groups “C10” versus “P10”. 
This model enables us to examine the effect of peripheral inflammation on the 
metabolic profile of CSF. This PLS-DA model is also performing well, since the overall 
correct classification for the test set is 100% (Table S2).   
 
P10 vs. P14: Evolution of peripheral inflammation   
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By studying groups “P10” and “P14” the evolution of peripheral inflammation may be 
investigated. We concluded from the “C14” vs. “P14” model that group “P14” was not 
inflamed anymore.  The PLS-DA model of “P10” vs. “P14” has perfect prediction ability. 
The key metabolites contributing to discrimination are mostly glutamine and citrate. This 
is indeed in agreement with the PLS-DA model of groups “C10” vs. “P10”, where the 
effect of peripheral inflammation was examined.  
 
Figure 1S. PLS-DA score plots derived from 1H-NMR spectra of rat CSF belonging to groups 
“C10” and “P10”. The amount of explained variance in Y for two latent variables was equal to 
88.5%. 
 
P10 vs. P14: Evolution of peripheral inflammation   
By studying groups “P10” and “P14” the evolution of peripheral inflammation may be 
investigated. We concluded from the “C14” vs. “P14” model that group “P14” was not 
inflamed anymore.  The PLS-DA model of “P10” vs. “P14” has perfect prediction ability. 
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The key metabolites contributing to discrimination are mostly glutamine and citrate. This 
is indeed in agreement with the PLS-DA model of groups “C10” vs. “P10”, where the 
effect of peripheral inflammation was examined.  
 
Table 2S. Summary of multivariate modeling diagnostic accuracy (PLS-DA) for the test set. 
Model Group Sensitivity [%] 
Specificity 
[%] 
Overall correct 
classification [%] 
Number of 
variables in PLS-
DA model 
C10 vs. 
N10 
C10 100 100 
100 45 
N10 100 100 
C10 vs. 
P10 
C10 100 100 
100 25 
P10 100 100 
P10 vs. 
N10 
P10 100 100 
62.5 20 
N10 58 33 
N10 vs. 
N14 
N10 100 100 
100 45 
N14 100 100 
C14 vs. 
N14 
C14 100 100 
100 40 
N14 100 100 
P10 vs. 
N14 
P10 100 100 
100 25 
N14 100 100 
 
Table 3S. Key metabolites discriminating groups based on PLS-DA models. 
PLS-DA model Key metabolites 
C10 vs. N10 fructose, glutamine, 3-hydroxyisovalerate, lysine, N-acetylaspartate 
C10 vs. P10 citrate, glutamine, N-acetyl-compound  and resonance at G0.8983 
which probably belongs to butyrate 
C14 vs. N14 
Lysine, arginine, alanine, pantothenate, malonate and unknown 
resonance at G1. 18 (variable 126) 
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N10 vs. N14 
arginine, dimethylamine, lysine, creatinie, pantothenate  and 
unknown resonances at G1.50 and G1.18 (variable 126). 
N10 vs. (C14&P14) lysine, arginine, pantothenate, malonate  
P10 vs. N14 lysine, pyruvate, choline, arginine, creatine, N-acetylaspartate 
 
Table 4S. Particular effect observed based on PLS-DA results. 
Groups Effect 
Comments 
 
Number 
of 
variables 
in PLS-
DA model 
C10 vs. 
N10 
Peripheral Inflammation& 
“neuroinflammation” 
Neuroinflammation 
was only present in 
some animals 
DAY 10 
 
C10 vs. 
P10 Peripheral inflammation 
 
P10 vs. 
N10 
“Neuroinflammation” & 
peripheral inflammation 
 
C14 vs. 
N14 Neuroinflammation 
Probably only the  
effect 
neuroinflammation is 
observed at Day 14 
and no effect 
peripheral 
inflammation is 
anymore present 
DAY 14 
 
C14 vs. 
P14 
Lack of peripheral inflammation; 
effect observed unrelated to 
peripheral inflammation 
 
N14 vs. 
(C14&P14) Neuroinflammation 
 
P14 vs. 
N14 Neuroinflammation 
 
P10 vs. P14 Peripheral inflammation  
DAY 10 & 
DAY 14 
 
N10 vs. 
N14 Evolution of disease 
  
P10 vs. 
N14 Neuroinflammation 
  
 
 
 301 
ANOVA-PCA results obtained at the onset of disease 
The first principal component (PC1), in Figure S2a, indicates variations, which 
distinguish between non-treated (“C10”) and the EAE affected group (“N10”). The 
second PC accounts for the discrimination between group “P10” and groups C10&N10. 
By visual inspection of Figure 4a group specific metabolites are found.  As an example, 
lactate (variable 116) and N-acetylaspartate (variable 90), have a high, positive 
interaction with group “N10, while citrate (variable 70) and glutamine (variable 72) 
interact negatively with this group.   
 
ANOVA-PCA results obtained for the peak of disease 
The first principal component of Figure S2b shows the variation, which differentiates the 
EAE-affected group at the second time point (group “N14”) from the other two groups. 
The second principal component represents the variation distinguishing groups “C14” 
and “P14”. However, the amount of variance explained by the second PC is low 
(12.3%), indicating that these groups are quite similar.  
 
ANOVA-PCA results obtained for all diagnostic groups 
Similarly we applied ANOVA-PCA to the metabolic profiles of all groups. The results are 
presented in Figures S2c and S2d. The first principal component of Figure S2c 
differentiates the group “N14” from other groups. It is also visible that the”N10” is 
different from the healthy group “C14” and group “P14”. Furthermore, groups “C14” and 
“P14” are highly collinear, which confirms their similarity in metabolic profiles.   
The score plot of the second and third principal component (Figure S2d) represents the 
distinction between the healthy group “C10” and group “N10”. By inspection of the 
reciprocal location of groups “C14” and “P14” on the plane of PC2 and PC3 similar 
conclusions can be drawn. These groups show collinearity in the metabolic profiles.   
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Figure 2S. Biplots of principal component analysis performed on the interaction between 
metabolites and treatments. Metabolites which are statistically significant are indicated with red 
squares. The arrows indicate the loadings of the treatments: (a) groups “C10”, “P10” and “N10”; 
(b) groups “C14”, “P14” and “N14”; (c) all groups plotted along two first principal components 
(PC1 and PC2); (d) all groups plotted along PC2 and PC3.    
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Table 5S. Group specific metabolites selected by mean of ANOVA-PCA. 
Group Metabolites with significant interactions 
C10 
healthy Day 10 
glutamine (variable 72) citrate (variable 70) 
variables 135 and 137 threonine (variable 36) 
3-hydroxyisovalerate 
(variable 120) succinate (variable 73) 
variable 77 variable 126 
variables 151 and 152 (probably butyrate) 
C14 
healthy Day 14 
myo-inisitol (variable 34) propylene glycol (variables 133, 134) 
citrate (variable 70) ornithine (variables 60 and 61) 
variables 135 variables 137 
P10 
peripheral inflammation Day 10 
cis-aconitate (variable 57) pyruvate (variable 76) 
P14 
peripheral inflammation Day 14 
glycerol (variable 38) ornithine (variables 60 and  61) 
variable 127 variable 129 
N14 
neuroinflammation Day 14 
lactate (variable 116) N-acetylaspartate (variable 90) 
N-acetyl-compounds 
(variables 88 and 89) 
methylmalonate (variable 
123) 
pyruvate (variable 76), lysine (variable 65) 
arginine (variables 100, 101 
and 102) 
pantothenate (variables 146 
and 148) 
N10 
neuroinflammation Day 10 
citrate (variable 70) malonate (variable 56) 
Methylmalonate (variable 
123) 
N-acetylaspartate (variable 
90) 
lysine (variable 65) arginine (variables 100, 101 and 102) 
pantothenate (variables 146 and 148) 
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Figure 3S. PLS-DA score plots derived from absolute concentration of metabolites specific for 
neuroinflammation for groups “P10” and “N14”. The amount of Y explained variance for one 
latent variable was equal to 91.3%. 
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Figure 1S. Typical disease progression in EAE model.  
 
 
Simulated data 
In order to represent the use of Hierarchical Model Fusion (HMF) a simulated data set 
was constructed. This data set contains 280 samples (corresponding to four classes, i.e. 
70 samples per class) and 105 variables. It was simulated in such way that the samples 
are represented by random vectors chosen from multivariate normal distribution. 5 
variables are informative and 100 are irrelevant for the discriminating classes. The 
informative traits were incorporated with random noise (approximately 6% of informative 
signal). The data were simulated in such way that: classes 1 and 2 overlap with each 
other as well as classes 3 and 4, while classes 2, 3 and 4 are the most dissimilar one. In 
Figure 2S the scatters plot of the simulated data in the plane of variable 5 and 2 (both 
informative) and Principal Component Analysis (PCA) score plot are shown. As can be 
observed from Figure 2Sa these two variables allow for discriminating classes. On the 
contrary, the PCA score plot (of autoscaled data, see Figure 2Sb) does not reveal any 
groupings.  Indeed, the four classes completely overlap in the plane defined by PC1 and 
PC2. 
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Figure 2S. Visualization of simulated data: (a) the scatter plot in the plane defined by the 
informative variables 5 and 2; (b) PCA score plot in the plane of PC1 and PC2.  
 
The data were divided into model (52 samples per class) and independent test set (18 
samples per class) using Duplex algorithm. In order to perform HMF three PLS-DA 
models were constructed, namely class 1 vs. class 2, class 2 vs. class 3 and class 3 vs. 
class 4 for autoscaled data. They were selected based on the information how the 
classes were simulated. The correct classification rate for the independent test set was 
equal 94.4%, 100% and 94.4%, respectively for the PLS-DA models.  
These three PLS-DA models were next used to obtain three new scores following the 
HMF procedure. We started with PLS-DA model of class 1 vs. class 2. This step enables 
of creating Xscore. This allows one to separate class 1 from the rest. In the next step 
PLS-DA model of class 2 vs. class 3 was used. Similarly to the first step a second score 
is generated, i.e. Yscore. At this point class 2 is separated. In the final step PLS-DA 
model of class 3 vs. 4 was utilized leading to Zscore. By concatenating these three new 
scores a graphical representation is obtained, showing all classes at once. In Figure 3S 
the graphical representation of the HMF applied to simulated data is presented. Note 
that this figure shows where the test samples (18 samples per class) are projected into 
these new scores. As can be noticed the test samples are correctly projected (95.3% 
test samples are correctly predicted by HMF). This demonstrates the statistical 
relevance of the obtained results. To show if classification results are better than any 
other random classification a permutation test was made. Of 3000 runs none had correct 
classification bigger than 95.03%, leading to p-value 0.0003. 
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To evaluate the performance of HMF we constructed PLS2-DA model on the same 
training set used for HMF. The correct classification for the independent test set was 
equal to 83.3%.  This result shows that PLS2-DA underperforms compared to HMF. 
 
 
 
Figure 3S. Graphical representation of the results of the HMF obtained on the simulated data.  
 
Addition of different noise levels 
 
In order to represent the effect of noise we added different levels of homoscedastic and 
heteroscedastic noise to informative variables in the simulated data. We created 6 
different levels and we repeated it 60 times. Every noise level comprised different 
percentage of informative traits (see Figure 4S on x-axis). 6 noise levels and 60 
repetition leads to 360 runs. For each run PLS-DA models were recalculated and HMF 
was applied as described above. Moreover we performed permutation test (3000 runs) 
to reduce the possibility of random classification.  
 
311 
 
In Figure 4S the average correct classification and standard deviation obtained for HMF 
applied to simulated data with different levels of noise in informative traits is presented. 
As can be observed the higher the noise level the less accurate results have become. 
The algorithm performs well in terms of correct predictions for independent test set up to 
situation number 4 (i.e. data containing 35% of noise in comparison to informative traits).  
However, for data containing 35% of noise the results become unstable, since the 
outcome of permutation test shows that for 3000 runs some had higher correct 
classification than for the original classification. For the first three noise levels, of the 
3000 permutations none had a number of correct classifications higher than for original 
classification, leading to a p-value of 0.0003. 
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Figure 4S. Average correct classification rate and standard deviation obtained for simulated 
data with 6 different noise levels. In the x-axis amount of noise with respect to relevant variables 
is indicated. For each noise level the results from permutation test are included on top of the 
triangular.  
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Pseudo code for LOO CV used for variable selection and model optimization 
 
Assuming a data matrix X for training set of size (n x p, where n is a number of samples 
and p a number of variables) a LOO CV is performed (separately for plasma and CSF) 
according to the following scheme, which was repeated for each sample (i) in X: 
 
Beginning of LOO CV 
1. One object (i) is removed from training data matrix X 
2. Autoscaling of the data matrix X with remaining objects (of size m-1 x p) 
3. RFE is performed on the autoscaled data matrix X with remaining objects (of size m-1 
x p) 
4. A ranking of variables is obtained 
End of LOO CV  
 
In next step a final ranking for variables is obtained. 
CSF and plasma training sets are concatenated and variables ranking is again 
performed with LOO CV; note that here X corresponds to concatenated plasma and 
CSF data: 
 
Beginning of LOO CV 
1. One object (i) is removed from training data matrix X 
2. Autoscaling of the data matrix X with remaining objects (of size m-1 x p) 
3. RFE is performed on the autoscaled data matrix X with remaining objects (of size m-1 
x p) 
4. A ranking of variables is obtained 
End of LOO CV  
 
The final ranking for concatenated data is obtained. 
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Optimization of PLS-DA model complexity (number of latent variables) for data matrix X 
(repeated for each object (i) in X). Note that here X can correspond to CSF data, plasma 
data or fused data sets: 
Beginning of LOO CV 
1. One object (i) is removed from training data matrix X (m x p) 
2. Autoscaling of the data matrix X with remaining objects (of size m-1 x p) 
3. Autoscaling of removed object (i) with mean and standard deviation delivered from the 
data matrix X with remaining objects 
4. Fit PLS-DA model to autoscaled data matrix X with remaining objects (size m-1 x p) 
5. Classify removed object (i)  
6. Calculation of the root mean square error of cross-validation (RMSECV). 
End of LOO CV 
 Model complexity= min(RMSECV) -> first minimum  
 
 
 
 
Figure 5S. Graphical representation of the results of the HMF obtained on the fused CSF and 
plasma datasets with indication of training and test samples. 
314 
 
 
Table 1S. Correct classification rate for independent test set obtained for individual analysis of 
plasma data, CSF data and fused datasets by PLS2-DA. Complexity of PLS2-DA models LV=3. 
Number of variables: 20 variables for plasma and 20 variables for CSF. 
Groups plasma CSF fused (plasma and CSF) 
C10 50% 67% 80% 
P10 100% 67% 80% 
N10 0% 0% 67% 
C14 0% 0% 0% 
P14 80% 100% 67% 
N14 100% 100% 100% 
 
 
 
Table 2S. Correct classification rate for independent test set obtained for individual analysis of 
plasma data, CSF data and fused datasets by PLS-DA.  
PLS-DA model plasma CSF fused (plasma and CSF) 
C10 vs. P10 62.50% 62.50% 93% 
P10 vs. N10 75% 50% 100% 
C10 vs. N10 62.5% 100% 100% 
N10 vs. N14 62.5% 100% 100% 
C14 vs. N14 100% 100% 100% 
C14 vs. P14 100% 100% 100% 
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Figure 5S. Density distribution of PLS-DA scores of fused data: (a) “C10” vs. “P10”, the amount 
of y variance for 1 LV is equal 76.2%; (b) Regression coefficients of “C10” vs. “P10” PLS-DA 
model; (c) “N10” vs. “N14”, the amount of y variance for 1 LV is equal 94.04%; (d) Regression 
coefficients of “N10” vs. “N14” PLS-DA model. 
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Table 1S. Metabolites  
Variable nr. Metabolite Variable nr. Metabolite 
1 citrate 39 leucine 
2 citrate 40 leucine 
3 glutamine 41 2-hydroxy-3-methylvalerate 
4 glutamine 42 unknown 
5 creatinine 43 unknown 
6 creatine 44 2-hydroxybutyrate 
7 lysine 45 2-hydroxybutyrate 
8 lysine 46 2-methyl-2-oxovalerate 
9 alanine 47 unknown 
10 arginine 48 1,5-anhydroglucitol 
11 choline 49 2,3-butanediol 
12 glucose+glyceric acid+ascorbate 50 3-methyl-2-hydroxybutanoic acid 
13 glucose+glyceric acid+ascorbate 51 Alanine 
14 glucose+unknown 52 Arabinose 
15 glucose+unknown 53 C16:0 fatty acid 
16 glucose +unknown 54 Citric acid 
17 glucose +unknown 55 Glucose 
18 glucose +unknown 56 Glutamine 
19 glucose+trimethylamine N-oxide 57 Glycerol 
20 glucose+carnitine 58 Lactic acid 
21 glucose+carnitine 59 Lysine 
22 glucose+phosphocholine 60 Mannose 
23 acetone 61 Myo-inositol 
24 acetate 62 Ornithine 
25 lactate 63 Phenylalanine 
26 lactate 64 Phosphate 
27 3-hydroxyisovaleriate 65 Pyruvic acid 
28 2-methyl-2-oxovalerate 66 Ribitol or arabitol 
29 unknown 67 Sucrose 
30 2-oxobutyrate 68 Threonine 
31 2-oxobutyrate 69 ascorbic acid derv 1 
32 valine 70 butanediol isomer 2 
33 2-oxobutyrate 71 erythronic acid 
34 valine 72 fructose 
35 unknown 73 inositol 
36 valine 74 meso-erythritol 
37 valine 75 sn-Glycerol-3-Phosphate 
38 leucine 76 urea 
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a) b)
c) d)
 
Figure 1S. Loading plot of pseudo samples trajectories for: (a) variables 1 till 19; (b) variables 
20 till 36; (c) variables 37 till 57 and (d) variables 58 till 76. Numbers correspond to variable 
numbers in Table 1S.   
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Figure 2S. The PLS-DA score plot of: (a)NMRdata; (b)GCMS data; (c) fused NMR and GC-MS 
in mid-level fashion. 
 
Clinical information  
Of the 26 patients in the MScl group in the NMR dataset, 19 patients had relapsing 
remitting (RR) MScl and 7 primary progressive (PP) MScl. In the GC-MS dataset of MScl 
patients, 7 patients were diagnosed with PP MScl and the others had PP MScl.  The 
number of patients with PP MScl in the overlap NMR/GC-MS set is equal to 4. In the 
NMR dataset, the group of the MScl patients contains 6 males and 20 females, while in 
the GC-MS MScl dataset 5 males and 19 females are found. In the NMR/GC-MS 
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overlap set (MScl) 4 patients are male. In the MScl NMR/GC-MS overlap set the median 
of the time of disease duration for the MScl patients at the moment of CSF sampling was 
4.5 years, while the average was 7.25 years with standard deviation of 6.6 years. For 
the complete NMR MScl set and GC-MS MScl set the disease duration was on average 
6 years with standard deviation of 5 years and 7.3 years with standard deviation of 5.7 
years, respectively. In the group of 20 patients with CIS, 5 are males and 15 are females 
in the NMR set. In the GC-MS dataset 4 patients are male. It is worthwhile to mention 
that all patients diagnosed with CIS have later developed MScl.  
 
 
Kernel transformations 
 Different kernels transformations, namely linear and polynomial (2nd and 3rd degree), 
were studied. However the correct classification did not extent 60% for independent test 
set. Moreover, these kernels transformation presented the lowest RMSECV for training 
set. 
 
Random division in training and independent test set 
 Random division (repeated 104 times) of the data was made and the MKL procedure 
was performed for each pair of training and independent test set. The average correct 
prediction of test set was equal to 90.5%. The average Receiver Operating 
Characteristics (ROC) curve of K-PLS-DA model is shown in Figure S3 with area under 
cure of 92.8%.   
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Figure 3S. Average Receiver Operating Characteristics derived from K-PLS-DA for random 
division of data. 
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